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Nature has been a perpetual source of inspiration for biochemists. It is not only the vast diversity 
of compounds that living beings can create, but also the extraordinary strategies of synthesis 
deployed. Evidently, the catalysts used by living beings -enzymes- are key to nature’s synthesis 
strategies. Biocatalysis is undoubtfully one of the most invaluable gifts given by nature to flourish 
the development of green chemical and pharmaceutical industries. With the development of 
protein and metabolic engineering tools and strategies, more and more enzymes have been used in 
the industries to improve the chemical processing; and microbes such as Escherichia coli and 
Saccharomyces cerevisiae have been engineered to produce a wide variety of value-added and 
bulk chemicals to replace traditional chemical synthesis. However, researchers have just explored 
the tip of the iceberg in the biocatalysis area. Proteins with new catalytic functionality should be 
discovered or engineered to broaden current biotransformation boundaries. New in vitro enzymatic 
or chemoenzymatic cascade reactions need to be designed and optimized to realize stronger 
synthetic power and more stable systems. Metabolic networks of traditional or new 
microorganisms should be largely rewired to meet the manufacturing standards.  
In this work, I aimed at designing and engineering multi-step (bio) catalytic systems for 
selective synthesis of value-added chemicals. Microorganisms synthesize complex molecules from 
simple substrates by a series of enzymes working cooperatively. Inspired by how aromatic 
polyketides are synthesized by the teamwork between enzymes, I sought to couple biocatalysis 
with organometallic catalysis, two distinct catalytic disciplines, in one pot to realize synthetic 
power that cannot be achieved by either of them. I first developed a modular, one-pot, sequential 
chemoenzymatic system for the formal enantioselective construction of C-C bond in 2-aryl 1,4-
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dicarbonyl compounds. This sequence comprises a rhodium-catalyzed diazocoupling that 
provides >9:1 selectivity for heterocoupling of two diazoesters and a reduction mediated by an 
ene-reductase (ER), which occurs in up to 99% enantiomeric excess (ee). The high yield and 
enantioselectivity of this system were resulted from the preferential generation of an (E)-alkene 
from the diazo coupling reaction and selective reduction of the (E)-alkene in a mixture of (E) and 
(Z) isomers by the ER. This work demonstrates the benefit of combining organometallic and 
enzymatic catalysis to create unusual overall transformations that do not require the isolation and 
purification of intermediates.  
To make the system works better on a broader range of substrates, I later developed a new 
class of cooperative chemoenzymatic reactions that combine photocatalysts that isomerize alkenes 
with ene-reductases that reduce carbon-carbon double bonds to generate valuable enantioenriched 
products. I demonstrated that this method enables the stereoconvergent reduction of E/Z mixtures 
of alkenes or reduction of the unreactive stereoisomer of an alkene in yields and ee’s that match 
those obtained from the reduction of the pure, more reactive isomer. This new cooperative system 
overcomes the limitations of both individual catalysts and affords a range of synthetically valuable 
and biologically active enantioenriched compounds. More generally, these results illustrate the 
value of driving a chemical reaction with light to ensure compatibility between the chemical and 
enzymatic catalysts.  
In vitro biocatalytic reaction normally has poor tolerance to harsh conditions such as low 
pH or high substrate concentrations. Cells membrane is natural compartmentalization and protects 
the enzymes from extracellular inhibitors. In addition, cell factories-based production provides an 
attractive alternative to chemical synthesis of value-added chemicals. I also worked on engineering 
a S. cerevisiae strain as a whole-cell catalyst for L-lactic acid overproduction in industrially 
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preferred low pH environment (pH 3) by metabolic engineering and genome-wide engineering 
methods. In addition, to establish an automated cellular engineering platform, I developed a 
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CHAPTER 1. Introduction  
1.1 Biocatalysis  
Biocatalysis is defined as the use of enzymes in their purified form, as part of cell lysates, or whole 
cells to convert a molecular substrate into a product of interest.1 In 1858, biologist Louis Pasteur 
provided the first example of modern biocatalysis by realizing the resolution of racemic tartaric 
acid through fermentation with microorganisms, such as the common mold Penicillium glaucum. 
He also laid the foundation of stereochemistry in those experiments where (-)-tartaric acid was 
accumulated while (+)-tartaric acid was consumed. At the end of the 19th century, the specific 
action of an enzyme with a specific substrate was explained using a “Lock and Key” analogy and 
it was firstly postulated by Emil Fischer.2 Meanwhile, Eduard Buchner discovered the cell-free 
fermentation for biocatalytic processes.3 
Those milestones led to discovery and development of numerous biocatalytic processes in 
the 20th century. Especially the unique characteristics and benefits of biocatalysis have kept on 
drawing biochemists’ strong interests in pushing the boundaries of natural-occurring 
biotransformations and bringing biocatalysis to industrial applications. Enzymes can be considered 
as green catalysts. Unlike transition metal-based chemical catalysts that rely on mining and harsh, 
energy intensive process conditions, biocatalysts are biodegradable and easily replaced through 
inexpensive and environmentally friendly fermentation processes. Transition metal catalysts 
normally have high turnover numbers (TONs), but the economic burden posed by enzymes can 
potentially be further minimized by engineering more active variants than that being found in 
nature, optimizing the expression efficiencies and fermentation yields, improving the enzymatic 
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stabilities, and immobilizing the enzymes for recycling. More importantly, the high regio-, stereo- 
and enantioselectivity of biocatalysis make it an invaluable alternative in pharmaceutical industries.  
One famous example on how enzymes can improve industrial chemical processing is 
acrylamide synthesis. As an alternative to Cu or Mg based chemical catalysis method, the use of 
nitrile hydratases has now converted acrylonitrile to acrylamide, the monomer used to prepare 
polyacrylamide, on tens of thousands of metric tons per year.4 The replacement largely reduced 
the catalyst waste generated per kilogram of the products. Another powerful example of 
biocatalytic applications exploiting the chiral nature of these catalysts is the use of ene-reductases 
to prepare a chiral precursor of pregabalin, the active agent in Lyrica® for treatment of epilepsy, 
neuropathic pain, fibromyalgia and generalized anxiety disorder.5 The manufacturing process of 
pregabalin involving old yellow enzymes (OYEs) has been patented by Pfizer Manufacturing 
Ireland.  
One of the major reasons prohibiting the broad application of biocatalysis in manufacturing 
of chemicals is that limited unnatural reactions could be catalyzed by biocatalysts. Beginning in 
the late 1970s with pioneering work of Michael Smith and later amplified by contributions from 
Pim Stemmer and Frances Arnold, microbiologists began developing techniques that enabled 
directed evolution of enzymes.6-8 This approach has been successfully used to engineer or 
customize the enzymes that react with unnatural substrates or under unnatural reaction conditions 
that are different from those found in natural systems. For example, carbonic anhydrase has been 
engineered to sustain catalytic activity at 107 °C at pH > 3;9 and proteins have been engineered to 
deliver chemical reactions such as enantioselective cyclopropanations,10 silylations,11 and 
borylation12 reactions which are unprecedented in nature. 
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There are also several applications of engineered biocatalysts in the pharmaceutical 
industry. Early examples include the development of a ketoreductase (CDX-026) capable of 
reducing the large, hydrophobic ketone substrate 1 to yield alcohol 2. 2 serves as a precursor to 
montelukast, widely used to treat asthma and seasonal rhinitis (Figure 1A).13 A Baeyer-Villiger 
monooxygenase (BVMO) has also been engineered to enantioselectively oxidize sulfide 3 to 
provide esomeprazole 4, used to treat acid reflux (Figure 1B). An engineered transaminase 
successfully converted the sitagliptin ketone 5 to sitagliptin 6, a DPP4 inhibitor used for the 
treatment of type II diabetes (Figure 1C).1  
 
Figure 1.1. A) Biocatalytic approach to montelukast; B) BVMO catalyzed sulfide oxidation to 
produce esomeprazole; C) Preparation of sitagliptin using an engineered transaminase.  
In addition to directed evolution, several new strategies in biocatalysis also have been 
developed and applied to further broaden the substrate scope, reaction type and reaction condition 
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of current biocatalysis applications. Those strategies include but are not limited to development of 
artificial metalloenzymes, enzyme catalyzed protein conjugations, biocatalytic cascades, 
chemoenzymatic tandem reactions, computational and library design strategies for enzyme 
engineering, and metabolic pathways for chemical biosynthesis. In my study, I focused on studying 
naturally-occurring biocatalytic cascade reactions, developing in vitro chemoenzymatic 
transformations and engineering metabolic pathways for chemical overproduction.     
1.2 Natural Product Synthesis: How Nature Make Complex Molecules 
In living organisms, an individual enzyme catalyzes limited simple reactions, but the cooperative 
action of a series of enzymes build up complex molecules from simple molecules to support the 
biological functions such as generation or storage of energy, and environmental sensing and 
communication. The cascade or concurrent reactions catalyzed by multiple enzymes demonstrate 
the strongest synthetic power in nature, which makes an irreversible process reversible, eliminates 
inhibition problems caused by excess product, or circumvents the lack of substrate scattered in 
bulk solution. 
Natural products are chemical compounds synthesized by a series of enzymes working 
cooperatively in organisms. Natural products have played key roles over the past century in the 
development of medicine. More than two-thirds of clinically used antibiotics are natural products 
or their semisynthetic derivatives.14 Studying the biosynthetic mechanisms of natural products also 
enables us to gain deeper insights into enzymatic teamwork, thus enlightening us design artificial 
enzymatic cascades for selective synthesis of valuable compounds.  
Type II polyketide synthase is one of the best examples to demonstrate production of 
aromatic polyketides by teamwork between enzymes. Type II polyketides comprise a large class 
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of structurally and functionally diverse bacterial natural products. This class is rich in 
pharmacologically relevant compounds, especially anticancer agents. In analogy to type II 
bacterial and plant fatty acid synthases, type II polyketides are comprised of several individual 
enzymes encoded by the genes clustered in the same region in the genomic DNA. Although 
different type II polyketides have very diverse structure, they all share a minimal set of iteratively 
used enzymes, each expressed from a distinct gene. In general, this so-called ‘minimal PKS’ 
consists of two ketosynthase units (KSα and KSβ) and an acyl carrier protein (ACP), which serves 
as an anchor for the growing polyketide chain. With a few exceptions, genes encoding these three 
proteins are grouped together, and show a typical KSα/KSβ/ACP architecture. Additional PKS 
subunits, including ketoreductases, cyclases and aromatases define the folding pattern of the 
nascent poly-β-ketone intermediates. Finally, the polyphenols are tailored by oxygenases, glycosyl 






Figure 1.2.  Schematic of type II polyketide synthase. Type II PKS gene clusters encode 
dissociable polyketide synthase assemblies. The minimal polyketide synthase (min-PKS) consists 
of three proteins: KSα KSβ and ACP. The nascent polyketide chains, ranging from 16 to 30 carbons, 
are constructed by iterative condensation of malonyl-CoA catalyzed by min-PKS. The reactive 
beta-keto chains are converted into structurally diverse molecules by the action of tailoring 
enzymes (T) including cyclases (Cyc) and reductases, giving rise to final branching, oxidation 
state, and cyclization pattern.  
Although natural products have been and continue to be the source and inspiration for a 
substantial fraction of human therapeutics and knowledge of biology, the discoveries of natural 
products with new structure and unique synthesis mechanism have been greatly hindered within 
recent decades. With the advent of fast and inexpensive next generation sequencing technologies, 
Additional numerous silent biosynthetic gene clusters (BGCs) coding uncharacterized secondary 
metabolites have been identified and they are the rich sources for the discovery of new compounds 
and enzymes. Because natural products encoded by silent BGCs are hard to be detected using 
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current analytical methods due to minimal or zero BGCs expression under laboratory conditions, 
strategies to activate BGC expression and trigger metabolite production are critical to realize the 
full potential of nature’s chemical repertoire. While heterologous expression bypasses native 
regulation networks and can be engineered rationally, the entire biosynthetic pathways, often 
spanning large areas of genomes, will have to be cloned and refactored.15 Importantly, some 
natural products cannot be produced in heterologous hosts due to lack of regulatory, enzymatic, or 
metabolic requirements for product biosynthesis. Technologies that improve the genetic 
manipulation of native hosts will expedite discovery and study of the BGCs in their native contexts. 
In the first part of the thesis, an efficient CRISPR-Cas9 knock-in strategy has been developed to 
active silent BGCs in Streptomyces viridochromogenes. A new type II polyketide has been 
characterized and its corresponding synthetic enzymes has been identified.  
1.3 In vitro Tandem Catalytic Reactions for Biochemical Productions  
The synergistic effect of natural synthetic networks inspires chemists to develop artificial multi-
step tandem reactions for selective synthesis of complex molecules.16 To date, tandem reactions 
by using whole microorganisms (in vivo) have been extensively studied in the synthetic biology 
and metabolic engineering fields.17 There are growing interests to build cooperative tandem 
reactions by coupling multiple enzymes or organometallic catalysts with biocatalysts in vitro since 
the resulting catalytic systems are simpler for optimization, generate less side products and waste, 
and allow for easy product purification.18 
To date, in vitro tandem enzymatic reactions have been well developed for the preparation 
of alcohols, acids and their derivatives, amino acids, amines, nucleosides/nucleotides, 
nucleosides/nucleotides derivatives, oligosaccharides and glycoconjugates.19 The field of tandem 
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chemo-enzymatic reaction is still in its infancy.20 Recently lipase has been successfully coupled 
with various transition metal complexes for readily deracemizing secondary alcohols and primary 
amines.21 This accomplishment clearly shows the advantages of multistep one-pot processes, so-
called tandem reactions. Compared with step-wise synthesis, one-pot tandem reactions improve 
overall synthetic efficiency and reduce waste generation by avoiding intermediate purification 
steps. Additionally, tandem reactions improve the overall asymmetric synthesis efficiency by 
converting achiral substrates to single enantiopure product containing a single enantiomer. Last 
but not least, the cooperative effect among different catalytic steps enhances the selectivity and 
activity by an equilibrium process.   
However, combining multiple enzymes or enzymes with chemical catalysts in a tandem 
process is not simply replicating the catalytic behavior of each catalyst. For multi-enzymatic 
reactions, several strategies have been developed to balance the reaction rate of each step and 
maintain enzymatic activity under reaction conditions, including cell free metabolic engineering 
(CFME) and modeling.22 Protein engineering methods have been applied, such as protein 
immobilization and fusion protein construction, to improve the overall efficiency of multi-
enzymatic reactions. 23,24 Specifically, it is more challenging to find conditions to enable catalytic 
activity of organometallic catalysts and biocatalysts in one-pot due to incompatibility and mutual 
inactivation. To overcome those difficulties, several novel strategies have been developed, 
including supramolecular assembly and compartmentalization.  
1.3.1. Enzymatic Tandem Reactions  
From aerobic respiration to photosynthesis, millions of compounds are synthesized through 
enzymatic reactions during the lifespan of all living organisms. These compounds, even those with 
very complex structures, are converted from simple chemical resources such as glucose, through 
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the metabolic network in the cell. Tandem enzymatic reactions, or pathways in other words, can 
be considered as subunits of the whole metabolic network. Although enzymatic reactions have 
long been used for chemical synthesis due to many of their excellent features, particularly the high 
selectivity and specificity, multiple tandem enzymatic reaction systems developed by chemists 
recently are not simple combinations of enzymatic reactions catalyzed by individual enzymes.  
Besides all the advantageous properties of enzymatic reactions, tandem enzymatic reactions can 
be much more cost-effective by using inexpensive substrates, potentially making them 
economically feasible. Moreover, one-pot tandem enzymatic reactions simply avoid the 
purification of the intermediates, which makes the process more efficient than step-wise enzymatic 
reactions.  
While such tandem enzymatic reactions can be accomplished in vivo, as widely used in 
today’s fermentation industry, there are many advantages to use in vitro systems. First, as no 
competing pathways exist in the in vitro system and no metabolic burden or toxicity issues need 
to be considered, the yield can be much closer to the theoretical yield than the in vivo system 
Second, due to its simplicity, it would be more practical and effective to optimize the system 
through modeling and adjusting the enzymes’ concentrations. Moreover, artificial tandem 
enzymatic reactions which can produce non-natural compounds are readily set up without potential 
toxicity issues brought by the product. In the past decade, many tandem enzymatic reaction 
systems have been developed to produce tremendous chemicals.25  
Although in vitro tandem enzymatic reactions have a number of advantages over in vivo 
tandem enzymatic reactions, their weaknesses are also obvious, with the main weakness being the 
decreased flexibility. For example, most of the tandem reactions only include two or three enzymes. 
For example, through computational design, researchers have engineered the promiscuous aldolase 
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RA95.5-8 to catalyze asymmetric Michael additions and Knoevenagel reactions via Schiff base 
intermediates. Recently Hilvert’s group discovered novel activities of those aldolase variants. The 
variant RA95.5-8F can catalyze the synthesis of (R)-methodol from acetone and 6-methoxy-2-
naphthaldehyde, while the variant T53L/K210H RA95.5-8 can catalyze the dehydrated (R)-
methodol to γ-nitroketones26,27. By combination of those two aldolase variants, they achieved 
similar yield and stereoselectivity in one-pot as the reaction using the purified intermediate (Figure 
1). 
 
Figure 1.3. Synthesis of γ-nitroketones by aldolase variants. 27 
In principle, an ideal in vitro tandem reaction system should be sufficiently flexible to 
generate a broader product scope while using the low-cost substrates. Therefore, in vitro tandem 
reaction systems with higher complexity for synthesizing chemicals, such as carbohydrates, fuels, 
and fine chemicals are desired. 28-32 In recent years, great efforts were spent in the emerging CFME 
field to address such a challenge.22 A CFME system usually involves four or more enzymes and 
uses inexpensive substrates if possible, as the cost-effectiveness is a required design criteria. 33,34 
Ideally, it should combine catabolic pathways and anabolic pathways, so that both the building 
blocks and the energy for synthesizing the target molecules can be generated from simple resources, 
such as glucose. However, the design and test of such a system would be very challenging as tens 
of enzymes might be involved.35 Recently, Bowie and coworkers successfully combined the 
Embden-Meyerhof-Parnas glycolytic pathway and the mevalonate pathway to produce 
monoterpenes.36 A super-complex system with 27 enzymes was reconstituted in one-pot which 
enabled the system to synthesize monoterpenes by using glucose as the only substrate. While 
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specific designs, such as the enzymatic purge valve nodes, helped the catabolic pathway and the 
anabolic pathway work harmonically in the system.37 By switching the monoterpene synthases in 
the system, different types of monoterpenes such as limonene, pinene and sabinene can be 
produced. This system can produce monoterpenes with titers an order of magnitude higher than 
the cellular toxicity limit (15 g/L) with an almost theoretical yield (>95%), which demonstrates 
the great advantage of using enzymatic tandem reaction in vitro.  
In addition to transferring the existing pathways from in vivo to in vitro, scientists are also 
able to design de novo complex pathways, which can accomplish difficult biosynthetic tasks. In 
2017, the crotonyl–coenzyme A (CoA)/ethylmalonyl-CoA/hydroxybutyryl-CoA (CETCH) cycle 
was constructed by Erb and coworkers, which provides a seventh CO2 fixation pathway besides 
the six naturally evolved ones (Figure 1.4).38 Instead of being restricted to known enzymes, the 
researchers sought for all reactions that are biochemically feasible. Multiple cycles were designed 
from scratch and their thermodynamic feasibility was evaluated. Then, enzymes that can catalyze 
the reactions in the CETCH cycle were identified from bioinformatics databases and characterized 
individually in vitro. After combining the auxiliary proofreading and cofactor regeneration 
processes, the CETCH cycle involves 17 enzymes in total which came from nine different 
organisms from all three domains of life. Through enzyme engineering and metabolic proofreading, 
the CETCH cycle can convert CO2 into organic molecules at a rate of 5 nanomoles of CO2 per 




Figure 1.4. The CETCH cycle contains 17 enzymes from 9 different organisms, which can convert 
CO2 into organic molecules at a rate of 5 nanomoles of CO2 per minute per milligram of protein 
38. Ccr: crotonyl-CoA carboxylase/reductase; Ecm: ethylmalonyl-CoA mutase; Epi: ethylmalonyl-
CoA/methylmalonyl-CoA epimerase; Fdh: formate dehydrogenase; Hbd: 4-hydroxybutyryl-CoA 
dehydratase; Hbs: 4-hydroxybutyryl-CoA synthetase; Kat: katalase; Mas: malate synthase; Mch: 
mesaconyl-CoA hydratase; Mcl: β-methylmalyl-CoA lyase; Mcm: methylmalonyl-CoA mutase; 
Mco: methylsuccinyl-CoA oxidase; Mct: malyl-CoA thioesterase; Pco: propionyl-CoA oxidase; 
Pkk: polyphosphate kinase; Scr: succinyl-CoA reductase; Ssr: succinic semialdehyde 
reductase. 
1.3.2. Chemoenzymatic Tandem Reactions  
Organometallic catalysis and biocatalysis are two different disciplines in terms of reaction 
categories, catalytic conditions, substrates scopes and selectivities. Organometallic catalysts have 
wide substrate scopes and high productivity and are still the key for bulk chemical manufacturing. 
Biocatalysis is becoming more widely used in the pharmaceutical industry due to its high regio-, 
stereo- and enantioselectivity, and growing advances in enzyme discovery and engineering. To 
access the advantages of both catalytic disciplines, there is a growing interest to combine 
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organometallic catalysts in tandem with enzymes to realize synthetic power that cannot be 
achieved by either of them alone.20,39 
Unlike developing tandem enzymatic reactions, it is more challenging to combine 
organometallic catalysts and biocatalysts due to incompatibility and mutual inactivation of metal 
complexes and enzymes. Up to date, only lipases and serine proteases could maintain high catalytic 
activity in organic solvents and at high temperature. Similarly, most transition-metal complexes 
are inhibited in aqueous solution with or without cellular components. In this section, we will 
summarize the major tandem chemo-enzymatic reactions developed in organic solvent and 
aqueous buffer solutions, and discuss the novel strategies used to combine organometallic catalysts 
with biocatalysts in one-pot.  
1.3.2.1. One-pot Chemo-enzymatic Reactions in Organic Solvent 
Dynamic kinetic resolution (DKR) of alcohols and amines based on transition metal-catalyzed 
racemization and lipase-catalyzed resolution in pure organic solvent has been developed towards 
a mature technology for preparation of enantiopure secondary alcohols and primary amines (Figure 
1.5). Lipase deracemizes a mixture of enantiomers by selectively acylating desired enantiomer. 
The drawback of such enzymatic kinetic resolution is that a maximum yield of only 50% can be 
obtained. However, it can be resolved by using a racemization catalyst to replenish the consumed 
enantiomer and drive the resolution up to 100% yield of desired enantiomer.  Since the pioneering 
demonstration of the DKR concept by the group of Williams,40 Bäckvall 41 and Kim,42 intense 
studies were conducted to develop efficient racemization catalysts, improve enzyme stability and 
expand substrate scope.20,21 To date, immobilized Candida antarctica lipase B (CALB) and C. 
antarctica lipase A (CALA) are the best enzymes of choice due to their robustness and activities 




Figure 1.5. Dynamic kinetic resolution of amines or alcohols by coupling CALB or CALA in 
tandem with racemization catalysts. 
 
Ruthenium, iridium, alumina and vanadium complexes are the most well-developed 
catalysts for alcohol racemization. They were used in tandem with various lipases to deracemize a 
wide range of functionalized secondary alcohols, including aliphatic, allylic alcohols, 
chlorohydrins, diols, homoallylic alcohols, and N-heterocyclic 1,2-aminos alcohols, α-hydroxyl 
ketones with excellent yields and enantiomeric excess (ee).21 Besides the above-mentioned 
homogeneous catalysts, heterogeneous acids, zeolites 44,45 and vanadium based mesoporous silica 
46 were also reported as racemization catalysts of secondary alcohols. The DKR of amines is more 
challenging due to a lack of efficient racemization catalysts. To date, coupling ruthenium 
complexes, analogues of Shvo catalyst, with CALB is the most practical approach for DKR of 
aliphatic or benzylic primary amines at 90 °C.21 In recent years, Pd nanoparticles-based 
heterogenous catalysts were employed for racemization of benzylic primary amines under mild 
conditions  However, they did not work well for aliphatic amines.47 
1.3.2.2. One-pot Chemo-enzymatic Reactions in Aqueous Solutions  
Except for lipases and serine proteases, most biocatalysts have poor stability in organic solvents 
and at elevated temperature. In the past 20 years, there has been a growing interest to develop 
tandem reactions in aqueous solutions to combine unique transformations catalyzed by 
organometallic catalysts and biocatalysts.20 The major motivation to associate biocatalysts with 
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organometal catalyst in one pot is to utilize the synthetic power from each discipline for specific 
transformations that could not be realized by either of them alone. In nature, enzymes have specific 
substrate binding site for highly regio- stereo- and enantioselective synthesis. Accordingly, 
organometallic catalysts could access some reactions that enzymatic processes do not exist or work 
only on limited substrate scope, for example, hydrogenation, cross-coupling reaction, Wacker-
oxidation, olefin metathesis, etc.  
Unlike the DKR system in organic solvents, the development of tandem chemo-enzymatic 
reactions in aqueous solution is still in its infancy. The number of transformations amenable to 
these processes are small portion of catalytic reactions reported in organometallic chemistry or 
synthetic biology. Table 1.1 summarizes the representative work of one-pot chemo-enzymatic 
reactions that can occur in aqueous-based solution. They are metal-catalyzed hydrogenation in 
tandem with isomerase or hydrolase catalyzed reactions; organometallic-catalyzed racemization 
in tandem with enantioselective hydrolysis; Pd/Cu catalyzed Wacker oxidation in tandem with 
enzymatic catalyzed asymmetric reduction or reductive amination; metal-catalyzed metathesis in 
tandem with enzymatic decarboxylation, ester hydrolysis or P450-catalyzed epoxidation; metal-
catalyzed cross coupling in tandem with enzymatic reduction, oxidation and hydrolysis; Au 
catalyzed isomerization in tandem with enzymatic hydrolysis.  
Those reactions were either performed in one-pot sequential manner by avoiding the 
purification of intermediates when different reaction conditions are required for organometallic 
and enzymatic step, or in concurrent manner when two catalytic steps are compatible with each 
other. Enlighteningly, a few cooperative concurrent reactions were reported to reveal the 
significance of tandem reactions compared with the sequential transformations. For example, Zhao 
and Hartwig groups jointly reported an example of Ru-catalyzed olefin metathesis coupled with a 
16 
 
P450-monooxygenase that selectively oxidized one of the cross-metathesis products against others. 
The overall yield of concurrent reactions is 1.5 times higher than the sequential one (Figure 1.6).48 
Table 1.1. Typical one-pot tandem chemo-enzymatic reactions in aqueous solution 














Rh (hydrogenation) HE hydrolase sequential L-alanine 52 






HO hydrolase DKR L-amino acid 53 
Fe (Hydrogenation-
racemization) 




Pd/Cu (Wacker oxidation) HO/Compart. 




Chiral alcohols 55,56 




concurrent Chiral amines 57 








Ru (metathesis) HO esterase (Hydrolysis) sequential 
Cyclic malonic acid 
monoesters 
59 




Ru (metathesis) HC MAO-N (Aromatizing) concurrent Pyrrolines 61 
Pd (Suzuki-coupling) HO ADH (Ketone reduction) 
concurrent 
/sequential 
Chiral biaryl alcohol 62,63 





















Au (cycloisomerization) HO lipase (hydrolysis) concurrent 2,5-dihydrofurans 67 
Au (hydroakyloxylation) 
Ru (olefin isomerization) 







HO ADH Concurrent 1,3-Diols  69 
Potassium phosphate 
(cyclization)  




Abbreviation: HO: homogeneous catalysts, HE: heterogeneous catalysts, Compat.: compartmentalization, Supramol. 





Figure 1.6. Concurrent olefin cross-metathesis/epoxidation of 10-undecenoic acid with trans-3-
hexene.  
Chemocataysts have also been extensively used to support the catalytic function of enzyme. 
The practical applications of one of the largest classes of enzymes, oxidoreductases, contributing 
to producing critical chemicals and pharmaceuticals, are limited by the dependence on high cost 
and instable cofactors that have to be regenerated. So far, NADP(H) regeneration by enzymes has 
been well-developed and applied practically at industrial scale. However, large quantity of water-
soluble byproducts generated causes enzyme deactivation and requires costly downstream 
purification. As a result, more cofactor generation methods have been researched and developed 
to target the goals of sustainability and productivity, including chemical, homogeneous catalytic, 
electrochemical, photocatalytic and heterogeneous catalytic approaches.71,72 Importantly, visible-
light photoredox catalysis has entered the realm of biocatalysis to form a synergistic framework to 
circumvent the application of cofactors.73-75 Recently, Park and co-workers employed eosin Y as 
a photosensitizer directly transferring photoinduced electrons to P450 heme domain under 
illumination.76 Instead of coupling with oxidation enzyme, Park and co-workers realized the direct 
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activation of ene-reductases by transferring photoexcited electrons from xanthene dyes to 
prosthetic flavin moiety, for the asymmetric reduction of C=C bonds.76 Although this technology 
is still in its infancy, it is the first case to realize direct electron transfer from water to enzyme with 
O2 as the sole by product.  
 
1.3.2.3. Novel Strategies to Combine Transition Metals and Enzymes in One-pot Tandem 
Reactions 
Incompatibility of the individual reaction steps with one another is the major challenge to 
combining transition metal catalysts with biocatalysts in one-pot. Besides immobilized lipases and 
serine proteases, the majority of biocatalysts have poor stability in organic solvents. Most of the 
transition metal catalysts are not active in aqueous solution. Mutual inactivation also occurs 
frequently due to the coordination of the transition metal complex to the protein catalysts. In this 
section, we will discuss some novel strategies developed so-far to combine transition metals and 
enzymes in one-pot, including supramolecular assemblies, artificial metalloenzymes, 
compartmentalization, whole cells, and co-immobilization (Table 1.2). 
Table 1.2. The novel strategies to couple transition metals (or chemical catalysts) with enzymes 
in one-pot tandem reactions.  
 




• realize catalytic activity of metal 
catalysts in aqueous solution  
• stabilize metal complexes and 
improve turn over number (TON) 
• prevent interaction of metal 
complexes with enzymes 
• provide extra selectivity of metal 
catalysts 
• Au or Ru in tandem with esterase, 
lipase, ADH;  
• Ir in tandem with oxidoreductases  
Compartmentalization • protect enzyme from organic 
solvent  
• protect metal catalysts from 
aqueous solution  
• prevent mutual inactivation  
• Ru in tandem with decarboxylase;  
• proline in tandem with ADH;  
• Wacker oxidation in tandem with 
enzymatic reduction or 
hydroamination   
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Table 1.2. cont. 
 
Whole-cell • protect biocatalysts from metal 
catalysts 
• prevent interaction of metal with 
cellular components  
• avoid protein purification  
• Pd(0)-catalyzed reduction in 
tandem with monoamine 
oxidation  
Co-immobilization • stabilize metal catalysts  
• improved synergic effect   
• catalyst regeneration  
• CALB and Pd nanoparticles co-
immobilized into the mesoporous 
silica for DKR of amine  
 
Incorporation of transition metal complexes within supramolecular hosts is a valuable way 
to solve those problems. A long-term goal of supramolecular chemistry is construction of 
assemblies that mimic the desirable qualities of protein catalysts.77 It has been found that 
supramolecular assemblies could stabilize reactive metal complexes and increase their turn over 
numbers.78 Additionally, supramolecular complexes enable the catalytic activity of several 
transition metal catalysts in water by providing a bio-inspired hydrophobic cavity.79-81 Importantly, 
supramolecular cage prevents the direct interaction of transition metal with enzymes, thereby 
averting their mutual inactivation.68,82 Lastly, supramolecular assemblies provide extra stereo-, 
regio- and enantio-selectivity by providing a well-defined cavity for the reaction compared with 
the reaction performed in bulk solvent.83,84 Using a supramolecular approach, Toste and coworkers 
created various tandem reactions employing esterases, lipases or alcohol dehydrogenase with gold 
(I) or ruthenium (II) complexes encapsulated in a Ga4L6 tetrahedral supramolecular cluster without 
mutual inactivation (Figure 1.7).68 Their findings suggested that supramolecular assemblies may 
provide a general strategy for carrying out classic organic reactions in tandem with enzymatic 




Figure 1.7. A, Esterase- or lipase-mediated acetate hydrolysis followed by Au (I)-catalyzed 
hydroalkoxylation. B, Ru(II)-mediated olefin isomerization followed by ADH-catalyzed 
reduction.68 
Artificial metalloenzyme resulting from encapsulation of transition metal catalyst within a 
protein scaffold is a special form of supramolecular host-assemblies. Ward and coworkers 
developed an artificial (R)-selective transfer-hydrogenase (ATHase) by incorporation of a 
biotinylated [Cp*Ir(Biot-p-L)Cl] complex within streptavidin (Sav). Sav worked as a neutral 
shield for the Ir complex to keep it from interacting with other biocatalysts. In that way, they 
successfully combined ATHase with various NADH-, FAD- and haem-dependent enzymes 
resulting in orthogonal redox cascades that could not be achieved when the free Ir-complex was 
used,82 including a double stereoselective amine deracemization, production of L-pipecolic acid 














Figure 1.8. A, (S)-selective monoamine oxidase (MAO-N) was coupled with (R)-selective 
ATHase for double stereloselective deracemization of amines. B, Production of L-pipecolic acid 
from L-lysine by combining (S)-selective ATHase with an L-amino acid oxidase (LAAO) and a 
D-selective amino acid oxidase (DAAO). Catalase was used to decompose H2O2 generated in 
both cases.82   
Compartmentalization is another strategy to couple chemical catalysts with biocatalysts in 
one-pot by protecting the enzymes from the organic solvent or metal catalysts from cellular 
components; as well as shielding catalytic centers from one another to avoid mutual inactivation. 
Besides the traditional biphasic system,85 more novel methods have been developed for 
compartmentalization purpose including hydrogel immobilization, membrane filtration and 
whole-cell isolation. Gröger and coworkers realized enzymatic decarboxylation58 and alcohol 
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dehydrogenation86 in organic solvent by encapsulating the enzymes in poly(vinyl 
alcohol)/poly(ethylene glycol) cryogels or acrylate-based superabsorbent polymer respectively. 
They coupled these two enzymes with ruthenium-catalyzed metathesis and a proline-derivative-
catalyzed aldol reaction for efficient preparation of antioxidants 4,4’-dihydroxystilbene and 1,3-
diols separately. In another study, they combined Wacker oxidation with enzymatic reduction or 
hydroamination in a one-pot process in aqueous media by withholding the detrimental effect of Cu 
ions from biotransformation in the interior of a polydimethylsiloxane thimble (PDMS) that only 
enabled the free exchange of organic chemical (Figure 1.9).55,57 
 
Figure 1.9. Site-isolation of catalysts using a PDMS thimble for the combination of a Wacker 
oxidation and an enzymatic reduction catalyzed by ADH or transamination catalyzed by 
transaminase.55 
Although supramolecular strategies have enabled the catalytic activity of several transition 
metal catalysts in aqueous environment, many metal cofactors are still inhibited by the cellular 
components and therefore require purified protein for tandem reactions in most cases. Using 
cellular membrane as a barrier to protect metal catalysts from cellular inhibitors is an attractive 
strategy. Recently, Ward and coworkers created an E. coli strain for periplasmic expression of Sav 
with a biotinylated Hoveyda-Grubbs catalyst for olefin metathesis in vivo.87 The periplasm 
provided an environment with low concentrations of inhibitors for metathesis and thus enabled the 
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high-throughput directed evolution of artificial metalloenzymes in vivo. Additionally, the use of 
whole cell provides a natural protection for biocatalysts. Lloyd and coworkers prepared (R)-1-
methyltetrahydroisoquinoline (MTQ) with 96% ee by a cooperative tandem reaction consisting of 
enantioselective monoamine oxidation catalyzed by an engineered E. coli strain and nonselective 
reduction catalyzed by nanoscale Pd (0) coated on the cell surface (Figure 1.10).51  
 
Figure 1.10. The cyclic deracemization of MTO through MDQ using palladized biocatalysts 
with the monoamine oxidase-N insert.51  
Another interesting strategy to enable chemo-enzymatic reactions in one pot is to create 
hybrid enzyme-metal nanoparticles that bear orthogonal but cooperative catalytic centers. This 
design straddles the disciplines of supramolecular and compartmentalization. The peptide is a 
robust biomaterial and can stabilize the performance of inorganic catalysts.88 The resulting 
enzyme-metal complex could work as a metalloenzyme with the catalytic activity originated from 
the introduced metal. Significantly, the surrounding proteins not only serve as protecting cage but 
also work as catalysts for distinct bioactivity.88-90 In one example, Bäckvall and coworkers created 
a hybrid catalyst consisting of CALB and Pd nanoparticles co-immobilized into the compartments 
of mesoporous silica for DKR of 1-phenylethylamine.90 The co-immobilization resulted in a more 
efficient cooperation between two catalysts and recyclability of both Pd nanoparticles and CALB 




Figure 1.11. DKR of amine with a bifunctional catalyst in which Pd nanoparticles and CALB 
are co-immobilized in the same pore of siliceous mesocellular foams.90 
1.4 Whole Cell Biocatalysis 
Chemical synthesis is a well-established route for bulk manufacturing of nutraceuticals, 
pharmaceuticals and other bulk chemicals. It lays the foundations for our daily life to provide 
necessities such as food, medicines and fuels. However, some drawbacks also exist in the process 
of chemical synthesis, such as unstable intermediates, multistep reactions, complex process control, 
etc., which result in high energy input, low production efficiency and tremendous waste generation. 
Those drawbacks are motivating the development of green and sustainable processes for chemical 
manufacturing. Cell factories-based production provides an attractive alternative to these 
challenges.  
Whole cell biocatalysis has several advantages. Microorganisms can convert renewable 
resources into fuels and value-added chemicals under mild fermentation condition that is 
environmentally friendly. Like proteins, whole-cell biocatalysis have relatively high selectivity 
over substrates and the products. High regio-, chemo-, diastereo- and enantioselectivity is very 
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desirable in chemical synthesis. Some chiral compounds or sophisticated chemicals that are 
challenges for chemical synthesis could be easily generated by biotransformation. The high 
specificity of biotransformation generally results in high catalytic efficiency, minimized side 
reactions and simplified downstream process. In addition, whole-cell biocatalysis has stronger 
tolerance against harsh reaction conditions compared with the naked enzymes. For example, the 
toxicity effect of concentrated substrates on enzyme could be largely alleviated by using 
microorganisms as a reaction unit. A few microorganisms have or can be engineered to have strong 
tolerance to elevated temperature or low pH.91,92 Last but not least, whole-cell biocatalysts allow 
for the facile implementation of enzymatic cascades that span multiple reactions, with an 
integrated supply of the myriad cofactors that are expensive but essential for complex 
biotransformation.93 This internal supply greatly simplifies cofactors regeneration and makes the 
addition of expensive external cofactors unnecessary.92 
Saccharomyces cerevisiae has been widely used in the industry for bioproduction of value-
added compounds or bulk chemicals such as ethanol, lipids,94 fatty acids,95 lactic acid,96 xylitol,97 
etc. Its “generally regarded as safe (GRAS)” status is suitable for large-scale operation. Unlike 
prokaryotes, S. cerevisiae has multiple organelles to compartmentalize different reactions. 
Furthermore, S. cerevisiae exhibits high tolerance against harsh industrial conditions, such as low 
pH and high glucose concentrations.98 Because microorganisms are evolved to maintain metabolic 
homeostasis under different conditions, their metabolisms must be intensively rewired to achieve 
high titer, rate, and yield for commercial production.  
As a model eukaryotic system, molecular and cell biology of S. cerevisiae has been studied 
in-depth with ample genetic engineering tools available. In addition, tremendous metabolic 
engineering strategies have also been developed on S. cerevisiae at the biological parts level, at 
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the pathway level, at the organelle level and at the systems levels.98 Those synthetic biology tools 
and metabolic engineering strategies play key roles in the science of rewiring cellular metabolism 
and has broad applications in cell factory development, including extended substrate scopes; 
increased production of the desired products; enabled production of novel compounds and 
improved cellular properties, such as tolerance to harsh industrial conditions. Among those 
strategies, there is growing interest to develop genome-wide engineering strategies for multiplex 
and precise genome editing of S. cerevisiae. Our lab has developed several genome-wide 
engineering tools such as, RNAi-Assisted Genome Evolution (RAGE),99 tri-functional CRISPR 
system for gene activation, interference and deletion (CRISPR-AID)100 and a CRISPR-CAS9 and 
homology-directed-repair-assisted-genome-scale engineering method (CHAnGE).101 Coupling 
those strategies with an automated cellular engineering platform, iBioFAB, we aim at engineering 
whole-cell biocatalysts with different properties in a high throughput manner.   
1.5 Project Overview  
My research was focused on designing and engineering of multi-step (bio) catalytic systems for 
selective synthesis of chiral building blocks of bioactive compounds or biodegradable polymers. 
In Chapter 2, my colleagues and I demonstrated that CRISPR-Cas9 can be used to efficiently and 
precisely introduce heterologous promoters into Streptomyces genomes for BGCs activation. I 
further applied this CRISRP-Cas9 promoter knock-in strategy in S. viridochromogenes to activate 
a few silent BGCs by precisely inserting strong constitutive promoters in front of target BGCs and 
successfully identified a new type II polyketide compound C22-1.102 This CRISPR-Cas9 mediated 
gene knock-out strategy was further used to narrow down the essential genes used for C22-1 
biosynthesis and a biosynthetic mechanism was proposed.  
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Inspired by the cooperated action of multiple enzymes for efficient synthesis, I started to 
combine transition metal catalysts with enzymes in one-pot to realize the synthetic power that 
cannot be achieved by using either of them. In Chapter 3, I described the development of a modular, 
one-pot, sequential chemoenzymatic system for the formal enantioselective construction of the C-
C bond in 2-aryl 1,4-dicarbonyl compounds. This sequence comprises a rhodium-catalyzed 
diazocoupling that provides >9:1 selectivity for heterocoupling of two diazoesters and a reduction 
mediated by an ene-reductase (ER), which occurs in up to 99% enantiomeric excess (ee). The high 
yield and enantioselectivity of this system result from the preferential generation of an (E)-alkene 
from the diazo coupling reaction and selective reduction of the (E)-alkene in a mixture of (E) and 
(Z) isomers by the ER. Screening of a panel of ERs revealed that OPR1 from Lycopersicum 
esculentum catalyzes the reduction of bulky tert-butyl or benzyl esters to afford chiral diesters that 
are poised for orthogonal reactions at the two distinct ester units of the product. Overall, this work 
demonstrates the benefit of combining organometallic and enzymatic catalysis to create unusual 
overall transformations that do not require the isolation and purification of intermediates.66 
The system developed in Chapter 2 has a few disadvantages. First, diazocoupling reaction 
is hard to scale up due to its strict reaction condition and explorable raw materials. However, if we 
prepare alkenes by the most convenient or scale-up friendly ways like Wittig-type reactions or 
olefin metathesis, we would obtain racemates with diastereomer unflavored by the ERs. In such 
case, our old system will result in low yield. This challenge inspired us to develop a new class of 
cooperative chemoenzymatic reactions that combine photocatalysts that isomerize alkenes with 
ene-reductases that reduce carbon-carbon double bonds to generate valuable enantioenriched 
products. In Chapter 4, we demonstrated that this method enables the stereoconvergent reduction 
of E/Z mixtures of alkenes or reduction of the unreactive stereoisomer of an alkene in yields and 
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ee’s that match those obtained from the reduction of the pure, more reactive isomer. This new 
cooperative system overcomes the limitations of both individual catalysts and affords a range of 
synthetically valuable and biologically active enantioenriched compounds. More generally, these 
results illustrate the value of driving a chemical reaction with light to ensure compatibility between 
the chemical and enzymatic catalysts.103 
Microbial lactic acid (LA) production under acidic fermentation conditions is highly 
desirable to reduce the production cost. However, overcoming the acid toxicity remains a major 
challenge. To develop whole-cell biocatalysis with higher tolerance to an industrially preferred 
low pH environment, in Chapter 5, I applied RAGE and CRISPR-AID guided genome-wide 
engineering methods to engineer S. cerevisiae and identify a few mutant strains with up to 3-fold 
improved acid tolerance and 1.5-fold higher LA production compared with the parent strain. The 
best mutant strain could produce 52 g/L LA in fed-batch fermentation with minimum medium at 
pH 3. In addition, to establish an Automated Cellular Engineering (ACE) platform, I developed a 
growth-based LA biosensor and an automated quantification assay by BioProfile Analyzer. 
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CHAPTER 2. Activation and Characterization of 
Biosynthetic Gene Clusters (BGCs) in Streptomyces 
viridochromogenes Using CRISPR-Cas System  
2.1 Introduction 
Streptomyces are among the most prolific and well-studied producers of diverse secondary 
metabolites that are rich sources of drugs and biologically active compounds.1 Genome sequencing 
efforts have identified a tremendous number of silent gene clusters encoding unknown secondary 
metabolites that have never been detected under laboratory conditions. Importantly, they have 
revealed a much larger capacity for biosynthesis of specialized natural products than previously 
thought. Study of these pathways also enables us to discover new enzymes with uncharacterized 
functionality and also to elucidate new biosynthetic mechanism, which greatly facilitates rational 
design of multi-step catalysis for selective synthesis of valuable compounds.   
Silent biosynthetic gene clusters (BGCs) can be activated by either: (i) manipulating of the 
native organisms or (ii) heterologously expressing silent BGCs in suitable hosts such as S. 
coelicolor, S. lividans, and S. albus.2 With the advent of recombinant DNA and synthetic biology 
technologies that enable efficient capture and refactoring of BGCs, heterologous hosts are 
increasingly employed for microbial natural product production. Those hosts have been well 
studied and plenty of genetic manipulation tools are available. However, the main drawback of a 
heterologous production system is the lack of critical biosynthetic precursors of enzyme function, 
which differ for different classes of BGCs. On the other hand, native hosts have all essential 




To expand the tools for genome editing of Streptomyces, we reconstituted Type II CRISPR 
(clustered regularly interspaced palindromic repeats) system in S. albus, S. lividans, and S. 
viridochromogenes to delete genes and BGCs or introduce point mutations with high efficiency 
(60-100%).3 Type II CRISPR-Cas9 technology has revolutionized genome engineering, enabling 
the genetic manipulation of a number of genetically recalcitrant organisms. Compared to other 
site-specific genome engineering technologies, the Cas9 nuclease can be directed to nearly any 
site on the genome simply by transcribing a synthetic guide RNA (sgRNA), requiring only a 
protospacer adjacent motif (PAM) sequence at the target site. Streptococcus pyrogens Cas9 PAMs 
(NGG) are especially abundant in the GC-rich Streptomyces genomes, greatly increasing the 
number of potential target sites and coverage of CRISPR-Cas9 genome editing in these prolific 
natural product producers.  
In this study, my colleagues and I demonstrated that CRISPR-Cas9 can be used to 
efficiently and precisely introduce heterologous promoters into Streptomyces genomes for BGC 
activation. We performed proof of concept experiments in model Streptomyces species: 
Streptomyces albus and Streptomyces lividans. I further applied this CRISRP-Cas9 promoter 
knock-in strategy in S. viridochromogenes to active a few silent BGCs by precisely inserting strong 
constitutive promoters in front of BGCs and successfully identified a new Type II PKS compound. 
My colleagues simultaneously applied this strategy to S. roseosporus and S. venezuelae to activate 





2.2 Results and Discussion  
2.2.1. CRISPR-Cas9 Strategy for Promoter Knock-in in Streptomyces Species  
To demonstrate that CRISPR-Cas9 can be used to precisely insert strong constitutive promoters 
into Streptomyces genomes for BGC activation, we selected the indigoidine (BLUE) cluster in S. 
albus as well as the actinorhodin (ACT) and undecylprodigiosin (RED) clusters in S. lividans. 
These transcriptionally silent BGCs have been characterized and their pigmented products make 
them excellent model clusters for testing our strategy for cluster activation.5 Using CRISPR–Cas9-
mediated knock-in, we replaced the upstream promoter regions of the main biosynthetic operons 
with a strong constitutive promoter kasO*p that worked in multiple Streptomyces species (Figure 
2.1A) and successfully activated ACT and RED gene clusters (Figure 2.2B).4 
In S. albus, CRISPR-Cas9 mediated double-stranded breaks upstream of the indigiodine 
synthetase gene significantly enhanced the knock-in efficiency of the constitutive kasO*p 
promoter (Figure 2.1B). The higher knock-in efficiency observed with editing templates 
containing 2 kb compared to 1 kb homologous arms was consistent with homology-directed repair 
mechanism of the double-stranded breaks. Co-introduction of heterologous genes, such as ~1 kb 
thiostrepton-resistance cassette (tsr) together with kasO*p, was also achieved at lower efficiencies, 
but still more efficient than inserting kasO*p alone by simple homologous recombination.4  
These results showed that CRISPR-Cas9 can be used to precisely introduce heterologous 
genetic elements into the genome of Streptomyces model strains at high efficiencies. Additionally, 
these relatively minor genetic manipulations can be enough to activate silent BGCs and trigger 
production of the encoded metabolites. Additionally, we also test the CRISPR-Cas9 guided 
promoter knock-in in other non-model Streptomyces species such as S. viridochromogenese, S. 
38 
 
roseosporus and S. venezuelae. The enhanced knock-in efficiencies observed in all cases would 
enable us to use donor DNA with shorter homology flanks as well as introduce larger genetic 
elements, both of which would have been challenging without the CRISPR-Cas9 system. Although 
homologous recombination occurs efficiently in some Streptomyces species like S. albus and S. 
lividans, the efficiency increase by CRISPR-Cas9 is essential in allowing genetic manipulation of 
otherwise challenging strains such as S. roseosporus (Figure 2.1B).   
 
Figure 2.1. CIRPSR-Cas9-based promoter knock-in strategy to activate silent biosynthetic gene 
clusters in sterptomyces. (A) Using CRISPR–Cas9, efficient and precise introduction of promoter 
cassettes (red-shaded arrows) drives expression of biosynthetic genes (blue) and triggers 
theproduction of unique metabolites (*) that are not detected in the parent strain. (B) Knock-in 
efficiencies with and without use of CRISPR–Cas9 in different Streptomyces species: (1) S. albus, 
(2) S. lividans, (3) S. roseosporus, and (4) S. venezuelae, (5) S. viridochromogenes. For S. albus, 
the knock-in efficiencies for different-sized inserts (100-bp versus 1-kb) using editing templates 
with different homology lengths (1-kb versus 2-kb) were examined. No knock-in was observed for 
S. roseosporus without CRISPR–Cas9. n.d., not determined. (C) Wild-type (wt) or indicated 
engineered S. albus strains on MGY or MGY + thiostrepton plates. (D) Wildtype and engineered 
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S. lividans strains with activated RED (left) or ACT (right) clusters on MGY plates. Ammonia 
fuming confirmed production of pH-sensitive actinorhodin-related pigments 
2.2.2. Activation Silent Biosynthetic Gene Clusters (BGCs) in Streptomyces 
viridochromogenes  
S. viridochromogenes is known to produce phosphinothricin, a well-known herbicide that 
irreversibly inhibits glutamine synthetase.6 Besides, there are additional 32 uncharacterized BGCs 
of secondary metabolites based on antiSMASH analysis (Table 2.1).7 Additionally, CRISPR-Cas9 
system has highest editing efficiency in S. viridochromogenes based on a previous study.8 It would 
be valuable and convenient to activate silent BGCs in this species. Target BGCs were chosen based 
on the following criteria: i) the BGCs must be uncharacterized, ii) the similarity between the 
selected BGCs and the characterized gene clusters in other species should be less than 70%; iii) 
most of the biosynthetic genes should be in the same operon. 7 BGCs were selected for activation, 










Table 2.1. AntiSMASH analyses of S. viridochromogenes DSM 40736 (NCBI Reference 
Sequence: NZ_ACEZ 00000000.1). 
Cluster Type From To Compound Study 
Cluster 1 Terpene-nrps-t1pks 147228 209213   
Cluster 2 Melanin-terpene 350984 374124   




925309 1004775   
Cluster 5 Lassopeptide 996947 1020529   
Cluster 6 T1pks 1023099 1074657 m/z 439 This study 
Cluster 7 T1pks 1068135 1123254 No New peak This study 
Cluster 8 Nrps-t1pks 1124345 1179652   
Cluster 9 Nrps-phosphonate 1172570 1240729 Phosphonothricin 
Metcalf et 
al, 20059 
Cluster 10 Ectoine 1986466 1997781 Ectoineb  
Cluster 11 NRPS-t1PKS 2482772 2542826   
Cluster 12 Terpene 2721388 2743906   
Cluster 13 Lassopeptide 3108492 3120837   
Cluster 14 Melanin 3108492 3120837   
Cluster 15 Siderophore 4468051 3223680   
Cluster 16 Butyrolactone 5785193 4479215   
Cluster 17 Lantipeptide 4691917 4720311   
Cluster 18 T1pks 4852429 4915920   
Cluster 19 Linaridin 4917000 4938204   
Cluster 20 Lantipeptide-nrps 5099822 5150004 No new peak This study 
Cluster 21 Terpene 5973704 5895857   
Cluster 22 T2pks 6046899 6089394 C22-1 This study 
Cluster 23 Siderophore 6516102 6529476   
Cluster 24 T1pks 6568627 6618163 No New peak This study 
Cluster 25 Ectoine 6692399 6703527   
Cluster 26 Bacteriocin 6914884 6926688   
Cluster 27 Terpene 6959775 6982425   
Cluster 28 Siderophore 7169194 7182469   
Cluster 29 Terpene 7611221 7638254   




8164951 8193467   
Cluster 32 T1pks 8282728 8326427 m/z 524 This study 
Cluster 33 Other 8476453 8521258   
a.100% of genes show similarity with coelichelin BGC of S. ceolicolor A3(2)10,11 
b100% of genes show similarity with ectoine BGCs of S. chrysomallus.12 
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For pathway-specific activation, we targeted single (kasO*p) or bi-directional (kasO*p-
rcfp) promoter cassettes to the start of the first ORF(s) of the main biosynthetic operon(s) predicted 
based on gene directionality alone (Figure 2.2A, B). The overall knock-in efficiency varied from 
80% to 100%. Introduction of bidirectional promoter cassettes into additional clusters of S. 
viridochromogenes led to overproduction of a compound that was poorly produced in the parent 
strain. For example, cluster C32 was predicted to encode a nucleoside type I polyketide synthase 
(PKS). It may be an iterative type I PKS where core catalytic domains occur on a single module 
that is used repetitively to generate the entire polyketide backbone. The core catalytic domains 
including ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP). The insertion 
of bidirectional promoter kasO*p and rcfp between the main gene module encoding a loading 
domain, PKS core catalytic domain, and an important decoration domain, aldo/keto reductase, 
triggered the overproduction of a major metabolite with m/z 524 by more than 10 thousand folds 
(Figure 2.2C).  
Introduction of a single promoter cassette upstream of the main synthetic containing-
operons activated the cryptic pathway and led to production of unique compounds that were not 
observed in the parent strains (Figure 2.2D and Figure 2.3). For example, a distinct compound with 
m/z 440 observed for another engineered S. viridochromogenes strain in which kas*Op was 
introduced upstream of a major operon including a few polyketide synthase modules encoding a 




Figure 2.2. Activation of biosynthetic gene clusters (A) C32 and (B) C6 in S. viridochromogenese. 
C) HPLC analysis of ethyl acetate extracts from wild-type S. viridochromogenese (black) and an 
engineered strain (red) in which kasO*p and rcpf bidirectional promoter was introduced in cluster 
32. The UV wavelength of detection is at 280 nm. Major metabolites uniquely produced by the 
engineered strains are not observed in wild-type strains are highlighted with indicated m/z value at 
524. D) HPLC analysis of ethyl acetate extracts from wild-type S. viridochromogenese (black) and 
an engineered strain (red) in which kasO*p promoter was introduced in cluster 6. The UV 
wavelength of the detection is at 210 nm. Major metabolites uniquely produced by the engineered 
strains are not observed in wild-type strains are highlighted with indicated m/z value at 439.  
2.2.3. Identification and Characterization of Novel Type II PKS Compound C22-1  
C22 (NZ_GG657757) was predicted to be a silent, uncharacterized type II PKS gene cluster. Based 
on protein-protein BLAST analysis, this operon contains evolutionarily conserved genes of type 
II PKS, including a ketosynthase KSα (SSQG_RS26900), chain-length factor KSβ 
(SSQG_RS26905), acyl carrier protein ACP (SSQG_RS26910), and three polyketide cyclases: 
TcmJ (SSQG_RS26895), TcmN (SSQG_RS26915) and TcmI (SSQG_RS26920). This core part 
has the same gene arrangement as the spore-pigment BGC in S. avermitilis (AB070937.1) with 
protein sequence homologies ranging from 64%-84%. Additionally, there are three extra tailoring 
enzymes: amidohydrolase (SSQG_RS26925), FAD-hydroxylase (SSQG_RS26930), and 
cytochrome P450 (SSQG_RS26935).  
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Compared to the wild type S. viridochromogenes, the engineered strain S. 
viridochromogenes-895 in which kas*Op was inserted in front of the main biosynthetic operon, 
SSQG_RS26895-RS26920 secreted an obvious brown pigment in both liquid and solid MYG 
medium before sporulation with a major unique metabolite C22-1 observed by HPLC (Figure 2.3). 
HRMS of the C22-1 predicted a molecular formula C23H16O (Figure 2.5). 
1H NMR, 13C NMR, 
COSY/TOCSY, HSQC and HMBC analyses revealed a novel polyketide with a dihydrobenzo [α] 
naphthacenequinone core that is shared by a family of polyketides including frankiamycin, 
benastatin, and pradimicin13 (Figure 2.3C). The cyclohexanone (ring E) in C22-1 is atypical and 
has not been observed for pentangular aromatic polyketides.14 
 
 
Figure 2.3. Activation of type II PKS biosynthetic gene cluster in S. viridochromogenes resulted 
in a mutant S. viridochromogenes-895 yielding a novel pigmented compound. (A) Partial 
schematic of NZ_GG657757 containing majority of biosynthetic genes (orange) and the position 
of promoter knock-in. (B) Production of brown pigment by the engineered strain and not wild type 
(wt) S. viridochromogenes on MGY medium. (C) HPLC analysis of extracts from an engineered 
S. viridochromogenes strain harbouring a kasO*p knock-in before SSQG_RS26895 (bottom) 
compared to that from the parent strain (top). Indicated is the major metabolite C22-1 that is 
uniquely produced by the engineered strain. (D) Chemical structure of compound C22-1. The five 




2.2.4. Investigation the Biosynthetic Mechanism of C22-1 
Based on the study of evolutionary chemical diversity by coordinated gene swaps in type II 
polyketide gene clusters,14 C22, similar to other BGCs annotated as spore pigments, belongs to 
ancestor 3 that is the antecedent of other aromatic polyketides with carbon ranging from 20-24, 
including most of identified bioactive compounds: Frankiamycin, Pradimicin, Benastatin, 
Medermycin, etc. Ancestor 3 is a big category and around 50% aromatic polyketides gene clusters 
belong to this family. More analyses have been done to locate the position of C22 in this big family. 
The whole gene cluster was blasted against a library of 480 Streptomyces species. 232 out of 480 
contain conserved synthetic genes (I-VII) arranged in the order as shown in Figure 2.4. Those 
clusters annotated as spore pigment should produce aromatic polyketides with similar core 
structures. Interestingly, when taking other tailoring enzymes into consideration, C22 belongs to a 
very special group (Figure 2.4), 15 out of 232, which have the most tailoring enzymes, including 
cytochrome P450 and amidohydrolase that cannot be found in other groups.  
 
Figure 2.4.  Schematic of major genes in different categories of Type II PKS gene clusters 
annotated as spore pigments. whiE-, sch- and cur- are all from category C.   
Real time qPCR was performed to elucidate the expression level of SSQG_RS26925, 
SSQG_RS26930 and SSQG_RS26935 in both wild type and mutant S. viridochromogenes-895. 
Gene KSα was only transcribed in the mutant S. viridochromogenes-895, which further proved that 
the silent gene cluster C22 was activated by introducing kasO*p in front of the core operon. Minor 
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expression of amidohydrolase (925), FAD-hydroxylase (930) and P450 (935) was detected in S. 
viridochromogenes-895. Interestingly, P450 was also detected in wildtype and it may not belong 
to the cluster C22 (Figure 2.5A).  
To investigate whether SSQG_RS26925, SSQG_RS26930, and SSQG_RS26935 were 
involved in the biosynthesis of C22-1 or any other additional new compounds, we created S. 
viridochromogenes-895-OE where SSQG_RS26925, SSQG_RS26930, and SSQG_RS26935 
were cloned in an operon and overexpressed by the constitutive strong promoter psf in an 
integration plasmid pET616. The kanamycin resistance gene was used as a reporter to confirm the 
translation of the whole operon (Figure 2.5C).  We also created S. viridochromogenes-895-KO 
with SSQG_RS26925, SSQG_RS26930, and SSQG_RS26935 being knocked out. Since the 
hypothetical protein SSQG_RS26890 is also a conserved gene in BGCs for spore pigment 
synthesis, S. viridochromogenes_kasO*p-890 was created by locating kasO*p in front of 
SSQG_RS26890. It is interesting to find that all mutants shared the same metabolic profile (Figure 
2.5B). Including the characterized C22-1, there are 8 major new peaks with retention time at 21.1, 
21.8, 22.5, 24.8, 25.1, 25.4, 26.2, and 26.4 min respectively compared with the wild type. C22-1 
(21.1 min) was the major product if the fermentation took more than 10 days. Compound C22-3 
(22.7 min), C22-4 (26.3 min) and C22-5 (26.5 min) were the major product if the fermentation 
were extracted within 5 days. They have m/z at 450, 546.5 and 547.5, respectively. Those data 
proved that SSQG_RS26925, SSQG_RS26930, and SSQG_RS26935 did not participate in the 




Figure 2.5. A) RT-qPCR analysis of S. viridochromogene-kas*Op-895, cluster 22. Relative gene 
expression of each indicated gene after normalization to the sigma factor for both wild type (blue) 
and engineered (red) strains. Error bars represent the standard deviation of biologically triplicates. 
(B) HPLC analysis of extracts from several engineered S. viridochromogenes strains compared to 
that from the wild type. Without specification, the fermentation took 5 days. (C) Part of scheme of 
pET616-pcf-SSQG-RS26930-925-935-neo for overexpression of SSQG-RS26930, 925 and 935 in 
a single operon.  
Based on the experimental data, the hypothetical biosynthetic mechanism of C22-1 was 
proposed as in Figure 2.6. The minimal polyketide synthase (min-PKS) consists of three proteins: 
KSα KSβ and ACP. The nascent polyketide chains consisting of 24 carbons, are constructed by 
iterative condensation of malonyl-CoA catalyzed by min-PKS. The reactive beta-keto chains are 
converted into hypothetical intermediate 1 by the action of tailoring enzymes TcmN, TcmI and 
TcmJ. It is not very clear how 1 was converted to C22-1. The reduction may occur spontaneously 
or catalyzed by another FAD-hydroxylase. Another major product C22-3 was also isolated and 
high-resolution electrospray ionization mass spectrometry in negative mode showed an m/z of 
449.1490 (calculated: 450.1490). However, we failed to characterize its structure since C22-3 was 
not stable in any tested NMR solvents. C22-1 was the only stable compound derived from gene 
cluster C22.  
Up to now, three BGCs have been experimentally related to spore pigments production. 
They are cur- from Streptomyces curacoi,15 sch- from Streptomyces halstedii,16 and whiE- spore 
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pigment cluster from Streptomyces coelicolor.17 However, none of them has been structurally 
elucidated. Although ectopic expression of the whiE-, sch- and cur- spore pigment gene clusters 
led to the isolation of polycyclic aromatic polyketides, those partially cyclized compounds were 
more likely to be fragments instead of the fully cyclized products. Thus, C22-1 was the only 
characterized structure of spore-pigment up to date.   
 
 
Figure 2.6. Proposed mechanism of C22-1 biosynthesis.  
2.3 Conclusion  
In this study, we showed that relatively small genome perturbations in the form of promoters being 
strategically introduced by CRISRP-Cas9 strategy are sufficient to activate the silent BGCs of 
different classes in multiple Streptomyces species with high to excellent efficiency, including type 
I (this study), type II (this study), and type III (our collaborator’s work), non-ribosomal peptide 
synthetase (NRPS, our collaborator’s work), hybrid PKS-NRPS (our collaborator’s work) and 
non-ribosomal peptide synthetase (NRPS, our collaborator’s work). With this strategy, one out of 
seven BGCs were overexpressed and 2 out of seven BGCs were activated. A novel type II PKS 
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compound C22-1 was characterized and it was the first fully characterized compound with 
completed cyclization corresponding to the spore pigment.  
2.4 Experimental Procedures  
2.4.1. Reagents and Media  
Unless otherwise indicated, all reagents are obtained from Sigma. 1 L of MGY medium contains 
10 g malt extract broth, 4 g Bacto yeast extract (BD Biosciences), 4 g glucose (1st Base, Axil 
Scientific) and for MGY agar plates, an additional 20 g of Bacto agar (BD Biosciences). 
Conjugation experiments involving WM6026 and WM3780 E. coli strains were performed on R2 
agar without sucrose: 0.25 g K2SO4, 10.12 g MgCl2.6H2O, 10 g glucose, 0.1 g Bacto casamino 
acids (BD Biosciences), 5.73 g TES, 20 g agar in 1 L water, autoclaved, after which 1 mL filter-
sterilized 50 mg/mL KH2PO4 solution and filter-sterilized 2.94 g CaCl2.2H2O and 3 g L-proline 
in 5 mL 1 N NaOH were added to the medium. 
2.4.2. Strains and Growth Conditions   
Strains and plasmids used in this study are listed in Table 2.2. Unless otherwise indicated, strains 
are propagated in MGY medium at 30 °C. Spore preparations and conjugation protocols were 
similar to those described by Keiser and Bibb.18 For spore preparations, 1:1000 of a spore 
preparation or 1:100 dilution of a saturated seed culture is plated on MGY plates and incubated at 
30 °C until thick spores are observed. Spores were removed from the plate using 5-mm glass beads 
(Sigma) and resuspended in sterile TX buffer (50 mM Tris, pH 7.4, 0.001% (v/v) Triton X) by 
vigorous vortexing for 30 s. The eluant containing free spores was pelleted by spinning at 
maximum speed in an Eppendorf 5810R centrifuge for 10 min, resuspended in 1 mL sterile water 
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and re-pelleted. The spores were then resuspended in water and stored at -80 °C. A typical spore 
prep contains ~107–109 spores per milliliter as determined by serial dilution plating.  
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2.4.3. Construction of Genome Editing Plasmids 
All DNA manipulations were carried out in Escherichia coli DH5α or NEB5α (New England 
Biolabs). Primers used in this study are listed in Table 2.3. Restriction enzymes were obtained 
from New England Biolabs. Helper pCRISPomyces-2 plasmids for making promoter knock-in 
50 
 
constructs were made by ligating adaptor sequences, containing restriction sites flanking the 
promoter of choice (Figure 2.7) to facilitate insertion of homology arms at the XbaI site of 
pCRISPomyces-2.8 The protospacer of a target cluster was first inserted via BbsI-mediated Golden 
Gate Assembly as previously described8. The helper plasmid (pCRISPomyces-2-kasO*p, 
pCRISPomyces-2-rcfp-kasO*p) was linearized using SpeI and assembled with the downstream 
homology arm (2-kb unless otherwise indicated) by Gibson assembly (New England Biolabs). The 
second upstream homology arm (2-kb unless otherwise indicated) was subsequently inserted by 
Gibson assembly using HindIII or NheI linearized construct containing the first homology arm. 
See Figure 2.8 for workflow to construct genome editing plasmids. 
Table 2.3. Oligonucleotides used in this study  
Primers Sequence Comments 
Complementary oligonucleotides for BsaI Golden Gate asssembly of protospacers. 20 bp protospacer 
sequences are represented in lowercase letters. 
pCm2-C22-for ACGCccatggtccgtctccaaggt 
Cluster 22 protospacer in S. viridochromogenes 
pCm2-C22-rev AAACaccttggagacggaccatgg 
pCm2-C24-for ACGCccccgtgtagctgcacaggg 
Cluster 24 protospacer in S. viridochromogenes 
pCm2-C24-rev AAACccctgtgcagctacacgggg 
pCm2-C32-for ACGCctcaactcccccacacagaa 
Cluster 32 protospacer in S. viridochromogenes 
pCm2-C32-rev AAACttctgtgtgggggagttgag 
pCm2-C17-1-for-v2 ACGCccgccatcagaattcgcctg 
Cluster 17 protospacer in S. viridochromogenes 
pCm2-C17-1-rev-v2 AAAC ccgccatcagaattcgcctg 
pCm2-C20-2-for ACGCgccaactcctctgagtaaat 
Cluster 20 protospacer in S. viridochromogenes 
pCm2-C20-2-rev AAACatttactcagaggagttggc 
pCm2-C16-for ACGCggggtatggcgcgttctcga 
Cluster 16 protospacer in S. viridochromogenes 
pCm2-C16-rev AAACtcgagaacgcgccatacccc 
pCm2-C6-1-for ACGCctcgatgagatcgccgatgg 























Figure 2.7. Constitutive promoters used for cluster activation. (A) sequences of constitutive 
promoters used in this study; (B, C) scheme and sequences of adapters introduced into 
pCRISPomyces at the XbaI site for making (B) monodirectional and (C) bidirectional promoter 





Figure 2.8. Workflow for constructing genome editing plasmid for promoter knock-in. Helper 
pCRISPomyces-2 plasmid (e.g. pCRISPomyces-2-kasO*p) for making promoter knock-in 
constructs were made by ligating adapter sequences, containing restriction sties flanking the 
promoter of choice to facilitate insertion of homology arms into pCRISPomyces-2. The 
protospacer of a target cluster was first inserted via BbsI-mediated Golden Gate Assembly. The 
final editing plasmid was achieved by sequential insertion of the first and second homology arms 
by Gibson assembly.   
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2.4.4. Interspecies Conjugation 
Promoter knock-in constructs were used to transform conjugating E. coli strains and colonies with 
the appropriate antibiotic resistance (for example, 50 mg/L apramycin) were picked into LB with 
antibiotics. WM6026 requires diaminopimelic acid in LB for growth, which was added to LB for 
subsequent wash and resuspension steps. Overnight cultures were diluted 1:100 into fresh LB with 
antibiotics and grown to an OD600 of 0.4–0.6. 400 µL of the culture was pelleted, washed twice 
and resuspended in LB without antibiotics. The washed E. coli cells were then mixed with spores 
at 1:5 volume ratio and spotted on R2 without sucrose plates. After incubation for 16–20 h at 30 °C, 
the plates were flooded with nalidixic acid and apramycin and incubated until exconjugants appear. 
Exconjugants were streaked onto MGY plates containing apramycin at 30 °C followed by 
restreaking to MGY plates at 37 °C to cure the CRISPR–Cas9 plasmid containing a temperature-
sensitive origin of replication. Apramycin-sensitive clones growing at 37 °C were then subjected 
to validation of promoter knock-in and genome editing as described in Section 4.4.5.  
2.4.5. Validation of Promoter Knock-in and Genome Editing 
Genomic DNA from wild type and exconjugants from the indicated strains were isolated from 
liquid cultures using the Blood and Tissue DNeasy kit (Qiagen) after pretreating the cells with 20 
mg/mL lysozyme for 0.5–1 h at 30 °C. PCR was performed using control primers beyond the 
homology regions or knock-in specific primers (Table 2.3) with KODXtreme Taq polymerase 
(Millipore). Where indicated, PCR products were subjected to digestion with specific restriction 
enzymes to differentiate between PCR products of wild type genomic sequences and successful 
genome editing by knock-ins. Positive samples were purified using Qiaquick PCR purification kit 




Figure 2.9. Diagnostic PCR verification of CRISPR-Cas9 mediated promoter knock-in for 
activation of silent BCGs. The positive candidates with correct promoter (P) cassette inserted 
should give 2kb band by using primer pairs 1 and 2. For the negative control, the PCR product 
should not show band with primer pairs 1 and 3.   
2.4.6. Metabolites Analysis 
Liquid seed cultures (2 mL MGY) of wild type and engineered S. viridochromogenes strains were 
inoculated from a plate or spore stock in 14-mL culture tubes. Seed cultures were incubated at 
30 °C with 250-rpm shaking until achieving turbidity or high particle density (typically 2–3 days). 
Seed cultures were diluted 1:100 into 50 mL of MGY broth in 250-mL baffled flasks containing 
~30–40 5-mm glass beads and incubated at 30 °C with 250-rpm shaking for 5 days. The cultures 
were harvested by pelleting at maximum speed in an Eppendorf 5810R centrifuge for 10 min. The 
cell pellet was stored at -80 °C while the supernatants were split into two 50-mL Falcon tubes. 
Culture supernatants were extracted three times with equal volume ethyl acetate. For solid state 
cultures, the strains were grown on MGY plates at 30 °C for 10 days. The plates were chopped 
into small pieces and extracted twice with ethyl acetate. Extracts were dried and resuspended in 
methanol and analyzed by LC-MS using ESI source in positive ion mode (Bruker, Amazon SL Ion 
Trap) equipped with a Kinetex 2.6 μm XB-C18 100 Å (Phenomenex). HPLC parameters were as 
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follows: solvent A, 0.1% trifluoroacetic acid in water; solvent B, 0.1% trifluoroacetic acid in 
acetonitrile; gradient at a constant flow rate of 0.2 mL/min, 10% B for 5 min, 10% to 100% B in 
35 min, maintain at 100% B for 10 min, return to 10% B in 1 min, and finally, maintain at 10% B 
for 10 min; detection by UV spectroscopy at 210, 254, 280, and 320 nm. 
2.4.7. Isolation and Nuclear Magnetic Resonance Spectroscopy Analysis of C22-1 
Large-scale cultivation on solid plates (equivalent to 5L liquid culture) of the knock-in strain was 
carried out to obtain enough amount of the potential new compound. 10-day-growth, solid plates 
were soaked in equal volume ethyl acetate overnight. The extract was fractionated using C18 flash 
column chromatography and the fraction containing the target compound was further subjected to 
silica gel flash column chromatography. The column elution was monitored by TLC and the 
fractions containing the target compound were further confirmed by HPLC. High-resolution 
electrospray ionization mass spectrometry in positive mode showed an m/z of 421.0934 (calculated: 
420.0934) and predicted molecular formula as C21H16O8 (Figure 2.10). Its chemical structure was 
elucidated by extensive one- and two-dimensional NMR spectroscopy (1H, 13C, Double-Quantum 
Filtered Correlation spectroscopy (COSY), Total correlation spectroscopy (TOCSY), 
Heteronuclear single-quantum correlation spectroscopy (HSQC), Heteronuclear multiple-bond 
correlation spectroscopy HMBC (Figure 2.11-2.17). NMR analysis was performed on an Agilent 





Figure 2.10. High-resolution electrospray ionization mass spectrometry in positive mode of 
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Table 2.4 NMR peak assignment of compound C22-1 
No. 
viridomycin A (1) 
δC δH (J in Hz) 
COSY/ 
TOCSY HMBC 
1 54.2 2.73, d (15.3)  2, 21, 22, 23 
  2.61, d (15.3)   
2 196.8    
3 150.7    
4 137.0    
5 115.2 9.30, s  7, 15, 17 
6 135.5    
7 183.5    
8 133.0    
9 105.8 7.07, s 11 7, 11, 13 
10 162.8    
11 108.1 6.52, s 9 9, 10, 12, 13 
12 164.4    
13 111.4    
14 184.1    
15 108.7    
16 169.2    
17 119.0    
18 175.2    
19 113.2 6.43, s 21 17, 20, 21 
20 117.1    
21 44.9 3.07, d (15.6) 19 1, 3, 19, 20, 22, 
23 
  2.95, d (15.6)   
22 69.6    
23 28.9 1.26, s  1, 21, 22 
10-OH  10.70, s  9, 10, 11 
12-OH  nd   
16-OH  nd   
18-OH  nd   
22-OH  4.77, s  1, 21, 22, 23 
 



































Figure 2.16. HMBC of C22-1 (DMSO-d6) 
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CHAPTER 3. Combining Rh-catalyzed Diazocoupling 
and Enzymatic Reduction to Efficiently Synthesize 
Enantioenriched 2-subsituted Succinate Derivatives  
 
3.1 Introduction 
The increasing demand for chiral building blocks, particularly those used for the preparation of 
biologically active compounds, has motivated the development of novel strategies for 
enantioselective synthesis. To this end, systems that catalyze enantioselective carbon-carbon bond 
formation have been studied intensively.1-3 Biocatalysts are increasingly employed to provide 
levels of chemo-, regio- and stereoselectivity that are challenging to achieve with a small-molecule 
catalyst, but applications of biocatalysts for carbon-carbon bond formation are limited.4-6 The 
combination of chemical and biological catalysts in one-pot could enable transformations that 
cannot be achieved by either of the two catalysts alone,4,7 and we considered that formal, 
enantioselective C-C bond formation could be achieved by combining a chemical catalyst that 
forms a C-C bond and an enzyme that can set a stereogenic center at one of the carbons of the new 
bond. 
Asymmetric 2-substituted succinic acid derivatives are versatile building blocks for the 
preparation of biologically active compounds,8-11 particularly natural products containing the γ-
butyrolactone-unit.12-16 Rhodium-catalyzed asymmetric hydrogenation of itaconic acid derivatives 
(Figure 3.1a) has been widely used to prepare enantiomerically enriched 2-subsituted succinic acid 
derivatives, but these methods are not applicable to the synthesis of 2-aryl substituted succinic acid 
derivatives.17-20 Meanwhile, the synthesis of 2-aryl succinic acid derivatives via organocatalytic 
and transition metal-catalyzed asymmetric hydrogenation of prochiral aryl-substituted fumaric (E) 
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and maleic (Z) acid derivatives remains challenging.21-36 Only recently did Pfaltz and coworkers 
report an enantioselective Ir-catalyzed hydrogenation of 2-aryl-substituted fumarates and maleates 
(Figure 3.1b).21 However, the hydrogenation reactions were limited to symmetric diesters and 
required high catalyst loadings and hydrogen pressure.   
Alternative methods to prepare enantioenriched 2-aryl succinic derivatives include Rh-
catalyzed 1,4-additions of arylboronic acids to fumarate derivatives (Figure 3.1c),37 Cinchona 
alkaloid-catalyzed parallel kinetic resolution of monosubstituted succinic anhydrides (Figure 
3.1d),38 or enantioselective N-heterocyclic carbene (NHC)-catalyzed β-protonation through the 
orchestration of three distinct organocatalysts: triazolium salt, thiourea (HDB), and DMAP (Figure 
3.1e).39 However, each reaction has its limitations, such as requiring di-tert-butyl fumarates for 
high enantioseletivity, forming inseparable mixtures of constitutional isomers from fumarates 
bearing two different ester functional groups, having a maximum yield of 50%, and forming 
product with lower ee at higher conversion.  
Enzymatic C=C bond reduction was once coupled with olefin synthesis to prepare non-
chiral products.40 Here we report a two-step, one-pot sequential chemoenzymatic transformation 
to prepare enantioenriched 2-aryl 1,4-dicarbonyl compounds with good yield and excellent 
enantioselectivity. This transformation combines a Rh(II)-catalyzed diazo coupling reaction with 
an enzymatic reduction into one-pot catalytic sequence that occurs in greater efficiency than the 
two individual steps, while avoiding purification of the alkene intermediates (Figure 3.1). This 
process constitutes a novel chemoenzymatic carbon-carbon bond formation with control of the 
absolute configuration of the new stereogenic center at one of the two carbons, while addressing 




Figure 3.1. Synthesis of 2-aryl succinate derivatives using sequential rhodium- and enzyme 




3.2 Results and Discussion  
3.2.1. Selective Synthesis of Unsymmetrical (E)-2-Aryl-substituted Alkenes  
To create a modular, enantioselective route to 2-aryl-fumarate derivatives, we first investigated the 
synthesis of unsymmetrical 2-aryl-substituted, alkenes containing carbonyl groups at the 1 and 4 
positions of the alkene. Davies and co-workers reported the [Rh2(OPiv)4]-catalyzed cross-coupling 
of diazo compounds to form 2-aryl-fumarate derivatives with high chemo- and stereoselectivity,3 
and we tested reactions catalyzed by both [Rh2(OPiv)4] and the commercially available 
rhodium(II) octanoate dimer [Rh2(Oct)4]. As shown in Table 3.1, cross-coupling of aryldiazo 
compounds 1 with diazoacetate derivatives 2 affords predominantly the dicarbonyl compounds 3a 
and 3b with only trace amounts (<5%) of homodimerization product 4. Importantly, the reaction 
catalyzed by [Rh2(OPiv)4] occurs with high selectivity for formation of E alkenes (100% 
stereoselectivity favoring the (E)-diester, >10:1 stereoselectivity favoring (E)-ketone-ester, except 
entry 8). The reactions catalyzed by [Rh2(Oct)4] occur with yields, chemoselectivity and 
stereoselectivity that are similar to those of reactions catalyzed by [Rh2(OPiv)4]. With improved 
methods for preparation of diazo-compounds,41,42 Rh(II)-catalyzed carbenoid-induced cross-
coupling of diazo compounds serves as an attractive convergent method for the synthesis of 








Table 3.1. Synthesis of asymmetric 2-aryl-sbustitued dicarbonyl alkenes by Rh-catalyzed cross-
coupling of diazo compounds  
 
Entry Ar R1 R2 
[Rh2(Oct)4]  [Rh2(OPiv)4] 
3aa 3ba  3aa 3bb  
1 Ph OMe OEt 44% -  67% - 
2 Ph OMe OtBu 57% -  74% - 
3 Ph OMe OBn 44% 6%  67% - 
4 Ph OtBu OEt 39% -  N.A. N.A. 
5 4-F-Ph Me OEt 64% 7%  57% 5% 
6 4-Cl-Ph Me OEt 68% 7%  64% 4% 
7 3-CF3-Ph Me OEt 47% 10%  46% 3% 
8 Ph OMe 4-F-Ph 32% 4%c  20% 3% 
 aIsolated yield. bYield determined by GC analysis. 
 
3.2.2. Enantioselective Enzymatic Reduction of C-C Double Bound  
Ene-reductase (ER) containing flavin mononucleotides (FMN) require NADPH or NADH as co-
factors to catalyze asymmetric reduction. In this study, glucose dehydrogenase (GDH) from 
Bacillus megaterium was used to recycle NADPH continuously by reduction of NADP+ with 
concomitant conversion of glucose to gluconic acid. We tested the reduction of the 2-aryl fumaric 
and maleic acid derivatives with a series of ERs originating from different organisms, including 
Old Yellow Enzymes OYE1, OYE2 and OYE3 from Saccharomyces cerevisiae, OYE4 from 
Achromobacter sp., 1, 2-oxophytodienoate reductases OPR1 and OPR3 from Lycopersicum 
esculentum, alkene reductase YersER from Yersinia bercovieri; thermophilic ‘ene’-reductase 
TOYE from Thermoanaerobacter pseudethanolicus, LacER from Lactobacillus casei, XenA and 
XenB from Pseudomonas putida, and NADPH dehydrogenase EBP1 from Candida albicans.  
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Most of the ERs catalyzed the reduction of the E isomers (3a) of 2-aryl-substitued, 1,4-dicarbonyl 
alkenes generated from the cross-coupling reactions of the diazo compounds, but some of them 
resulted in products with poor ee (Table 3.3). None of the ERs we tested reduced the trace amount 
of Z isomers 3b (<5%), based on GC evaluation. Table 3.2 shows the asymmetric reduction of (E)-
2-aryl-substitued, 1,4-dicarbonyl alkenes by the ERs that gave the product in 65%-85% yield. In 
general, ERs catalyzed the reduction of the alkenes containing two esters with excellent 
enantioselectivity (>99%) (Entries 1&2) and the reduction of alkenes containing one ketone and 
one ester with good to excellent enantioselectivity (85%-99%) (Entry 5-8). OPR1 is the only 
enzyme we tested that reduced the unsaturated 1,4-dicarbonyl compounds containing bulky ester 
groups at the carbon β to the aryl group (Entries 2&3) to form enantioenriched 2-aryl succinate 
derivatives bearing two distinct esters that allow orthogonal reactivity at each terminus.39 None of 
the enzymes catalyzed the reduction of the substrate containing a bulky ester group and aryl group 
on the same alkene carbon (Entry 4). 
Compared to metal-catalyzed hydrogenation of dimethyl 2-phenylmaleates,21 the enzymatic 
reduction offers several advantages. The turnover numbers for the enzymatic reduction were 
seventy times higher than those obtained with current catalysts, and the process occurred with 
excellent enantioselectivity (>99%) at room temperature, in phosphate buffer under atmospheric 
pressure. Furthermore, YersER tolerates both water miscible organic solvents, such as DMSO and 
ethylene glycol, and immiscible organic solvents such as hexane and toluene.43 This tolerance 







Table 3.2. Enzymatic reduction of (E)-2-aryl-sbustitued, 1,4-dicarbonyl alkenes by ene-reductases 
 
Entry Ar R1 R2 Yielda 4 %ee 
Most 
selective ER 
Large scale  
isolated yieldb 
TONe 
1 Ph OMe OEt 
91% 
71%f 
>99%c YersER 84% 
455 
7071f 
2 Ph OMe OtBu 76% >99% c OPR1 65% 650 
3 Ph OMe OBn 86% >99% c OPR1 80% 430 
4 Ph OtBu OEt - - - - - 
5 4-F-Ph Me OEt 80% 87% c YersER 75% 375 
6 4-Cl-Ph Me OEt 85% 85%d YersER 78% 423 
7 3-CF3-Ph Me OEt 78% 85% d YersER 70% 322 
8 Ph OMe 4-F-Ph 87% >99% d OYE2 80% 460 
    74% >99% d YersER 69% 370 
    93% 93% d OPR1 85% 465 
aGC yield. blarge-scale (0.2 mmol) reactions and isolated yield. cee determined by chiral SFC. dee 
determined by chiral HPLC. eTurn over number (TON) is defined as the number of moles of substrate that 
a mole of catalyst can convert before becoming inactivated. KPi: sodium phosphate buffer. fReaction with 
































































3.2.3. Two-step Sequential Reaction to Synthesize Enantioenriched 2-Aryl-
Substituted Succinate Derivatives   
Having identified an ER that reduces the substrates of the Rh-catalyzed coupling of 
diazocompounds, we sought to develop conditions to conduct the two reactions in one pot without 
purification of the intermediates. After conducting the diazo coupling reaction, we evaporated the 
DCM, added all reagents and the ER for the reduction step into the crude mixture. The one-pot 
process formed the enantioenriched succinate derivatives in >70% yield by completely converting 
the (E)-alkenes, the major product from cross-coupling reaction (Table 3.4) and leaving the (Z)-
alkene unreacted. Similar yield and enantioselectivity were observed with purified samples of the 
alkene (Table 3.2), suggesting that the ERs are compatible with the Rhodium(II) catalyst and trace 
amounts of chemical impurities contained in the crude cross coupling reaction. 













3ab 3bb 4c 
1 Ph OMe OEt 78% 0% 93% >99% 62% 465 
2 Ph OMe OBn 72% 0% 88% >99% 54% 440 
3 Ph OMe 4-F-Ph 38% 4% 90% >99% 26% 450 
4 3-CF3-Ph Me OEt 56% 4% 82% 89% 37% 410 
aDetermined by GC analysis. bTrace amount of reaction mixture was taken after the diazocoupling reaction and 
evaluated by GC analysis. cCalculated based on the starting materials for enzymatic reaction. dee determined by 
chiral HPLC. eCalculated based on the starting materials of the cross-coupling reaction. 
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3.2.4. Docking Experiments   
To provide possible explanations of the origin of the selectivity of ERs for (E)-alkenes over (Z)-
alkenes, we conducted computational docking studies. Docking of 4-ethyl 1-methyl 2-
phenylfumarate and 4-ethyl 1-methyl 2-phenylmaleate into the active site of OPR1 was 
conducted using the crystal structure of OPR1 (Figure 3.2) containing p-hydroxybenzoic acid 
(PHB) bound to the active site. 
 As shown in Figure 3.3A, the carbonyl oxygen of 4-ethyl 1-methyl 2-phenylfumarate is 
hydrogen bonded to His-187 Nϵ2 and His-190 Nδ1 with distances of 3.2 Å and 2.8 Å 
respectively. The distance between the N(5) of FMNH2 (transferring a hydride) and the carbon 
of the alkene that is β to the aryl group (β-carbon) of the substrate is 4.0 Å, and the distance 
between the Tyr 192 (a proton donor) and α-carbon of the substrate is 3.9 Å. The (Z)-alkene 4-
ethyl 1-methyl 2-phenylmaleate binds to the same site of OPR1 (Figure 3.3B). However the 
distance between N(5) of FMNH2 and the β carbon is more than 5.0 Å. This distance would be 
too large for the reaction to occur. In addition, the more hindered 4-(tert-butyl) 1-methyl 2-
phenylfumarate did not dock into most of the ERs (data are not shown), but it did dock into 
OPR1. As shown in Figure 3.3C, the distance between the N(5) of FMNH2 and the β-carbon of 
4-(tert-butyl) 1-methyl 2-phenylfumarate, and the distance between Tyr 192 and α-carbon of 4-
(tert-butyl) 1-methyl 2-phenylfumarate are both 4.0 Å. These distances are comparable to those 
between the proton and hydride donors of OPR1 to 4-ethyl 1-methyl 2-phenylfumarate. A pocket 
formed by Tyr-78, Lys-79 and Tyr-358 at the entrance of active site accommodates the phenyl 





Figure 3.2. Docking of p-hydroxybenzoic acid (PHB) into the active site of OPR1 in the crystal 
structure. (Left) Overlay of docked PHB (green) with original PHB (orange) in the crystal structure. 
(Right) Surface representation of the active site view of OPR1 with PHB docked at the active site.  
 
 
Figure 3.3. Docking of A) 4-ethyl 1-methyl 2- phenylfumarate, B) 4-ethyl 1-methyl 2- 
phenylmaleate, and C) 4-(tert-butyl) 1-methyl 2-phenylfumarate within the active site of OPR1. 
D) the surface representation of the active site view of OPR1 with 4-(tert-butyl) 1-methyl 2-
phenylfumarate docked at active site. In the stick models, substrates shown in green, FMN shown 




3.3 Conclusions and Outlook 
In summary, we have developed a one-pot, sequential catalytic system for the synthesis of 2-
aryl-succinate derivatives by formal asymmetric C-C bond formation created by integrating a 
transition-metal catalyst with an enzyme, whereby a Rh-catalyzed cross-coupling of car-bene 
units is followed by an ER-catalyzed enantioselective reduction of (E)-2-aryl-substituted 
dicarbonyl alkenes among a mixture of the E and Z isomers. With this system, 2-aryl-substituted 
succinate derivatives are generated from two different diazaoesters or ketones and reducing 
equivalents in high yield and excellent ee with-out purification of the alkene intermediates or 
separation of E and Z isomers. Evaluation of a panel of ERs as catalyst led to the identification 
of OPR1, which reacts with substrates containing bulky tert-butyl esters and produces 
enantioenriched, chiral unsymmetrical diesters that have great potential as synthetic 
intermediates. 
3.4 Experimental Procedures  
3.4.1. Materials  
Unless otherwise stated, all chemicals, reagents and catalysts were purchased from Sigma-Aldrich. 
E. coli DH5α cells were purchased from the Cell Media Facility at the University of Illinois at 
Urbana-Champaign (Urbana, IL). Escherichia coli BL21 (DE3) and plasmid pET28a+ were 
purchased from Novagen (Madison, WI). Oligonucleotides for cloning were purchased from 
Integrated DNA Technologies (IDT) (Coralville, IO). Restriction enzymes were purchased from 
New England Biolabs (Ipswich, MA). NADPH was purchased from Enzo Life Sciences 
(Farmingdale, NY). NADP+ was purchased from Roche Diagnostics (Indianapolis, IN). Isopropyl-
β-D-thiogalactoside (IPTG) was purchased from GoldBio (St. Louis, MO). The strain Bacillus 
megaterium (B14308) was obtained from the NRRL culture collection (Peoria, IL).  
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3.4.2. Cloning, Expression and Purification of Enzymes  
The YersER investigated in this research is from Yersinia bercovieri. The codon-optimized gene 
was synthesized by IDT and cloned in pET28a with N-terminal His-tag. For expression of YersER, 
a BL21 clone harboring pET28a-YersER was inoculated in 5 mL LB medium containing 100 
µg/mL ampicillin and grown overnight at 37 ºC. This overnight culture was used to inoculate 500 
mL of TB medium containing 50 µg/mL kanamycin, which was grown at 37 ºC until an OD of 
~0.6 was reached, and subsequently induced with the addition of 0.3 mM IPTG. The induced 
culture was placed at 25 ºC, 250rpm, for 16 h for protein production. 
The OYE1/2/3 investigated in this research is from baker’s yeast. The plasmid pET30a-
OYE1/2/3 with N-terminal His-tag was a gift from Dr. Francesco G. Gatti. The plasmid was 
transformed into E. coli BL21. For expression of OYE1/2/3, a BL21 clone harboring pET30a-
OYE1/2/3 respectively was inoculated in 5 mL LB medium containing 50 µg/mL kanamycin and 
grown overnight at 37 ºC. This overnight culture was used to inoculate 500 mL of LB medium 
containing 50 µg/mL kanamycin, which was grown at 37 ºC until an OD of ~0.6 was reached, and 
subsequently induced with the addition of 0.1 mM IPTG. The induced culture was placed at 25 ºC, 
250 rpm, for 16 h for protein production.  
The OPR1 investigated in this research is from Lycopersicon esculentum (tomato). The 
plasmid pET21b-OPR1 with C-terminal His-tag was a gift from Dr. Kurt Faber. The plasmid was 
transformed into E. coli BL21. For expression of OPR1, a BL21 clone harboring pET21b-OPR1 
was inoculated in 5 mL LB containing 100 µg/mL ampicillin and grown overnight at 37 ºC. This 
overnight culture was used to inoculate 500 mL of TB medium containing 100 µg/mL ampicillin, 
which was grown at 37 ºC until an OD of ~0.6 was reached, and subsequently induced with the 
78 
 
addition of 1 mM IPTG. The induced culture was placed at 25 ºC, 250 rpm, for 16 h for protein 
production.  
The OPR3 investigated in this research is from Lycopersicon esculentum (tomato). The 
plasmid pET21b-OPR3 with C-terminal His-tag was a gift from Dr. Kurt Faber. The plasmid was 
transformed into E. coli BL21. For expression of OPR3, a BL21 clone harboring pET21b-OPR3 
was inoculated in 5 mL LB medium containing 100 µg/mL ampicillin and grown overnight at 37 
ºC. This overnight culture was used to inoculate 500 mL of TB medium containing 100 µg/mL 
ampicillin, which was grown at 37 ºC until an OD of ~0.6 was reached, and subsequently induced 
with the addition of 1 mM IPTG. The induced culture was placed at 25 ºC, 250 rpm, for 16 h for 
protein production.  
KYE1 is from Kluyveromyces lactis NRRL Y-1140. The gene was synthesized by IDT and 
codon-optimized for E. coli expression. The gene was cloned into pET28a using restriction 
enzymes NdeI and XhoI. The plasmid pET28a-KYE1 was transformed into E. coli BL21 with N-
terminal His-tag. For expression of KYE1, a BL21 clone harboring pET28a-KYE1 was inoculated 
in 5 mL LB medium containing 50 µg/mL kanamycin and grown overnight at 37 ºC. This overnight 
culture was used to inoculate 500 mL of TB medium containing 50 µg/ml kanamycin, which was 
grown at 37 ºC until an OD of ~0.5-0.6 was reached, and subsequently induced with the addition 
of 0.1 mM IPTG. The induced culture was placed at 25 ºC for 16 h for protein production. 
MorR is from Pseudomonas putida. The gene was synthesized by IDT and codon-
optimized for E. coli expression. The gene was cloned into pET28a using restriction enzymes NdeI 
and XhoI with N-terminal His-tag. The plasmid pET28a-MorR was transformed into E. coli BL21. 
For expression of MorR, a BL21 clone harboring pET28a-MorR was inoculated in 5 mL LB 
medium containing 50 µg/mL kanamycin and grown overnight at 37 ºC. This overnight culture 
79 
 
was used to inoculate 500 mL of TB medium containing 50 µg/ml kanamycin, which was grown 
at 37 ºC until an OD of ~0.5-0.6 was reached, and subsequently induced with the addition of 1 mM 
IPTG. The induced culture was placed at 20 ºC for 16 h for protein production. 
SYE1 is from Shewanella oneidensis MR-1. The gene was synthesized by IDT and codon-
optimized for E. coli expression. The gene was cloned into pET28a between restriction enzymes 
NdeI and XhoI with N-terminal His-tag. The plasmid pET28a-SYE1 was transformed into E. coli 
BL21. For expression of MorR, a BL21 clone harboring pET28a-SYE1 was inoculated in 5 mL 
LB medium containing 50 µg/mL kanamycin and grown overnight at 37 ºC. This overnight culture 
was used to inoculate 500 mL of TB medium containing 50 µg/ml kanamycin, which was grown 
at 37 ºC until an OD of ~0.5-0.6 was reached, and subsequently induced with the addition of 0.5 
mM IPTG. The induced culture was placed at 28 ºC for 15 h for protein production. 
The XenA and XenB investigated in this research are from Pseudomonas putida ATCC 
17453. The plasmid pGaston-xenA and pGaston-xenB with C-terminal His-tag was a gift from Dr. 
Uwe T. Bornscheuer. The plasmid was transformed into E. coli BL21. For expression of xenA or 
xenB, a BL21 clone harboring pGaston-xenA/xenB was inoculated in 5 mL LB medium containing 
100 µg/mL ampicillin and grown overnight at 37 ºC. This overnight culture was used to inoculate 
500 mL of LB medium containing 100 µg/mL ampicillin, which was grown at 37 ºC at 180 rpm 
until an OD of ~0.6-0.8 was reached, and subsequently induced with the addition of 0.2% (w/v) r-
rhamnose. The induced culture was placed at 25 ºC (XenB) or 30 ºC (XenA) for 8 h.  
The LacER investigated in this research is from Lactobacillus casei, The plasmid 
pET21a(+)-LacER with C-terminal His-tag was a gift from Dr. Dunming Zhu. The plasmid was 
transformed into E. coli BL21. For expression of LacER, a BL21 clone harboring pET21b-LacER 
was inoculated in 5 mL LB medium containing 100 µg/mL ampicillin and grown overnight at 37 
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ºC. This overnight culture was used to inoculate 500 mL of LB medium containing 100 µg/mL 
ampicillin, which was grown at 37 ºC until an OD of ~0.6-0.8 was reached, and subsequently 
induced with the addition of 1 mM IPTG. The induced culture was placed at 30 ºC, 250 rpm, for 
15 h for protein production 
The TOYE investigated in this research is from Thermoanaerobacter pseudetahnolicus 
E39. The plasmid pET21b-TOYE with C-terminal His-tag was a gift from Dr. Uwe T. Bornscheuer. 
The plasmid was transformed into E. coli BL21. For expression of TOYE, a BL21 clone harboring 
pET21b-TOYE was inoculated in 5 mL LB medium containing 100 µg/mL ampicillin and grown 
overnight at 37 ºC. This overnight culture was used to inoculate 500 mL of LB medium containing 
100 µg/mL ampicillin, which was grown at 25 ºC at 250 rpm until an OD of ~0.5 was reached, 
and subsequently induced with the addition of 0.4 mM IPTG. The induced culture was placed at 
25 ºC for 12 h.  
The GDH used in this research is from Bacillus megaterium B14308. B14398 was 
inoculated in 5 mL TGY medium and grown at 30 ºC for 18 h. Genomic DNA was isolated using 
the Wizard® Genomic DNA purification kit from Promega according to the manufacturer’s 
protocol. The gene encoding the gdh was amplified from the genome of B. megaterium using 
primers gdh-NdeI-for and gdh-HindIII-rev. Restriction sites are underlined. The gene was ligated 
into pET28a+ and transformed into E. coli DH5α. The plasmid pET28a-gdh was transformed into 
E. coli BL21. For expression of GDH, a BL21 clone harboring pET28a-gdh was inoculated in 5 
mL LB medium containing 50 µg/mL kanamycin and grown overnight at 37 ºC. This overnight 
culture was used to inoculate 500 mL of TB medium containing 50 µg/ml kanamycin, which was 
grown at 37 ºC until an OD of ~0.7 was reached, and subsequently induced with the addition of 
0.3 mM IPTG. The induced culture was placed at 25 ºC for 16 h for protein production. 
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All proteins were purified in the same way. Following expression, BL21 cells were 
recovered by centrifugation (6000 x g for 15 min), lysed by sonication and clarified by 
centrifugation (18 000 x g for 30 min). The protein was subsequently purified by affinity 
chromatography using a HisTrap column fitted to an AKTA FPLC system (GE Health Life 
Sciences, Pittsburgh, PA). The purified protein was buffer exchanged against 100 mM phosphate 
buffer, pH 8.1 using an Amicon Ultra concentration tube (10 kDa cut-off) before being stored in 
15% glycerol as 100 µL aliquots at -80 ºC.  
3.4.3. General Procedure for Alkene Synthesis via Rh-catalyzed Diazocoupling  
To a solution of rhodium carboxylate dimer, 1 mol % of either Dirhodium(II) tetrakispivaloate 
[Rh2(OPiv)4] or rhodium(II) octanoate dimer [Rh2(Oct)4] in dichloromethane at –78 ºC was added 
an equimolar solution of a donor–acceptor diazocompound and an α-diazocarbonyl compound in 
dichloromethane (0.2 M final concentration) in 3 portions over 30 minutes. The reaction was 
stirred at –78 ºC for 1 hour before slowly warming to room temperature. The solvent was removed 
in vacuo and the crude product purified by silica gel chromatography.  
The yield of 4-Ethyl 1-Methyl 2-phenylfumarate is 44% by [Rh2(Oct)4] and 67% by 
[Rh2(OPiv)4]. 1H NMR (600 MHz, Chloroform-d) δ 7.38–7.35 (m, 3H), 7.23 (m, 2H), 7.02 (s, 
1H), 4.04 (q, J = 7.1 Hz, 2H), 3.81 (s, 3H), 1.06 (t, J = 7.1 Hz, 3H). Characterization data matches 
those previously reported.3  
The yield of 4-(tert-Butyl) 1-Methyl 2-phenylfumarate is 57% by [Rh2(Oct)4] and 74% by 
[Rh2(OPiv)4]. 1H NMR (600 MHz, Chloroform-d) δ 7.37–7.35 (m, 3H), 7.22 (m, 2H), 6.97 (s, 
1H), 3.79 (s, 3H), 1.23 (s, 9H). Characterization data matches those previously reported.44 
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The yield of 4-Benzyl 1-Methyl 2-phenylfumarate is 49% (E:Z = 8:1) by [Rh2(Oct)4] and 
67% by [Rh2(OPiv)4]. 1H NMR (600 MHz, Chloroform-d) δ 7.40–7.31 (m, 3H), 7.30–7.28 (m, 
3H), 7.23 (m, 2H), 7.10 (m, 2H), 7.07 (s, 1H), 5.03 (s, 2H), 3.80 (s, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 166.7, 165.0, 144.0, 135.0, 133.8, 128.9, 128.8, 128.6, 128.4, 128.2, 128.2, 127.9, 
126.7, 117.2, 66.7, 52.9. IR (film): 3034, 2953, 1715, 1633, 1497, 1435, 1380, 1352, 1249, 1023 
cm-1. HRMS–ESI (m/z): [M+H]+ calculated for C18H16O4H: 297.1127, found: 297.1126. 
The yield of Methyl (E)-4-(4-Fluorophenyl)-4-oxo-2-phenylbut-2-enoate is 36% (E:Z = 
8:1) by [Rh2(Oct)4] and 22.8% (E:Z = 7:1) by [Rh2(OPiv)4]. Alkene geometry was assigned based 
on comparison with the 1H NMR data of similar alkenes reported by Davies and coworkers.Error! B
ookmark not defined. 1H NMR (600 MHz, Chloroform-d) δ 7.83 (m, 2H), 7.64 (s, 1H), 7.24–7.17 (m, 
5H), 7.02 (t, J = 8.6 Hz, 2H), 3.87 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 192.24, 166.07 (d, J = 
256.1 Hz), 165.22, 140.68, 136.12, 133.74, 132.78, 132.76, 131.79 (d, J = 9.6 Hz), 129.50, 128.86, 
128.11, 115.90 (d, J = 22.1 Hz), 53.05. 19F NMR (376 MHz, CDCl3) δ -105.94. IR (film): 3060, 
2954, 1716, 1668, 1595, 1506, 1435, 1410, 1259, 1154, 1098, 1077 cm-1. HRMS–ESI (m/z): 
[M+Na]+ calculated for C17H13FO3Na: 307.0741, found: 307.0742.  
The yield of Ethyl (E)-4-oxo-3-(3-(trifluoromethyl)phenyl)pent-2-enoate is 47% by 
[Rh2(Oct)4] and 56.4% by [Rh2(OPiv)4]. Alkene geometry was assigned based on comparison 
with the 1H NMR data of similar alkenes reported by Davies and coworkers.Error! Bookmark not defined. 1
H NMR (600 MHz, Chloroform-d) δ 7.64 (d, J = 8.9 Hz, 1H), 7.52 (t, J = 7.5 Hz 1H), 7.43 (s, 
1H), 7.36 (d, J = 7.5 Hz, 1H), 6.84 (s, 1H), 4.04 (q, J = 7.4 Hz, 2H), 2.38 (s, 3H), 1.05 (t, J = 7.0 
Hz, 3H). 13C NMR (152 MHz, CDCl3) δ 197.98, 165.16, 149.37, 135.40, 132.23,130.67 (d, J = 
130 Hz), 128.81, 128.61, 125.7 (q, J = 4.05 Hz),125.34 (q, J = 3.77), 163.66 (d, J = 273.6), 61.53, 
27.72, 13.82. 19F NMR (470 MHz, CDCl3) δ -63.04. IR (film): 3071, 2988, 2976, 2940, 2359, 
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1737, 1726, 1711, 1691, 1681, 1639, 1631, 1611, 1467 1486, 1441, 1433, 1368, 1351, 1324, 1162, 
1096, 1074, 1036, cm-1. HRMS–ESI (m/z): [M+H]+ calculated for C14H13F3O3H: 287.0895, found: 
287.0900. 
The yield of Ethyl (Z)-4-oxo-3-(3-(trifluoromethyl)phenyl)pent-2-enoate is 10% by 
[Rh2(Oct)4] and 1.3% by [Rh2(OPiv)4]. Alkene geometry was assigned based on comparison with 
the 1H NMR data of similar alkenes reported by Davies and coworkers.Error! Bookmark not defined. 1H N
MR (600 MHz, Chloroform-d) δ 7.70 (s, 1H), 7.69 (d, J = 8.18 Hz, 1H), 7.605 (d, J = 7.78 Hz 
1H), 7.54 (t, J = 8.0 Hz, 1H), 6.19 (s, 1H), 4.25 (q, J = 5.3 Hz, 2H), 2.44 (s, 3H), 1.32 (t, J = 7.3 
Hz, 3H). 13C NMR (152 MHz, CDCl3) δ 203.71, 165.17, 156.66, 133.97, 130.12, 129.88, 127.155 
(q, J = 3.57 Hz), 123.68 (q, J = 3.90 Hz), 117.62, 110.18, 102.57, 61.45, 30.53, 14.25. 19F NMR 
(470 MHz, CDCl3) δ -63.25. HRMS–ESI (m/z): [M+H]
+ calculated for C14H13F3O3H: 287.0895, 
found: 287.0890. 
The yield of Ethyl (E)-3-(4-fluorophenyl)-4-oxopent-2-enoate is 64% by [Rh2(Oct)4] and 
156% by [Rh2(OPiv)4]. Each alkene was isolated separately ([Rh2(Oct)4]: 0.34 g, 64% yield; 
[Rh2(OPiv)4]: 0.30g, 56.4% yield). 
1H NMR (600 MHz, Chloroform-d) δ 7.14 (m, 2H), 7.08 (t, J 
= 8.0 Hz, 2H), 6.77 (s, 1H), 4.06 (q, J = 7.2 Hz, 2H), 2.34 (s, 3H), 1.10 (t, J = 7.1 Hz, 3H). 13C 
NMR (151 MHz, CDCl3) δ 198.77, 165.48, 163.79, 162.15, 150.00, 130.68 (d, J = 8.2 Hz), 127.65, 
115.32 (d, J = 21.6 Hz), 61.14, 27.88, 13.99. 19F NMR (376 MHz, CDCl3) δ -115.16. IR (film): 
2985, 2939, 1732, 1716, 1699, 1634, 1602, 1465, 1368, 1225, 1157, 1097, 1035 cm-1. HRMS–ESI 
(m/z): [M+Na]+ calculated for C13H13FO3Na: 259.0741, found: 259.0740. 
The yield of Ethyl (Z)-3-(4-fluorophenyl)-4-oxopent-2-enoate is 7 % by [Rh2(Oct)4] and 
0.8% by [Rh2(OPiv)4]. Each alkene was isolated separately ([Rh2(Oct)4]: 0.038 g, 7% yield; 
[Rh2(OPiv)4]: <0.005g, <1% yield). 
1H NMR (500 MHz, Chloroform-d) δ 7.43 (m, 2H), 7.10 (m, 
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2H), 6.10 (s, 1H), 4.23 (q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, Chloroform-d) δ 204.48, 165.48, 165.23, 163.22, 157.10, 128.97 (d, J = 8.8 Hz), 116.48 (d, 
J = 21.6 Hz), 115.46, 61.23, 30.51, 14.26. 19F NMR (376 MHz, CDCl3) δ -111.61. IR (film): 3076, 
2984, 2939, 1715, 1699, 1616, 1601, 1506, 1417, 1370, 1277, 1239, 1185, 1108, 1032 cm-1. 
HRMS–ESI (m/z): [M+Na]+ calculated for C13H13FO3Na: 259.0741, found: 259.0739. 
The yield of Ethyl (E)-3-(4-chlorophenyl)-4-oxopent-2-enoate is 68% by [Rh2(Oct)4] and 
64% by [Rh2(OPiv)4]. 1H NMR (600 MHz, Chloroform-d) δ 7.36 (m, 2H), 7.11 (m, 2H), 6.77 (s, 
1H), 4.07 (q, J = 7.1 Hz, 2H), 2.34 (s, 3H), 1.11 (t, J = 7.2 Hz). 13C NMR (151 MHz, Chloroform-
d) δ 198.47, 165.34, 149.91, 134.77, 132.99, 130.17, 128.49, 127.81, 61.22, 27.89, 13.99. HRMS–
ESI (m/z): [M+Na]+ calculated for C13H13ClO3Na: 275.0451, found: 275.0463. 
The yield of Ethyl (E)-3-(4-chlorophenyl)-4-oxopent-2-enoate is 7% by [Rh2(Oct)4] and 
3.3% by [Rh2(OPiv)4]. 1H NMR (600 MHz, Chloroform-d) δ 7.38 (m, 4H), 6.13 (s, 1H), 4.23 (q, 
J = 7.1 Hz, 2H), 2.42 (s, 3H), 1.31 (t, J = 7.2 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 
204.14, 165.38, 156.99, 136.96, 131.41, 129.99, 128.21, 116.10, 61.30, 30.52, 14.27. HRMS–ESI 
(m/z): [M+Na]+ calculated for C13H13ClO3Na: 275.0451, found: 275.0450. 
3.4.4. General Procedure for Enzymatic Alkene Reduction and Quantification 
To a solution of NADP+ (80 μL of 20 mM stock, 0.04 equiv), glucose (200 μL of a 1 M stock, 5 
equiv), GDH (1 U/mL) and enoate reductase (0.2 mol %) in 200 mM pH 7.5 phosphate buffer 
(6.08 mL) was added a solution of enoate (0.04 mmol, 1 equiv) in DMSO (200 μL) at room 
temperature. Final concentrations are as follows: 0.2 mM NADP+, 25 mM glucose, 1 U/mL GDH, 
10 μM ene-reductase, 5 mM enoate substrate, 2.5 v/v% DMSO. The reaction was incubated 
overnight at 27 ºC and 100 rpm before the addition of EtOAc (3 mL) and dodecane (200 μL of 20 
μL/mL stock in EtOAc). An aliquot was removed from the organic layer for GC (ZB-5MS) 
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analysis. The reaction mixture was extracted twice with EtOAc and the combined organic layers 
were concentrated in vacuo and purified by preparative TLC. The partially purified product was 
analyzed by chiral SFC or Chiral HPLC as described below. In some cases, the alkene starting 
material co-elutes with one of the product enantiomers and complete consumption of the starting 
material was required for chiral SFC analysis. 
Molar concentration of ene-reductase was obtained by diving the mass concentration, 
obtaining from Bradford Assay, by its molecular weight. 
Isolated yields were obtained by performing 10 times scale-up reaction in conical flask and 
extracting the reaction mixture 3 times with EtOAc. The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by silica gel 
chromatography. 
The isolated yield of 4-Ethyl 1-Methyl (R)-2-Phenylsuccinate is 84%. 1H NMR (600 MHz, 
Chloroform-d) δ 7.33 (t, J = 7.5 Hz, 2H), 7.30–7.25 (m, 3H), 4.13 (q, J = 7.3 Hz, 2H), 4.09 (dd, J 
= 10.2, 5.3 Hz, 1H), 3.68 (s, 3H), 3.19 (dd, J = 16.9, 10.2 Hz, 1H), 2.66 (dd, J = 17.1, 5.4 Hz, 1H), 
1.22 (t, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 173.6, 171.6, 137.9, 129.0, 127.9, 127.8, 
60.9, 52.5, 47.3, 38.1, 14.3. Chiral SFC: AD-H column, 2.5% iPrOH, 2.5 mL/min, 220 nm; 
tR(major): 2.07 min, tR(minor): not observed, >95% ee. [α]D
25: –128º (c = 1.0, CHCl3). 
Characterization data matches those previously reported.44 
The isolated yield of 4-(tert-Butyl) 1-Methyl (R)-2-Phenylsuccinate is 65%. 1H NMR (600 
MHz, Chloroform-d) δ 7.32 (m, 2H), 7.30–7.26 (m, 3H), 4.02 (dd, J = 10.0, 5.4 Hz, 1H), 3.67 (s, 
3H), 3.11 (dd, J = 16.7, 10.1 Hz, 1H), 2.60 (dd, J = 16.6, 5.4 Hz, 1H), 1.40 (s, 9H). 13C NMR (151 
MHz, CDCl3) δ 173.66, 170.78, 137.98, 128.92, 127.97, 127.70, 81.11, 52.38, 47.54, 39.25, 28.15. 
IR (film): 2979, 1732, 1497, 1435, 1455, 1393, 1368, 1257, 1149, 1032, 1005, 953 cm-1. HRMS–
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ESI (m/z): [M+Na]+ calculated for C15H20O4Na: 287.1254, found: 287.1250. Chiral SFC: AD-H 
column, 2.5% iPrOH, 2.5 mL/min, 220 nm; tR(major): 1.53 min, tR(minor): not observed (3.29 
min), >99% ee. 
The isolated yield of Ethyl 3-(4-Fluorophenyl)-4-oxopentanoate is 75%. 1H NMR (500 
MHz, Chloroform-d) δ 7.18 (m, 2H), 7.03 (m, 2H), 4.17 (dd, J = 9.4, 5.3 Hz, 1H), 4.09 (m, 2H), 
3.16 (dd, J = 16.9, 9.6 Hz, 1H), 2.50 (dd, J = 16.9, 5.3 Hz, 1H), 2.11 (s, 3H), 1.21 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 13C NMR (126 MHz, CDCl3) δ 206.82, 172.04, 162.41 
(d, J = 247.0 Hz), 133.26 (d, J = 3.2 Hz), 129.94 (d, J = 8.1 Hz), 116.22 (d, J = 21.4 Hz), 60.88, 
54.08, 37.26, 29.05, 14.26. IR (film): 2984, 2934, 1733, 1716, 1601, 1507, 1418, 1374, 1354, 1293, 
1190, 1161, 1099, 1029 cm-1. HRMS–ESI (m/z): [M+Na]+ calculated for C13H15FO3Na: 261.0897, 
found: 261.0896. Chiral SFC: AD-H column, 2.5% iPrOH, 2.5 mL/min, 220 nm; tR(major): 1.79 
min, tR(minor): 3.06 min, 87% ee. [α]D
25: –253º (c = 1.0, CHCl3). 
The isolated yield of Ethyl 3-(4-chlorophenyl)-4-oxopentanoate is 78%. 1H NMR (600 
MHz, Chloroform-d) δ 7.31 (d, J = 8.5 Hz, 2H), 7.16 (d, J = 8.5 Hz, 2H), 4.15 (dd, J = 9.6, 5.4Hz, 
1H), 4.09 (m, 2H), 3.16 (dd, J = 17.9, 10.1 Hz, 1H), 2.50 (dd, J = 17.2, 5.4Hz, 1H), 2.11 (s, 3H), 
1.21 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 206.43, 171.90, 136.04, 133.90, 129.72, 
129.69, 60.90, 54.26, 37.13, 29.07, 14.26.  HRMS–ESI (m/z): [M+Na]+ calculated for 
C13H15ClO3Na: 277.0607, found: 261.0609. Chiral HPLC: OJ-H column, 100% Hexane, 0.8 
mL/min, 220 nm; tR(major): 22.24 min, tR(minor): 23.92 min, 85% ee.  
The isolated yield of Ethyl 4-oxo-3-(3-(trifluoromethyl)phenyl)pentanoate is 70%. 1H 
NMR (600 MHz, Chloroform-d) δ 7.555 (d, J = 7.5 Hz, 1H), 7.49 (s, 1H), 7.415 (d, J = 7.7 Hz, 
1H), 4.26 (dd, J = 9.8, 5.5 Hz, 1H), 4.10 (m, 2H), 3.21 (dd, J = 17.2, 9.7 Hz, 1H), 2.54 (dd, J = 
17.9, 6.1 Hz, 1H), 2.14 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 13C 
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NMR (126 MHz, CDCl3) δ 205.12, 170.73, 137.54, 130.66, 130.71 (q, J = 32.7 Hz), 128.82, 124.21 
(q, J = 3.4 Hz), 123.85 (q, J = 3.7 Hz), 122.04, 60.00, 53.61, 36.23, 28.28, 13.24. 19F NMR (470 
MHz, CDCl3) δ -63.08. HRMS–ESI (m/z): [M+Na]
+ calculated for C14H15F3O3Na: 311.0871, 
found: 311.0870. Chiral HPLC: OJ-H column, 5% iPrOH, 0.8 mL/min, 220 nm; tR(major): 10.78 
min, tR(minor): 12.77 min, 85% ee. 
The isolated yield of Methyl 4-(4-fluorophenyl)-4-oxo-2-phenylbutanoate is 69%~85%. %. 
1H NMR (500 MHz, Chloroform-d) δ 8.00 (m, 2H), 7.35 (m, 4H), 7.30 (m, 1H), 7.12 (m, 2H), 
4.29 (dd, J = 10.3, 4.1 Hz, 1H), 3.92 (dd, J = 18.7, 10.3 Hz, 1H), 3.70 (s, 3H), 3.23 (dd, J = 18.0, 
4.0 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 13C NMR (126 MHz, CDCl3) δ 196.18, 171.97, 
165.87 (d, J = 255Hz), 138.37, 133.00 (d, J = 3.8 Hz), 130.92, 130.85, 129.10, 127.94, 127.76, 
115.95, 115.81, 52.53, 46.49, 42.87. 19F NMR (470 MHz, CDCl3) δ -106.15. HRMS–ESI (m/z): 
[M+Na]+ calculated for C17H15FO3Na: 309.0903, found: 309.0900. Chiral HPLC: OJ-H column, 
5% iPrOH, 0.8 mL/min, 220 nm; tR(major): 29.40 min, tR(minor): not observed (~25.875 min), >99% 
ee. 
3.4.5. General Procedure for One-Pot Sequential Diazocoupling–Enzymatic 
Alkene Reduction 
To a solution of rhodium carboxylate dimer, 1 mol % of either Dirhodium(II) tetrakispivaloate 
[Rh2(OPiv)4] or in dichloromethane at –78 ºC was added an equimolar solution of methyl 2-diazo-
2-phenylacetate (0.25 g, 1.5 mmol) and ethyl 2-diazoacetate (0.16 mL, 0.17 g, 1.6 mmol) in 
dichloromethane (0.2 M final concentration) in 3 portions over 30 minutes. The reaction was 
stirred at –78 ºC for 1 hour before slowly warming to room temperature. The solvent was removed 
in vacuo and the crude product was re-dissolved in 3.75 mL DMSO.  
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To a solution of NADP+ (3 mL of 20 mM stock, 0.04 equiv), glucose (7.5 mL of a 1 M 
stock, 5 equiv), GDH (2 U/mL) and enoate reductase (0.2 mol %) in 200 mM pH 7.5 phosphate 
buffer (150 mL) was added a previously prepared solution of chemical in DMSO (3.75 mL) at 
room temperature. Final concentrations are as follows: 0.4 mM NADP+, 50 mM glucose, 2 U/mL 
GDH, 20 μM enoate reductase, 10 mM enoate substrate, 2.5 v/v% DMSO. The reaction was 
incubated overnight at 27 ºC and 100 rpm. 1 mL reaction mixture was extracted by the addition of 
EtOAc (2 mL) and dodecane (20 μL of 20 mg/mL stock in EtOAc). An aliquot was removed from 
the organic layer for GC (ZB-5MS) analysis. The reaction mixture was later extracted twice with 
EtOAc (100 mL) and the combined organic layers were concentrated in vacuo and purified by 
silica gel chromatography (neutral pH silica). The purified product was dried in vacuo and further 
dried under high vacuum system. The purified product was verified by 1H NMR and analyzed by 
chiral HPLC as described in section 2.4.4.  
3.4.6. Synthesis of Racemic Products: Representative Procedure for Alkene 
Hydrogenation 
Preparation of 4-Ethyl 1-Methyl (±)-2-Phenylsuccinate:  
 
Procedure adapted from the literature.45 A solution of 4-ethyl 1-methyl 2-phenylfumarate (25 mg, 
0.11 mmol, 1 equiv) in ethanol (1.1 mL, 0. 1 M) was added to a vial containing Pd(OAc)2 (2.4 mg, 
0.01 mmol, 10 mol %) and activated charcoal (22 mg). The resulting suspension was transferred 
to a hydrogenation bomb and charged with H2 (50 psig). The reaction was stirred overnight at 
room temperature. The reaction mixture was filtered through Celite and solvent remove in vacuo. 
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The product was obtained in >90% purity (1H NMR) and could be purified further using 
preparative TLC (10% EtOAc/hexanes). Characterization data matches those obtained from 
enzyme catalyzed reduction. The same method was used to prepare other racemic products: 4-
(tert-butyl) 1-methyl 2-phenylsuccinate, ethyl 3-(4-fluorophenyl)-4-oxopentanoate, ethyl 3-(4-
chlorophenyl)-4-oxopentanoate, ethyl 4-oxo-3-(3-(trifluoromethyl)phenyl)pentanoate and methyl 
4-(4-fluorophenyl)-4-oxo-2-phenylbutanoate.  
To prepare 4-benzyl 1-methyl 2-phenylsuccinate, benzylation was performed after normal 
hydrogenation as described above. Procedure adapted from the patent.46 Na2CO3 (34.98 mg, 0.33 
mmol, 3 equiv) and benzyl bromide (18.81 mg, 0.11 mmol, 1 equiv) were added to a solution of 
4-methoxy-4-oxo-3-phenylbutanoic acid (22.88 mg, 0.11 mmol, 1 equiv) from hydrogenation of 
4-benzyl 1-methyl 2-phenylfumarate, in DMA (3.154 mL). The mixture was stirred for 18 hours 
under nitrogen at room temperature. Water (6 mL) was added and then the mixture was extracted 
twice with toluene (3.5 mL). The combined organic layers were washed twice with (2 mL) water 
and the solvent was removed under reduced pressure. The product was purified by preparative 
TLC (15% EtOAc/hexanes). Characterization data matches those obtained from enzyme catalyzed 
reduction.  
3.4.7. GC/MS Method  
1 L was injected in a split mode (20:1) into the GC-MS system consisted of an Agilent 
6890 (Agilent Inc, Palo Alto, CA, USA) gas chromatograph, an Agilent 5973 mass selective 
detector and Agilent 7683B autosampler. Gas chromatography was performed on a 30 m Optima-
5 column with 0.25 mm inner diameter (I.D.) and 0.5 m film thickness (Macherey-Nagel, 
Germany) with an injection temperature of 2500C, MSD transfer line of 2500C, and the ion source 
adjusted to 2300C. The helium carrier gas was set at a constant flow rate of 1 ml min-1. The 
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temperature program was different for different samples . 2-min at 1000C, followed by an oven 
temperature ramp of 80C min-1 to 2800C for 1 min, then 150C min-1 to 3100C a final 5 min. The 
mass spectrometer was operated in positive electron impact mode (EI) at 69.9 eV ionization energy 
in m/z 30-500 scan range. The spectra of all chromatogram peaks were evaluated using the HP 
Chemstation (Agilent, Palo Alto, CA, USA). 
3.5 Representative Traces  
3.5.1. Representative NMR Traces    
1-diazo-1-(3-(trifluoromethyl)phenyl)propan-2-one 
 









13C NMR (154 MHz, Chloroform-d)  
 
 
4-Benzyl 1-Methyl 2-phenylfumarate (~8:1, E:Z)  










13C NMR (151 MHz, Chloroform-d) 
 
 
4-benzyl 1-methyl (R)-2-phenylsuccinate 





13C NMR (151 MHz, Chloroform-d) 
 
4-Ethyl 1-Methyl-2-Phenylsuccinate  









4-(tert-Butyl) 1-Methyl (R)-2-Phenylsuccinate  
1H NMR (600 MHz, Chloroform-d) 
 
 





1H NMR (600 MHz, Chloroform-d)  
 
 














1H NMR (600 MHz, Chloroform-d) 
 




Ethyl (Z)-3-(4-fluorophenyl)-4-oxopent-2-enoate  
1H NMR (600 MHz, Chloroform-d) 
 
 
















Ethyl (E)-3-(4-fluorophenyl)-4-oxopent-2-enoate  










Ethyl 3-(4-Fluorophenyl)-4-oxopentanoate  
1H NMR (500 MHz, Chloroform-d) 
 
 





1H NMR (600 MHz, Chloroform-d) 
  
 






1H NMR (600 MHz, Chloroform-d) 
 
 
13C NMR (152 MHz, Chloroform-d) 
 
Ethyl 4-oxo-3-(3-(trifluoromethyl)phenyl)pentanoate 










Methyl (E)-4-(4-Fluorophenyl)-4-oxo-2-phenylbut-2-enoate  
1H NMR (600 MHz, Chloroform-d) 
 





1H NMR (600 MHz, Chloroform-d) 
 




3.5.2. Representative HPLC and SFC Traces    
4-Ethyl 1-Methyl -2-Phenylsuccinate: SFC, AD-H column, 2.5% iPrOH, 2.5 mL/min, 220 nm. 
 
 
Racemate: tR= 2.09, 4.86 min (area = 50:50) 
 
Reaction with YERS-ER: tR= 2.07 min, >99% ee 
 



















Diazocoupling reaction followed by reduction with Yers-ER: tR= 13.43min, >99% ee 
 
 








Full conversion of SM required for chiral SFC analysis. 















Full conversion of SM required for chiral SFC analysis. 
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Racemate: tR= 1.79, 3.06 min (area = 50:50)  
 
Reaction with Yers-ER: tR= 1.69, 2.89 min, 87% ee  
 
Ethyl (R)-4-oxo-3-(3-(trifluoromethyl)phenyl)pentanoate: NP HPLC, OJ-H column, 95:5 
Hexanes: IPA, 0.8 mL/min, 220 nm 
 
Full conversion of SM required for chiral HPLC analysis. 





Reaction with Yers-ER: tR= 10.190, 11.950 min, 92% ee 
 
 





Methyl (R)-4-(4-fluorophenyl)-4-oxo-2-phenylbutanoate: NP HPLC, OJ-H column, 95:5 
Hexanes : IPA, 0.8 mL/min, 220 nm. 
 
 
Full conversion of SM required for chiral HPLC analysis. 
Racemate: tR= 23.799, 29.397 min (area = 50:50)  
 





Diazocoupling reaction followed by reduction with OYE2: tR= 29.174 min, >99% ee. Other 
peaks are impurities.  
 
 
4-Benzyl 1-methyl (R)-2-phenylsuccinate: NP HPLC, OJ-H column, 95:5 Hexanes: IPA, 0.8 
mL/min, 220 nm. 
 
Full conversion of SM required for chiral HPLC analysis. 





Reaction with OPR1: tR= 47.557 min, >99% ee 
 
Tandem reaction: OJ-H column (250 mm), 90:10 Hexanes: IPA, 1 mL/min, 220 nm. 
Racemate: tR= 37.005, 43.485 min (area = 50:50)  
 
 
Diazocoupling reaction followed by reduction with OPR1: tR= 43.115 min, >99% ee. The 
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CHAPTER 4. Cooperative Asymmetric Reactions 
Combining Photocatalysis and Enzyme Catalysis 
 
4.1 Introduction 
Living organisms generate complex natural products from simple chemical precursors through 
simultaneous reactions that are catalyzed by mutually compatible enzymes. Many of these 
enzymes have been refined by evolution to be chemoselective, to react with high total turnover 
numbers, and to be highly selective. Enzymes, such as isomerases, work cooperatively with other 
enzymes, to generate products in yields and ee’s that cannot be obtained from the sequential 
reactions of the individual catalysts on their respective substrates 1,2.  In contrast, artificial organic 
total syntheses of natural products consist of sequential reactions with intermediate purification 
steps that causes these syntheses to be labor intensive, to generate large quantities of waste, and to 
generate products in low overall yields. However, chemical catalysts enable valuable 
transformations that have no biological counterpart. But the selectivity of chemical catalysts is 
often lower than that of enzymes. 
To combine the advantages of the biological systems with the reactivity of artificial 
chemical catalysts, chemists have devised sequential, concurrent, and cooperative 
chemoenzymatic reactions that combine enzymatic and artificial catalysts (Figure 4.1).3-11 
Sequential Chemoenzymatic Reaction is a chemoenzymatic reaction that consists of at least 
two distinct steps that do not occur simultaneously. A solvent exchange may be required, and/or a 
catalyst, reagent, or enzyme may be added to the reaction mixture without intermediate purification 
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step. Similar (and sometimes superior) product yields and ee’s of products can usually be achieved 
when the two reactions are conducted in different vessels.   
 
Figure 4.1. Schemes for different types of chemoenzymatic reactions  
Concurrent chemoenzymatic reaction is a chemoenzymatic reaction that includes at least 
one catalyst and at least one enzyme that simultaneously catalyze two reactions in the same 
medium (biphasic and heterogeneous systems are included). Mutual catalyst deactivation must not 
occur for these systems to operate. Similar (and sometimes superior) yields and ee’s of products 
can usually be achieved if the two reactions are conducted in a sequential manner or in different 
vessels.  
Cooperative chemoenzymatic reaction is a chemoenzymatic reaction that includes at least 
one catalyst and at least one enzyme that simultaneously catalyze two reactions in the same 
medium (biphasic and heterogeneous systems are included). The catalysts in these systems must 
operate concurrently and be mutually compatible. Cooperative chemoenzymatic processes 
generate products in yield or selectivities or both that cannot be obtained from the sequential 
reactions of the individual catalytic reactions. This unique feature of cooperative processes makes 
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them the most valuable type of chemoenzymatic process.  However, cooperative chemoenzymatic 
processes are difficult to develop because chemical and enzymatic catalysts generally operate in 
different media at different temperatures and can deactivate each other. As a result, the scope of 
cooperative chemoenzymatic processes that have been reported over the last 30 years has been 
narrow 9,11,12.  
The majority of cooperative chemoenzymatic processes that have been reported over the 
last 30 years can be divided into two categories: 1) chemoenzymatic dynamic kinetic resolutions 
of alcohols and amines, and 2) enzymatic reactions requiring the simultaneous regeneration of a 
cofactor 6,7,13. The first category of reactions has been explored extensively because of the synthetic 
utility of the products and because the esterases employed in these reactions are unusually stable 
in organic solvent at elevated temperatures. The second category of reactions has been studied 
because of the need to recycle or replace expensive or unstable biological cofactors with 
inexpensive terminal oxidants or reductants. New approaches to the development of 
chemoenzymatic reactions are needed to enable valuable chemical transformations beyond kinetic 
resolutions and cofactor regenerations. 
Chemoenzymatic transformations of alkenes would be valuable because alkenes are 
common reactants in chemical synthesis, and enantioselective reactions of alkenes are the most 
practiced class of enantioselective catalytic processes. Ene-reductases react with α,β-unsaturated 
carbonyl compounds and nitriles to generate saturated products with high enantioselectivity. 
However, these enzymes often react with just one E or Z isomer of an alkene 14. The limitations of 
my previous work (Chapter 3) on a (non-cooperative) sequential one-pot reaction in which a 
rhodium-catalyzed diazocoupling reaction generated alkenes which were reduced by ene-
reductases to provide enantioenriched 2-substituted acid diesters, inspired efforts to develop a 
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conceptually new cooperative system. In cases in which the diastereoselectivity of the diazo-
coupling reaction was low, and the ene-reductase only selectively reduced one of the isomers of 
substrate, the overall process was low yielding. Many of the most widely employed synthetic 
methods to form alkenes, including modern catalytic processes, like olefin metathesis, and 
traditional methods, like olefinations of carbonyl compounds, yield E/Z mixtures that must be 
separated before catalytic reduction to achieve high enantioselectivity. Other methods selectively 
generate an isomer of an alkene that is unreactive in the presence of common ene-reductases. Thus, 
we envisioned a chemoenzymatic reduction of olefin mixtures to highly enantioenriched products 
by combining a chemical catalyst to effect alkene isomerization and an ene-reductase to reduce 
one of the alkene isomers of the mixture. However, because thermal alkene isomerization is often 
a high-temperature process that is incompatible with enzymes, we considered the potential of a 
photocatalytic approach for the isomerization of alkenes. Here, we report a cooperative 
chemoenzymatic reaction that combines the photoisomerization of alkenes with an enzymatic 
reduction of one isomer of a mixture of E and Z alkenes (or pure Z alkenes). This system enables 
the stereoconvergent reduction of alkenes to form enantioenriched carbonyl compounds and 
nitriles (Figure 4.2) and shows the value of combining a photocatalyst with an enzyme catalyst to 
achieve cooperative processes beyond cofactor regeneration. 
 
Figure 4.2. Combining of photocatalytic isomerization and enzymatic reduction of alkenes.  
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4.2 Results and Discussion  
To develop a stereoconvergent enzymatic reduction of an isomeric mixture of alkenes, initial 
reactions were conducted with the model substrate 2-phenylbut-2-enedioic acid dimethyl ester (1a). 
YersER, an ene-reductase isolated from Yersinia bercovieri, exclusively reduces the E isomer of 
2-phenylbut-2-enedioic acid dimethyl ester ((E)-1a) to dimethyl 2-phenylsuccinate (2a) in high 
yields with excellent ee’s in the presence of a glucose dehydrogenase (GDH) enzyme for cofactor 
regeneration. To develop a stereoconvergent reduction reaction, a catalyst for the E/Z 
isomerization of olefins that is compatible with ene-reductases needed to be identified. An 
appropriate catalyst would 1) operate in aqueous solution at ambient temperature, 2) isomerize 
alkenes at rates that significantly exceed the rates of enzymatic reduction, 3) remain active in the 
presence of ene-reductases, substrates, and products in the reaction mixture, 4) isomerize olefins 
at the low substrate concentrations required for enzymatic reduction, and 5) generate the more 
reactive isomer of a substrate from the less reactive isomer. The isomerization catalyst must also 
6) be mutually compatible with the ene-reductases, 7) be mutually compatible with a glucose 
dehydrogenase NADPH regeneration system, 8) and not racemize the product. 
4.2.1. Development of Conditions for Cooperative Reaction 
Negligible isomerization was observed in our initial attempts to isomerize (E)-1a or (Z)-1b in the 
presence of various metal salts and organic catalysts in Tris buffer at ambient temperature (Data 
were not shown). Inspired by the work of Gilmour et al. and Weaver et al., we considered that 
photocatalytic isomerization of alkenes 15-18 could be combined with enzymatic reduction to create 
the envisioned cooperative chemoenzymatic process. Gilmour et al. reported the 
photoisomerization of α,β-unsaturated monoesters with riboflavin in the presence of UV (402 nm) 
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light in acetonitrile 15. This reaction is proposed to proceed via preferential singlet or triplet energy 
transfer from a photocatalyst to one alkene isomer.  
We began our investigation by assessing the photoisomerization of (Z)-1a in solvent 
mixtures appropriate for catalytic function of ene-reductases 19. We found that limited 
isomerization of (Z)-1a was observed in the semi-aqueous media (1:9 DMSO:Tris buffer) in the 
presence of blue light (450-470 nm) and in the absence of a photocatalyst (Figure 4.3). However, 
extensive isomerization of (Z)-1a was observed when the reaction was conducted with riboflavin 
in the presence of blue light. A photostationary state (PS) consisting of a 9:1 ration of (E) to (Z) 1a 
was obtained after (Z)-1a was irradiated with blue light for 24 h in the presence of 5% riboflavin 
(Figure 4.3). However, only 18% yields of 2a were obtained when YersER and riboflavin were 
employed concurrently in the presence of the blue light. This result demonstrated the importance 





Figure 4.3. Isomerization and Reduction of (Z)-1a in the Presence of a Series of Photocatalysts 
and Blue Light.  aPS is the % of (E)-1a present after (Z)-1a was irradiated with blue light in the 
presence of 5% photocatalyst for 24 h. The PS values for experiments labeled “None*” and “None” 
in have been corrected for initial trace quantities of (E)-1a. Experiments labeled “None*” were 
conducted in the presence of ambient light.  Ribo: Riboflavin, FMN: Flavin Mononucleotide, FAD: 
Flavin Adenine Dinucleotide, EosY: Eosin Y, Fluor: Fluorescein, RuBipy: Ru(Bipy)3Cl2, RuBpz: 
[Ru(Bpz)3](PF6)2, Ir-80: CAS 808142-80-5, Ir-67: CAS 676525-77-2, Ir-16: CAS 1607469-49-7, 
Ac: Acridinium Salt CAS - 674783-97-2.  
Before we evaluated the compatibility between various photocatalysts and ERs, we 
investigated the effects of DMSO concentration on the rate of alkene isomerization and enzymatic 
reduction. Higher (E)-1a:(Z)-1b ratios were obtained when the photoisomerization was conducted 
in semi-aqueous media with lower DMSO concentration within 15 minutes (Figure 4.4a). 
Isomerization rate in 5% DMSO was comparable with that in 10% DMSO and dropped 
tremendously when DMSO increased to 20%. The standard substrate cyclohexen-1-one of ERs 
was used to evaluate the catalytic activity of YersER. The depletion rate of reducing cofactor 
NADPH indicates the reducing rate of cyclohexen-1-one by YersER. The enzymatic activity will 
127 
 
be tremendously inhibited when DMSO more than 10% (Figure 4.4b). We chose 10% DMSO in 
Tris buffer as final solution to improve the solubility of substrate in aqueous solution.  
 
Figure 4.4. The effect of DMSO concentration on a) alkene photoisomerization rate and b) 
enzymatic reducing rate. *Control: the same reaction system without cyclohexen-1-one added. 
NAPDH has strongest absorption at 340nm. 2-3 minutes lag in NADPH depletion may be due to 
the substrate-enzyme binding process.  
 
We hypothesized that competitive binding of riboflavin to the flavin-binding site of YersER 
led to the inhibition of enzymatic activity 20. Thus, we sought alternative photocatalysts that would 
lead to isomerization of (Z)-1a without inhibiting YersER or the cofactor regeneration system. The 
E/Z isomerization of (Z)-1a was evaluated in the presence of a series of organometallic and organic 
photocatalysts in 1:9 DMSO:50 mM Tris buffer, and the PS for each combination is recorded in 
Fig 3.3. Greater than 40% conversion of (Z)-1a to (E)-1a was observed when the substrate was 
irradiated in the presence of the majority of the photocatalysts, and the highest E/Z ratios exceeded 
8:1 (Figure 4.3). Increasing catalyst loading and increasing light intensity enhanced the rate of 




Figure 4.5. The effect of photocatalyst loading on the %(E)-1a at photostationary state. a) 
photoisomerization of (Z)-1a by Ir-16 and b) FMN. (Data provided by Zachary C. Litman)  
 
Figure 4.6. Light intensity (distance of reaction from light source) versus % (E)-1a After 15 min 
(Data provided by Zachary C. Litman) 
 
Having identified a series of photocatalysts for the isomerization of (Z)-1a to (E)-1a in a 
semi-aqueous medium, we evaluated the “toxicity effect” of various photocatalysts on enzymatic 
system by reducing (E)-1a with YersER in the presence of photocatalysts with or without blue 
light. Riboflavin, Fluorescent and EosinY inhibited the enzymatic activity tremendously (Figure 
4.7). Although ruthenium catalysts did not jeopardize the enzymatic function, they greatly 





Figure 4.7. Enzymatic reduction of (E)-1a (more reactive isomer) in the presence of different 
photocatalysts with or without blue light 
  
We further evaluated the concurrent cooperative photoisomerization and enzymatic 
reduction of (Z)-1a with the same photocatalysts (Figure 4.3). Moderate to high yields of 2a were 
obtained when a range of catalysts were used in the cooperative process. The highest conversions 
and yields were obtained when the cooperative reaction was conducted with 5% of flavin 
mononucleotide (FMN) or 1% of the cationic iridium(III) complexes [Ir(dmppy)2(dtbbpy)]PF6 (Ir-
16), [Ir(dtbbpy)(ppy)2]PF6 (Ir-67), and [Ir(dtbppy)2(dtbbpy)]PF6 (Ir-80). High isomerization rate 
























Figure 4.8. Photoisomerization of (Z)-1a with 5% FMN or 1% Ir-16 
4.2.2. Substrates Scope  
The high yields and ee’s obtained from the cooperative reduction of the model diester (Z)-
1a encouraged us to investigate the cooperative reduction of other aryl diesters. We identified 
enzymes that preferentially reduce the E isomers of diesters 1b-1f in Figure 4.9 in high yields and 
ee’s (Table 4.2). These enzymes were then employed in the cooperative reduction of the Z isomers 
of 1b-1d with Ir-16 or FMN as a photocatalyst in the presence of blue light. High yields of product 
were obtained from the cooperative isomerization and reduction of each of the diesters, including 
those containing electron-rich ((Z)-1b) and electron-poor aryl groups ((Z)-1d) with either FMN or 
Ir-16 as photocatalysts and the enzymes YersER, XenB, or OPR1 (Table 4.2). The yields and ee’s 
of the products obtained from the cooperative reductions of the Z isomers of 1b-1d were equivalent 
to those obtained from the enzymatic reduction of the E isomers of substrates 1b-1d in the absence 
of the photocatalyst. This result implies that the cooperative reduction of any E/Z mixture of these 
alkenes should give high yields and ee’s of reduced products. This feature of the cooperative 
system was crucial for obtaining high yields and ee’s for the reduction of 1e and 1f, which were 
synthesized as inseparable mixtures of E and Z alkenes. The cooperative chemoenzymatic 
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reduction of a 62:38 mixture of E and Z isomers of 1e afforded 2e in 74% yield and >99% ee, and 
the cooperative reduction of a 61:39 mixture of E and Z isomers of 1f afforded 2f in 94% yield and 
91% ee. The yields and ee’s from the cooperative reduction of (E/Z)-1e and (E/Z)-1f indicate that 
the reactions were stereoconvergent. The enzymatic reductions of 1e and 1f in the absence of a 
photocatalyst and light formed the reduced products in only 58% and 60% yield, reflecting the 
reaction with only the E isomer of the E/Z mixture (Table 4.1). 
To determine if the cooperative reaction would give high yields and high 
enantioselectivities with alkenes other than diesters, the cooperative reduction of unsaturated 
compounds containing diverse combinations of functional groups was evaluated. The ene-
reductases OPR1, TOYE, OYE2, YersER, and SYE1 preferentially reduced the E isomers of 
alkenes 1g-1o to form 2g-2o in high yields and ee’s. The cooperative reactions of the Z isomers of 
1g-1o were then conducted with Ir-16 or FMN in the presence of blue light. The results from the 
combination of photocatalyst and enzyme that generated the products in the highest yields and ee’s 
from the Z isomers of 1g-1o are shown in (Table 4.2). High yields and ee’s were obtained for the 
cooperative reduction of β-cyano-α,β-unsaturated ester (Z)-1h,  α-cyano-α,β-unsaturated esters 
(Z)-1i and (Z)-1j, and amidocyanate (Z)-1k. High yields and ee’s were also obtained from the 
reactions of cyanoketone (Z)-1l, β-keto-α,β-unsaturated esters (Z)-1m and (Z)-1n, and α-keto-α,β-
unsaturated ester (Z)-1o. The cooperative reductions of amidoacrylate (Z)-1g and amidocyanate 
(Z)-1k are noteworthy because enzymatic reductions of alkenes containing Weinbreb amides have 
not been reported to our knowledge. Control experiments revealed that (Z)-1l, (Z)-1m, and (Z)-1n 
undergo enzymatic reduction to generate products in high yields and ee’s in the presence of blue 
light but in the absence of an added photocatalyst (Table 4.2). In these cases, the alkenes (1l-1n) 




Figure 4.9. Scope of the cooperative photoisomerization and reduction and comparison to 
sequential reactions.  
 
 
Figure 4.10. Photoisomerization of alkenes under different conditions. Red bar indicated the 
reactions conducted with 5% FMN, 50 mM Tris buffer at pH 7.5, and 5% DMSO at RT in the 
presence of blue light. Orange bar indicated the reactions conducted with 1% Ir-16, 50 mM Tris 
buffer at pH 7.5, and 5% DMSO at RT in the presence of blue light. Blue bar indicated reactions 
conducted with 50 mM Tris buffer at pH 7.5, and 5% DMSO at RT in the presence of blue light. 
Grey bar indicated reactions conducted with 50 mM Tris buffer at pH 7.5, and 5% DMSO at RT 
in the presence of ambient light. (The detailed of experimental setting and values are presented in 



































5% FMN 1% Ir-16 Blue Light Only Ambient Light
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Table 4.1. Enantioselective enzymatic reduction of substrates 1a to 1p 
 
Entry Substrate Enzyme % Conversiona % Yielda % eeb 
1 E-1a YersER 100% 88% >99% 
2 Z-1a YersER 0% 0% - 
3 E-1b YersER 100% 87% >99% 
4 Z-1b YersER 0% 0% - 
5 E-1c XenB 90% 82% >99% 
6 Z-1c XenB 0% 0% - 
7 E-1d xenB 98% 92% 93% 








XenB 60% 60% 88% 
11 E-1g OPR1 100% 92% >99% 
12 Z-1g OPR1 0% 0% - 
13 E-1h TOYE 98% 93% >99% 
14 Z-1h TOYE 0% 0% - 
15 E-1i OYE2 100% 98% 94% 
16 Z-1i OYE2 7% 3% - 
17 E-1j OYE2 100% 94% 76% 
18 Z-1j OYE2 0% 0% - 
19 E-1k YersER 100% 87% 99% 
20 Z-1k YersER 10% 6% - 
21 E-1l OYE2 100% 98% >99% 
22 Z-1l OYE2 0% 0% - 
23 E-1m OPR1 100% 90% >99% 
24 Z-1m OPR1 30% 26% - 
25 E-1n SYE1 100% 96% 89% 
26 Z-1n SYE1 0% 6% - 
27 E-1o YersER 100% 80% 98% 
28 Z-1o YersER 0% 0% - 
29 Z-1p SYE1 100% 78% >99% 
30 E-1p YersER 14% 14% - 
Standard conditions: reactions were conducted with 0.5% ene-reductase, 1 U/mL GDH, 25 mM glucose, 0.2 
mM NADP+, 50 mM Tris buffer at pH 7.5, and 10% DMSO at RT. a Year and conversion determined by GC. 
bee determined by chiral HPLC.  
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Table 4.2. Cooperative photoisomerization and reduction of substrates 1a to 1p 
 
Entry Substrate Type Enzyme Photocat. PS (%E)c % Conversiona % Yielda % eeb 
1 Z-1a I YersER - - 8% 4% - 
2 Z-1a II YersER 5% FMN 94% 99% 70% >99% 








III YersER 1% Ir-16 - 96% 89% >99% 
6 Z-1b I YersER - - 7% 7% - 
7 Z-1b II YersER 5% FMN 61% 72% 63% 92% 
8 Z-1b III YersER 1% Ir-16 69% 89% 89% >99% 
9 Z-1c I XenB - - 15% 14% - 
10 Z-1c II XenB 5% FMN 92% 58% 39% - 
11 Z-1c III XenB 1% Ir-16 68% 89% 89% >99% 
12 Z-1d I XenB - - 12% 11% - 
13 Z-1d II XenB 5% FMN 94% 70% 58% - 
















I XenB - - 63% 63% - 
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21 Z-1g I OPR1 - - 9% 9% - 
22 Z-1g II OPR1 5% FMN 97% 28% 21% - 
23 Z-1g III OPR1 1% Ir-16 88% 98% 82% >99% 
24 Z-1h I TOYE* - - 7% 7% - 
25 Z-1h II TOYE* 1% FMN 69% 99% 98% >99% 
26 Z-1h III TOYE* 1% Ir-16 68% 88% 87% >99% 
27 Z-1i I OYE2* - - 10% 5% - 
28 Z-1i II OYE2* 1% FMN 46% 100% 94% 99% 




II OYE2* 1% FMN - 99% 94% 98% 
31 (50/50) 
(E/Z)-1i 
III OYE2* 1% Ir-16 - 99% 92% 98% 
32 Z-1j I OYE2 - - 3% 3% - 
33 Z-1j II OYE2 5% FMN 3% 78% 60% 90% 
34 Z-1j III OYE2 5% Ir-16 9% 92% 80% 92% 
35 Z-1k I YersER* - - 26% 20% - 
36 Z-1k II YersER* 5% FMN 71% 100% 82% 99% 
37 Z-1k III YersER* 1% Ir-16 70% 100% 96% 99% 
38 Z-1l I OYE2 - 89% 100% 95% >99% 
39 Z-1l II OYE2 5% FMN 87% 94% 46% - 
40 Z-1l III OYE2 1% Ir-16 73% 99% 86% - 
41 Z-1m I OPR1 - 92% 100% 80% >99% 
42 Z-1m II OPR1 5% FMN 82% 100% 73% 95% 
44 Z-1m III OPR1 1% Ir-16 83% 100% 81% >99% 
45 Z-1n I SYE1 - 77% 78% 65% - 
46 Z-1n II SYE1 5% FMN 80% 39% 3% 76% 
47 Z-1n III SYE1 1% Ir-16 78% 65% 60% 88% 
48 Z-1o I YersER - - 24% 20% - 
49 Z-1o II YersER 5% FMN 89% 100% 90% 86% 
50 Z-1o III YersER 1% Ir-16 76% 100% 92% 96% 
51 E-1p I
d OYE2 - - 48% 8% - 
52 E-1p II
d OYE2 5% FMN 14% 89% 22% - 
53 E-1p III
d OYE2 1% Ir-16 14% 98% 74% >99% 
Type I reaction: reactions were conducted with 0.5% ene-reductase, 1 U/mL GDH, 25 mM glucose, 0.2 mM NADP+, 50 mM Tris buffer at pH 7.5, and 10% DMSO at RT in the 
presence of blue light. Type II reaction: reactions were conducted with 0.5% ene-reductase, 1 U/mL GDH, 5% FMN, 25 mM glucose, 0.2 mM NADP+, 50 mM Tris buffer at pH 
7.5, and 10% DMSO at RT in the presence of blue light. Type III reaction: Type II reaction: reactions were conducted with 0.5% ene-reductase, 1 U/mL GDH, 1% Ir-16, 25 mM 
glucose, 0.2 mM NADP+, 50 mM Tris buffer at pH 7.5, and 10% DMSO at RT in the presence of blue light. a Year and conversion determined by GC. bee determined by chiral 
HPLC. c PS is the % E of a substrate present after the Z isomer (or E/Z isomer mixture) was irradiated with light in the presence of either 5% FMN or 1% Ir-16 for 24 h. In the 
case of 1p, (E)-1p was irradiated with blue light in the presence of FMN and Ir-16 for 24 h, and the % of (Z)-1p was determined. dIsomers used in these experiments different 




4.2.3. Cooperative Concurrent Reaction Versus Sequential Reaction  
The cooperative enzymatic reductions of alkenes 1i and 1j shown in Fig. 3.11 illustrate the benefits 
of a cooperative system over two sequential reactions. The photoisomerization of (Z)-1i and (Z)-
1j with Ir-16 or FMN result in E/Z mixtures in which the less reactive Z isomer is the major 
component. As a result, low yields were obtained from the sequential isomerization and reduction 
of (Z)-1i and (Z)-1j. The ee of 2i obtained from the sequential isomerization and reduction of (Z)-
1i was slightly lower than the ee obtained from the enzymatic reduction of the pure, more reactive 
isomer (E)-1i, and this difference likely results from the slow reduction of the Z isomer of 1i after 
rapid consumption of the E isomer during the second stage of the sequential process Figure 4.11. 
In contrast, the simultaneous, cooperative reduction of (Z)-1i and (Z)-1j generated products 2i and 
2j in both high yields and ee’s.  
 
Figure 4.11. Comparison of sequential (1) vs. cooperative reduction (2) of cyanoacrylates 1i and 




An enzyme that selectively reduces the E isomer of trifluoromethylcyanate 1p in high yield and 
ee could not be identified, but OYE2 selectively reduces the Z isomer of 1p in high yield and ee 
(Table 4.1). To determine if a cooperative reaction could convert (E)-1p to 2p in high yield and ee, 
the ability of (E)-1p to undergo photoisomerization in the presence of Ir-16 and blue light was 
evaluated. An 86:14 ratio of the E/Z isomers of 1p was established after 24 h of irradiation with 
blue light in the presence of Ir-16. Although the photostationary state of 1p favors the less reactive 
E isomer, the cooperative reaction of (E)-1p to 2p occurred in high yield and ee with Ir-16 as the 
photocatalyst and OYE2 as the reductase. This example illustrates an important benefit of the 
cooperative chemoenzymatic reaction: the system enables either the isomerization of a Z alkene 
with simultaneous enzymatic reduction of the E isomer or the isomerization of an E alkene with 
simultaneous enzymatic reduction of the Z isomer. The conversion of (E)-1p to 2p is also 
noteworthy because enzymatic reduction to generate a product containing a stereogenic center 
substituted with a trifluoromethyl group is rare.  
4.2.4. Derivatization of Synthesized Enantioenriched Products 
To demonstrate the synthetic value of this new method, preparative scale cooperative reactions 
were conducted with 1% Ir-16 and 40-60 mg of (Z)-1a, a 62:38 mixture of the E and Z isomers of  
1e, (Z)-1g, (Z)-1h, and (Z)-1o. Product 2a was isolated in 87% yield and >99% ee, product 2e was 
isolated in 79% yield and >99% ee, product 2g was isolated in 71% yield and >99% ee, product 
2h was isolated in 96% yield and 92% ee, and product 2o was isolated in 79% yield and >99% ee 





Table 4.3. Summary of prep scale cooperative reactions 
 
Entry Substrate Enzyme Time % Conversiona % Yielda % eeb 






96% 79% >99% 
3 Z-1g OPR1 24h 92% 71% >99% 
4 Z-1h TOYE 24h 100% 96% 92% 
5 Z-1o YersER 24h 98% 79% >99% 
. a Isolated yield. bee determined by chiral HPLC. c Conducted with 0.2% OPR1.  
 
The enantioenriched compounds that were obtained from the cooperative isomerization 
and enzymatic reduction system can be transformed into a variety of biologically active molecules 
and valuable synthetic intermediates (Fig. 3.12). For example, the selective hydrolysis of the tert-
butyl ester in compound 2e followed by a Curtius rearrangement yielded 3e, a β2-amino ester. The 
β-amino ester was isolated in 90% yield without significant erosion of enantiomeric excess (98% 
ee). The selective reduction of the Weinreb amide in compound 2g with Schwartz’s reagent yielded 
methyl 4-oxo-2-phenylbutanoate (3g) in 74% isolated yield and 99% ee. This compound is an 
intermediate in the synthesis of protein kinase inhibitors and microsomal triglyceride transfer 
protein inhibitors.21,22 Acid-catalyzed hydrolysis of the nitrile in 2p yielded 4,4,4-trifluoro-3-
phenylbutanoic acid (3p) in 96% yield and >99% ee. This versatile synthetic intermediate has 
previously been employed in the synthesis of inhibitors of beta amyloid production.23,24 Reduction 
of 2a with lithium aluminum hydride formed 2-phenylbutane-1,4-diol (3a) in 93% yield and >99% 
ee. This diol is a synthetic precursor to inhibitors of matrix metalloproteases.25 Other products of 
139 
 
the cooperative reactions are known precursors to biologically active compounds. For example, 2i 
and 2j have been converted previously to -amino acids (including balcofen and phenibut) and -
lactams,26 2h has been converted into a 2 amino ester and a 2 lactam,27 and 2m has been converted 
into calyxolanes, which are cyclic ether natural products.28 Thus, the products of the cooperative 
chemoenzymatic reduction are precursors to valuable synthetic intermediates by both newly 
disclosed and previously reported transformations. (Derivatizations were performed by Zachary 
Litman. The detailed steps were presented in SI of publication: Nature, volume 560, pages355–
359 (2018)).  
 
Figure 4.12. Derivatization of enantioenriched products.  
 
A short summary of the previously reported and newly disclosed transformations of the 
products of the chemoenzymatic cooperative reduction of alkenes are follows. (1) Conversion 2a 
to 3a: 4.0 equiv LiAlH4, THF, 5 h, RT. (2) Conversion of 2e to 3e: i. 1:1 TFA:DCM, 3 h, RT. ii. 
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1.7 equiv NEt3, DCE, and 1.5 equiv DPPA, 65 ºC, 2 h.  iii. 0.10 equiv of Mo(O)2Cl2, t-BuOH, 65 
ºC, 1 h 10 min. (3) Conversion of 2g to 3g: 1.4 equiv Cp2Zr(H)Cl, 1.0 equiv ZrF4, 1:1 THF:DCM, 
3 h, RT. (4) Conversion of 2h to 3h was previously reported.27 (5) Conversion of 2i to 3i was 
previously reported.26 (6) Conversion of 2j to 3j was previously reported.26 (7) Conversion of 2m 
to 3m was previously reported.28 (8) Conversion of 2p to 3p: 1:1 H2O:H2SO4, 6 h, 120 ºC.  
4.3 Conclusion  
The combination of a photocatalytic process and an enzymatic reaction enables transformations 
that combine the reactivity of chemical catalysts with the selectivity of enzymes. Two features of 
photocatalytic reactions make them, in general, suitable for chemoenzymatic processes: 1) 
photochemical reactions typically occur at or near room temperature, making them compatible 
with thermal requirements of enzymatic systems, and 2) photocatalysts often react by mechanisms, 
such as outer-sphere electron transfer or energy transfer, that involve intermediates that are stable 
to water and the functional groups in proteins. These considerations, in combination with the 
renewed interest in photocatalysis and the rapidly advancing tools of molecular biology, should 
create opportunities for the development of a wide range of new cooperative chemoenzymatic 
transformations.  
4.4 Experimental procedures  
4.4.1. General Materials   
All air-sensitive manipulations were conducted in a nitrogen-filled glovebox or by standard 
Schlenk technique under nitrogen. All glassware was heated in an oven and cooled under an inert 
atmosphere prior to use. Vials (4 mL) were used as reaction vessels and were sealed with Teflon-
lined-lined caps. Products were visualized on TLC plates with an anisaldehyde stain and a heat 
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gun. 1H and 13C NMR spectra were acquired on 300 MHz, 400 MHz, 500 MHz, or 600 MHz 
Bruker instruments at the University of California. 19F NMR spectra were obtained at 376 MHz 
on a 400 MHz instrument – chemical shifts relative to CFCl3 at 0 ppm. NMR spectra were 
processed with MestReNova 5.0 (Mestrelab Research SL). Chemical shifts are reported in ppm 
and referenced to residual solvent peaks (CHCl3 in CDCl3: 7.26 ppm for 
1H and 77.16 ppm for 
13C). Coupling constants are reported in hertz. Flash chromatography was performed with a 
Teledyne ISCO CombiFlash RF 200 with Gold-Top silica. E/Z ratios were determined by 1H NMR 
spectroscopy and corrected values obtained from GC analysis. High-resolution mass spectra were 
obtained via the Micro-Mass/Analytical Facility operated by the College of Chemistry, University 
of California, Berkeley. Organometallic photocatalysts were purchased from Aspira Scientific. 
Organic photocatalysts were purchased from Sigma Aldrich. 
Chiral HPLC analyses were performed 3 instruments: HPLC1 - GL science GL-7400 
instrument using Daicel Chiracel columns at 35 ˚C, HPLC2 - Agilent 1100 series, HPLC3 - 
Shimadzu Prominence HLPC system with SPD-M20A UV/VIS Photodiode array detector. A 
mixture of HPLC-grade hexanes and isopropanol were used as eluents. Chiral SFC analyses were 
performed on a Jasco instrument using Daicel Chiracel columns at 40 ˚C and HPLC-grade 
isopropanol as the co-eluent. Optical rotations were measured on Perkin Elmer 241 and JASCO 
P-1030 polarimeters equipped with sodium vapor lamps at 589 nm and sample concentrations are 
denoted as c. (in g/100 mL). 
E. coli DH5α cells were purchased from the Cell Media Facility at the University of Illinois 
at Urbana-Champaign (Urbana, IL). Escherichia coli BL21 (DE3) and plasmid pET28a+ were 
purchased from Novagen (Madison, WI). Oligonucleotides for cloning were purchased from 
Integrated DNA Technologies (IDT) (Coralville, IO). Restriction enzymes were purchased from 
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New England Biolabs (Ipswich, MA). NADPH was purchased from Enzo Life Sciences 
(Farmingdale, NY). NADP+ was purchased from Roche Diagnostics (Indianapolis, IN). Isopropyl-
β-D-thiogalactoside (IPTG) was purchased from GoldBio (St. Louis, MO). The strain Bacillus 
megaterium (B14308) was obtained from the NRRL culture collection (Peoria, IL).  
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4.4.3. Experimental Apparatus   
Blue Light Source (Blue LED Lamp): 34 W Kessil KSH150B Blue LED Grow Light with cooling 
fan. Unless otherwise indicated, all reactions requiring blue light were conducted with the Kessil 
blue lamp positioned 20 cm from the base of the stir plate. Both 4 mL and 20 mL vials were placed 
horizontally on the stir-plate (Figure 4.13). http://kessil.com/photoredox/Products.php 
  
Figure 4.13. Blue LED Light Setup and Emission Spectrum of Blue LED Light 
 
4.4.4. Cloning, Expression and Purification of Enzymes 
YersER  
The YersER employed in this research was originally isolated from Yersinia bercovieri. The 
codon-optimized gene was synthesized by IDT and cloned in pET28a with N-terminal His-tag. 
For expression of YersER, a BL21 colony harboring pET28a-YersER was inoculated in 5 mL LB 
containing 100 µg/mL ampicillin and grown overnight at 37 ºC. This overnight culture was used 
to inoculate 500 mL of TB medium containing 100 µg/mL ampicillin, which was grown at 37 ºC 
until an OD of ~0.6 was reached. Protein expression was subsequently induced with the addition 
































The OYE1/2/3 ene-reductases employed in this research were originally isolated from baker’s 
yeast. The plasmids pET30a-OYE1/2/3 with N-terminal His tag were gifts from Dr. Francesco G. 
Gatti’s lab. The plasmids were transformed into E. coli BL21. For expression of OYE1/2/3, BL21 
colonies harboring pET30a-OYE1/2/3 respectively were inoculated in 5 mL LB containing 50 
µg/mL kanamycin and grown overnight at 37 ºC. These overnight cultures were used to inoculate 
500 mL of LB medium containing 50 µg/mL kanamycin, which were grown at 37 ºC until ODs of 
~0.6 were reached. Protein expression was subsequently induced with the addition of 0.1 mM 





























The OPR1 employed in this research was originally isolated from Lycopersicon esculentum 
(tomato). The plasmid pET21b-OPR1 with C-terminal His tag was a gift from Dr. Kurt Faber’s 
group. The plasmid was transformed into E. coli BL21. For expression of OPR1, a BL21 colony 
harboring pET21b-OPR1 was inoculated in 5 mL LB containing 100 µg/mL ampicillin and grown 
overnight at 37 ºC. This overnight culture was used to inoculate 500 mL of TB medium containing 
100 µg/mL ampicillin, which was grown at 37 ºC until an OD of ~0.6 was reached. Protein 
expression was subsequently induced with the addition of 1 mM IPTG. The induced culture was 










The XenB employed in this research is from Pseudomonas putida ATCC 17453. The plasmid 
pGaston-XenB with C-terminal His-tag was a gift from Dr. Uwe T. Bornscheuer’s group. The 
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plasmid was transformed into E. coli BL21. For expression of XenB, a BL21 colony harboring 
pGaston-XenB was inoculated in 5 mL LB containing 100 µg/mL ampicillin and grown overnight 
at 37 ºC. This overnight culture was used to inoculate 500 mL of LB medium containing 100 
µg/mL ampicillin, which was grown at 37 ºC at 180 rpm until an OD of ~0.6-0.8 was reached. 
Protein expression was subsequently induced with the addition of 0.2% (w/v) r-rhamnose. The 










The TOYE employed in this research was originally isolated from Thermoanaerobacter 
pseudetahnolicus E39. The plasmid pET21b-TOYE with C-terminal His tag was a gift from Dr. 
Uwe T. Bornscheuer’s group. The plasmid was transformed into E. coli BL21. For expression of 
TOYE, a BL21 colony harboring pET21b-TOYE was inoculated in 5 mL LB containing 100 
µg/mL ampicillin and grown overnight at 37 ºC. This overnight culture was used to inoculate 500 
mL of  LB medium containing 100 µg/mL ampicillin, which was grown at 25 ºC at 250 rpm until 
an OD of ~0.5 was reached. Protein expression was subsequently induced with the addition of 0.4 












The SYE1 employed in this research was originally isolated from Shewanella. The codon-
optimized gene was synthesized by IDT and cloned in pET28a with N-terminal His-tag. For 
expression of SYE1, a BL21 colony harboring pET28a-SYE1 was inoculated in 5 mL LB 
containing 100 µg/mL ampicillin and grown overnight at 37 ºC. This overnight culture was used 
to inoculate 500 mL of TB medium containing 100 µg/mL ampicillin, which was grown at 37 ºC 
until an OD of ~0.6 was reached. Protein expression was subsequently induced with the addition 











GDH from Bacillus megaterium  
Bacillus megaterium B14308 was inoculated in 5 mL TGY medium and grown at 30 ºC for 18 h. 
Genomic DNA was isolated using the Wizard® Genomic DNA purification kit from Promega 
according to the manufacturer’s protocol. The gene encoding the gdh was amplified from the 
genome of B. megaterium using primers gdh-NdeI-for and gdh-HindIII-rev. Restriction sites are 
underlined. The gene was ligated into pET28a+ and transformed in E. coli DH5α. 
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The plasmid pET28a-gdh was transformed into E. coli BL21. For expression of GDH, a BL21 
colony harboring pET28a-gdh was inoculated in 5 mL LB containing 50 µg/mL kanamycin and 
grown overnight at 37 ºC. This overnight culture was used to inoculate 500 mL of TB medium 
containing 50 µg/ml kanamycin, which was grown at 37 ºC until an OD of ~0.7 was reached. 
Protein expression was subsequently induced with the addition of 0.3 mM IPTG. The induced 
culture was placed at 25 ºC for 16 h for protein production. 
Following expression, BL21 cells were recovered by centrifugation (6000 x g for 15 min), lysed 
by sonication and clarified by centrifugation (18 000 x g for 30 min). The protein was subsequently 
purified by affinity chromatography using a HisTrap column fitted to an AKTA FPLC system (GE 
Health Life Sciences, Pittsburgh, PA). The purified protein was buffer exchanged against 100 mM 
KPi buffer, pH 8.1 using an Amicon Ultra concentration tube (10 kDa cut-off) before being stored 
in 15% glycerol as 100 µL aliquots at -80 ºC 
4.4.5. GC/MS Methods and Calibration Curve  
Instrument 1: 1 L was injected in a split mode (20:1) into the GC-MS system consisting of an 
Agilent 6890 (Agilent Inc, Palo Alto, CA, USA) gas chromatograph, an Agilent 5973 mass 
selective detector, and Agilent 7683B autosampler. Gas chromatography was performed on a 30 
m HP-5MS with 0.25 mm inner diameter (I.D.) and 0.25 m film thickness (Agilent, USA) with 
an injection temperature of 250 ºC, MSD transfer line of 250 ºC, and the ion source adjusted to 230 
ºC. The helium carrier gas was set at a constant flow rate of 1 ml min-1. The temperature program 
for different samples is listed below. The mass spectrometer was operated in positive electron 
impact mode (EI) at 69.9 eV ionization energy in m/z 30-500 scan range. The spectra of all 
chromatogram peaks were evaluated using the HP Chemstation (Agilent, Palo Alto, CA, USA). 
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Instrument 2: 1 L was injected in a split mode (20:1) into the GC-MS system consisting of an 
Agilent 6890N (Agilent Inc, Palo Alto, CA, USA) gas chromatograph, an Agilent 5975B mass 
selective detector, and Agilent 7683B autosampler. Gas chromatography was performed on a 30 
m DB-5MS column with 0.25 mm inner diameter (I.D.) and 0.25 m film thickness (Agilent 
Technologies, USA) with an injection temperature of 300 ºC, MSD transfer line of 230 ºC, and 
the ion source adjusted to 230 ºC. The helium carrier gas was set at a constant flow rate of 1 ml 
min-1. The temperature program was different for different samples. The mass spectrometer was 
operated in positive electron impact mode (EI) at 69.9 eV ionization energy in m/z 30-500 scan 
range. The spectra of all chromatogram peaks were evaluated using the HP Chemstation 
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Figure 4.15. cont.  
 
 
4.4.6. Photocatalyzed Isomerization of Alkenes and Control Experiments   
The isomerization reactions presented in Figure 4.3 were conducted on a 0.5 mL scale in the 
absence of an ene-reductase, GDH, NADP+, and glucose. E/Z ratios were determined by GC 
analysis. The experiment labeled “None*” was conducted in the absence of a photocatalyst under 
ambient light. The experiment labeled “None” was conducted in the presence of blue light, but in 
the absence of a photocatalyst. Both “None” and “None*” were corrected for initial trace 
quantities of (E)-1a present in the starting material (Z)-1a.  
The isomerization reactions presented in Figure 4.10 were conducted on a 0.5 mL scale in 
the absence of an ene-reductase. The PS values (photostationary states) for the isomerization of 
substrates in the presence of Ir-16 and FMN are listed on the table below.  (62/38) (E/Z)-1e, and 



























































Table 4.4. Tabulated Results of Figure 4.10 for the Photoisomerization of Alkenes Under 












1% Ir- 16 
blue light 
1a Ph Est 0.1a 1.2a 93.9 77.9 
1b p-OMe Est 3.4a 7.6a 60.9 69.0 
1c p-F Est 0.0a 1.4a 92.1 67.9 
1d p-CF3 Est 0.0 0.0 93.5 72.3 
1e tBu Est 62.3 62.5 93.1 66.6 
1f Py Est 61.3 63.7 96.0 81.3 
1g Est Wein 0.0a 1.1a 96.9 87.6 
1h Est CN 0.3a 0.4a 71.9 67.9 
1i CN Est 0.0 0.0 45.3 60.9 
1j p-Cl CN Est 0.0 0.0 2.9 9.0 
1k CN Wein 0.0a 2.8a 70.9 69.8 
1l CN Ph Keto 16.7 88.6 87.3 72.5 
1m Est Ph Keto 2.9 92.3 82.0 83.3 
1n Est Me Keto 24.8 76.8 79.9 77.8 
1o top Keto Est 0.0a 1.0a 88.5 75.7 
a Initial trace quantities of E substrate were subtracted from values obtained after subjecting (Z)-
1x to various conditions. b 1% FMN. c 1% FMN, 2h. d 5% Ir-16.  
It is unlikely that substrates 1e and 1f undergo isomerization in the presence of ambient 
light (the E/Z ratios obtained from the reactions conducted in ambient light closely match the 
initial E/Z ratios). Because of 1e’s structural similarity to 1a and other related diesters, and the 
high yields obtained in the cooperative experiments (see section G), it is highly likely that 1e 
undergoes rapid isomerization in the presence of blue light and 1% Ir-16 (even though the final 
photostationary ratio with Ir-16 closely resembles the initial E/Z ratio).  Substrates 1l, 1m, and 
1n undergo some isomerization in the presence of ambient light at room temperature. The Z 
isomers of 1l, 1m, and 1n, could be isomerized in the presence of blue light alone. However, the 
reduction of the Z isomer of these substrates could only be accomplished in high yields when the 
reactions were conducted in the presence of blue light (with or without a catalyst).  
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Since (Z)-1p is the more reactive isomer for OYE2, (E)-1p was used as the starting material for 
isomerization experiments involving 1p. All other experimental details were identical to the ones 
described above. 
4.4.7. General Synthetic Procedures for the Cooperative and Non-Cooperative 
Enzymatic Reduction of Alkenes  
General Procedure 1: Enzymatic Reduction of Alkenes 
 
To a 4 mL vial containing a magnetic stir bar, a solution of NADP+ (5.00 μL of 20.0 mM stock, 
0.0400 equiv), glucose (12.5 μL of a 1.00 M stock, 5.00 equiv), GDH (1.00 U/mL) and ene-
reductase (0.200 or 0.500 mol %) in 50 mM pH 7.5 Tris buffer (~450 uL) was added a solution 
of alkene (0.00250 mmol, 1.00 equiv, in 25.0 μL DMSO) at room temperature. The final solution 
volume was ~500 μL. The final reagent and catalyst concentrations were as follows: 0.200 mM 
NADP+, 25.0 mM glucose, 1 U/mL GDH, 10 or 25 μM ene-reductase, 5.00 mM substrate, 5.00 
v/v% DMSO. The reaction was incubated for ~15 h at 24 ºC on a magnetic stirrer. At the end of 
this period, EtOAc (1 mL) and dodecane (10.0 μL of 0.0200 g/mL stock in EtOAc) were added. 
An aliquot was removed from the organic layer, and the yield and conversion of the reaction 
were determined by GC analysis with dodecane as the internal standard.  
The ee of the product was obtained from a separate reaction conducted on a 5 mL scale 
(10 X scale of the general procedure listed above) in a 20 mL vial. Concentrations of all reagents 
and catalysts were identical to those listed above. After the reaction was incubated for ~15 h at 
24 ºC, EtOAc was added, and the organic layer was extracted three times. The combined organic 
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layers were concentrated under vacuum and purified by preparative TLC. The ee of the product 
was determined by Chiral HPLC or SFC. 
 
General Procedure 2: Reactions Conducted in the Absence of a Photocatalyst but in the 
Presence of Light 
 
To a 4 mL vial containing a magnetic stir bar, a solution of NADP+ (5.00 μL of 20.0 mM 
stock, 0.0400 equiv), glucose (12.5 μL of a 1.00 M stock, 5.00 equiv), GDH (1.00 U/mL) and ene-
reductase (0.200 or 0.500 mol %) in 50 mM pH 7.5 Tris buffer (~450 uL) was added a solution of 
alkene (0.00250 mmol, 1.00 equiv, in 25.0 μL DMSO) at room temperature. The final solution 
volume was ~500 μL. The final reagent and catalyst concentrations were as follows: 0.200 mM 
NADP+, 25.0 mM glucose, 1 U/mL GDH, 10 or 25 μM ene-reductase, 5.00 mM substrate, 5.00 
v/v% DMSO. The reaction was irradiated with a with a blue LED lamp positioned 20 cm above 
the reaction vial for ~15 h at 24 ºC on a magnetic stirrer. At the end of this period, EtOAc (1 mL) 
and dodecane (10.0 μL of 0.0200 g/mL stock in EtOAc) were added. An aliquot was removed 
from the organic layer, and the yield and conversion of the reaction were determined by GC 
analysis with dodecane as the internal standard.  
The ee of the product was obtained from a separate reaction conducted on a 5 mL scale 
(10 X scale of the general procedure listed above) in a 20 mL vial. Concentrations of all reagents 
and catalysts were identical to those listed above. After the reaction was incubated for ~15 h at 
24 ºC, EtOAc was added, and the organic layer was extracted three times. The combined organic 
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layers were concentrated under vacuum and purified by preparative TLC. The ee of the product 
was determined by Chiral HPLC or SFC. 
 
General Procedure 3: Cooperative Enzymatic Reduction of Alkenes in the Presence of a 
Photocatalyst and Light 
 
To a 4 mL vial containing a magnetic stir bar, a solution of NADP+ (5.00 μL of 20.0 mM 
stock, 0.0400 equiv), glucose (12.5 μL of a 1.00 M stock, 5.00 equiv), GDH (1.00 U/mL) and ene-
reductase (0.200 or 0.500 mol %) in 50 mM pH 7.5 Tris buffer (~425 uL) was added a solution of 
alkene (0.00250 mmol, 1.00 equiv, in 25.0 μL DMSO) at room temperature. A solution containing 
FMN or Ir-16 (1.00 or 5.00 mol %) and 25.0 μL of DMSO was added. The final solution volume 
was ~500 μL. The final reagent and catalyst concentrations were as follows: 0.200 mM NADP+, 
25.0 mM glucose, 1 U/mL GDH, 10 or 25 μM ene-reductase, 5.00 mM substrate, 0.250-0.0500 
mM FMN or Ir-16, and 10.0 v/v% DMSO. The reaction was irradiated with a with a blue LED 
lamp positioned 20 cm above the reaction vial for ~15 h at 24 ºC on a magnetic stirrer. At the end 
of this period, EtOAc (1 mL) and dodecane (10.0 μL of 0.0200 g/mL stock in EtOAc) were added. 
An aliquot was removed from the organic layer, and the yield and conversion of the reaction were 
determined by GC analysis with dodecane as the internal standard.  
The ee of the product was obtained from a separate reaction conducted on a 5 mL scale (10 
X scale of the general procedure listed above) in a 20 mL vial. Concentrations of all reagents and 
catalysts were identical to those listed above. After the reaction was incubated for ~15 h at 24 ºC, 
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EtOAc was added, and the organic layer was extracted three times. The combined organic layers 
were concentrated under vacuum and purified by preparative TLC. The ee of the product was 
determined by Chiral HPLC or SFC. 
4.4.8. Procedure for Sequential Isomerization and Reduction of Alkenes 
 
To a 4 mL vial containing a magnetic stir bar, a solution of alkene (0.00250 mmol, 1.00 
equiv, in 25.0 μL DMSO), a solution containing FMN or Ir-16 (1.00 or 5.00 mol %) and 25.0 μL 
of DMSO, and 50 mM pH 7.5 Tris buffer (~425 uL) were added at room temperature. The vial 
was sealed with a Teflon cap, and the solution was irradiated with a with a blue LED lamp 
positioned 20 cm above the reaction vial for 8 h at 24 ºC on a magnetic stirrer. At the end of this 
period, the vial was uncapped and a solution of NADP+ (5.00 μL of 20.0 mM stock, 0.0400 equiv), 
glucose (12.5 μL of a 1.00 M stock, 5.00 equiv), GDH (1.00 U/mL), and OYE2 (0.200 mol %) 
were added. The final solution volume was ~500 μL. The reaction mixture was re-sealed and 
incubated for 15 h at 24 ºC on a magnetic stirrer under ambient conditions and light. At the end of 
this period, EtOAc (1 mL) and dodecane (10.0 μL of 0.0200 g/mL stock in EtOAc) were added. 
An aliquot was removed from the organic layer, and the yield and conversion of the reaction were 
determined by GC analysis with dodecane as the internal standard.  
The ee of the product was obtained from a separate reaction conducted on a 5 mL scale 
(10 X scale of the general procedure listed above) in a 20 mL vial. Concentrations of all reagents 
and catalysts were identical to those listed above. After the reaction was incubated for ~15 h at 
24 ºC, EtOAc was added, and the organic layer was extracted three times. The combined organic 
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layers were concentrated under vacuum and purified by preparative TLC. The ee of the product 
was determined by Chiral HPLC or SFC 
4.4.9. Preparative Scale Cooperative Reactions 
Preparative scale cooperative reactions were conducted with the same relative concentrations of 
reagents as those listed in General Procedure 3 on a 100 X scale. 
To a 125 mL Erlenmeyer flask containing a magnetic stir bar, a solution of NADP+ (0.500 
mL of 20.0 mM stock, 0.0400 equiv), glucose (1.25 mL of a 1.00 M stock, 5.00 equiv), GDH (1.00 
U/mL), and ene-reductase (0.200 or 0.500 mol %) in 50 mM pH 7.5 Tris buffer (42.5 mL) was 
added a solution of alkene (0.250 mmol, 1.00 equiv) in 2.50 mL of DMSO. A solution containing 
Ir-16 (1.00 mol %) and 2.50 mL of DMSO was added. The final concentrations were as follows: 
0.200 mM NADP+, 25.0 mM glucose, 1 U/mL GDH, 10.0 or 25.0 μM enoate reductase, 5.00 mM 
substrate, 0.0500 mM Ir-16, 10.0 v/v% DMSO. The reaction was flask was placed inside a dewar 
containing 300 mL of water at room temperature on a stirplate. A blue LED lamp was placed 20 
cm above the base of the stirplate and a thermometer was inserted in the water bath. The reaction 
was irradiated with light for 7-15 h, and the temperature of the water bath was maintained at 24 
ºC. At the end of this period, the reaction mixture was transferred to a separatory funnel containing 
brine and extracted with EtOAc. The organic layers were combined and concentrated under 
vacuum and purified by automated silica gel chromatography (combiflash), eluting with a mixture 





The substrate (Z)-1a (0.250 mmol, 1.00 equiv) was allowed to react according to the 
general procedure for preparative scale reactions with 0.2% YersER and 1% Ir-16. The reaction 
time was 7 h. The product was purified by automated silica gel chromatography (combiflash), 
eluting with a mixture of ethyl acetate and hexanes (gradient 0:100 to 15:95 EtOAc:Hexanes).  
The product (R)-2a was obtained as a clear oil (0.0481 g, 0.217 mmol, 87% yield, >99% ee). The 




A (62:38) mixture of (E/Z)-1e (0.250 mmol, 1.00 equiv) was allowed to react according to 
the general procedure for preparative scale reactions with 0.5% OPR1 and 1% Ir-16. The reaction 
time was 24 h. The product was purified by automated silica gel chromatography (combiflash), 
eluting with a mixture of ethyl acetate and hexanes (gradient 0:100 to 10:90 EtOAc:Hexanes).  
The product (R)-2e was obtained as a clear oil (0.0520 g, 0.197 mmol, 79% yield, >99% ee). The 





The substrate (Z)-1g (0.200 mmol, 1.00 equiv) was allowed to react according to the 
general procedure for preparative scale reactions with 0.2% OPR1 and 1% Ir-16. The reaction 
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time was 24 h. The product was purified by automated silica gel chromatography (combiflash), 
eluting with a mixture of ethyl acetate and hexanes (gradient 0:100 to 40:60 EtOAc:Hexanes).  
The product (R)-2g was obtained as a clear oil (0.0356 g, 0.142 mmol, 71% yield, >99% ee). The 
spectra of the product matched those of (rac)-2g. For relevant HPLC traces see section K. 
 
 
The substrate (Z)-1h (0.241 mmol, 1.00 equiv) was allowed to react according to the 
general procedure for preparative scale reactions with 0.2% TOYE and 1% Ir-16. The reaction 
time was 24 h. The product was purified by automated silica gel chromatography (combiflash), 
eluting with a mixture of ethyl acetate and hexanes (gradient 0:100 to 20:80 EtOAc:Hexanes).  
The product (R)-2h was obtained as a clear oil (0.0438 g, 0.231 mmol, 96% yield, 92% ee). The 






The substrate-1j (0.150 mmol, 1.00 equiv) was allowed to react according to the general 
procedure for preparative scale reactions with 0.2% OYE2 and 1% Ir-16. The reaction time was 
24 h. The product was purified by automated silica gel chromatography (combiflash), eluting with 
a mixture of ethyl acetate and hexanes (gradient 0:100 to 20:80 EtOAc:Hexanes).  The product 
(R)-2j was obtained as a clear oil (0.0205 g, 0.0917 mmol, 61% yield, 91% ee). The spectra of the 
product matched those of (rac)-2j. For relevant HPLC traces see section K. 
 
 
The substrate-1o (0.200 mmol, 1.00 equiv) was allowed to react according to the general 
procedure for preparative scale reactions with 0.2% YersER and 1% Ir-16. The reaction time was 
24 h. The product was purified by automated silica gel chromatography (combiflash), eluting with 
a mixture of ethyl acetate and hexanes (gradient 0:100 to 20:80 EtOAc:Hexanes).  The product 
(R)-2o was obtained as a clear oil (0.0326 g, 0.158 mmol, 79% yield, >99% ee). The spectra of 




4.4.10. Investigating the Plausibility of Direct Photoreduction of (Z)-1a and the 
Photoracemization of (R)-2a 
Reactions 1 and 2 were conducted on a 0.5 mL scale with 5mM (R)-2a 
 
Scheme 1. Subjecting (R)-2a to Photoisomerization Conditions to Determine if Racemization of 2a Occurs 
 
 
No erosion of ee observed 
 
 
No erosion of ee observed 
 
 
HPLC1 - OJ-H column, 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (minor): 26.397 min, 
tR(major): 32.417 
 











(R)-2a HPLC1 trace from Reaction 1 with 1%  Ir-16 
 
 




Authentic (R)-2a HPLC1 trace 
 
 
Scheme 2. Testing for Photoreduction of (Z)-1a 
 
Sub. Type Photocat. Conv. Yield  
Z-1a X 5% FMN 0% 0% 




Reaction 3 was conducted on a 0.5 mL scale with 5 Mm (Z)-1a. The Z isomer of a substrate was allowed 
to react in the presence of GDH, NADP+, and glucose. No ene-reductase was present in this type 
of experiment. In the absence of an ene-reductase, only direct photoreduction of the substrate 
(with NADPH) should generate saturated products. Any products generated by photoreduction 
should be racemic since no ene-reductase is present in this type of experiment 
 
Reaction 4 was conducted on a 5 mL scale according to General Procedure 1 for the cooperative reduction 
of alkenes with (Z)-1a. The % ee of (R)-2a in Reaction 4 matched that obtained in the same reaction 
conducted in air. This suggests that neither photoracemization of the product nor photoreduction of the 
substrate occurs in a nitrogen atmosphere. 












4.5 HPLC Traces for the Cooperative Enzymatic Reduction of Alkenes 
and Control Experiments 
 
Separation Method/Eluent: 
HPLC2 - OJ-H (150mm), 5% iPrOH, 95% hexanes 0.8 mL/min, 220 nm; tR (minor):  15.752 min, 
tR(major): 19.953 
 











Table 4.1 Entry 1 
(R)-2a HPLC2 trace from the enzymatic reduction of (E)-1a with 0.2% YersER (>99% ee)
 
 
HPLC2 - OJ-H (150mm), 5% iPrOH, 95% hexanes 0.8 mL/min, 220 nm; tR (minor):  14.787 
min, tR(major): 18.704 





Table 4.2 Entry 2 
(R)-2a HPLC2 trace from the cooperative enzymatic reduction of (Z)-1a with 0.5% YersER and 





Table 4.2 Entry 3 
 (R)-2a HPLC2 trace from the cooperative enzymatic reduction of (Z)-1a with 0.5% YersER and 











Table 4.2 Entry 4 
 (R)-2a HPLC2 trace from the cooperative enzymatic reduction of (50/50) (E/Z)-1a with 0.5% 




Table 4.2 Entry 5 
 (R)-2a HPLC2 trace from the cooperative enzymatic reduction of (50/50) (E/Z)-1a with 0.5% 






Table 4.1 Entry 3 
Separation Method/Eluent: 
HPLC1 - OJ-H column, 10% iPrOH, 90% hexanes 1.0 mL/min, 220 nm; tR (major): 27.704 min, 
tR(minor): 31.059 min 
Enantiomeric Excess = >99% ee 









Table 4.2 Entry 7 
Separation Method/Eluent: 
HPLC2 - OJ-H (250mm), 50% iPrOH, 50% hexanes 0.5 mL/min, 254 nm; tR (major):  18.695 min, 
tR(minor): 20.156 
 





(R)-2b HPLC2 trace from the cooperative enzymatic reduction of (Z)-1b with 0.5% YersER and 




Table 4.2 Entry 8 
 (R)-2b HPLC2 trace from the cooperative enzymatic reduction of (Z)-1b with 0.5% YersER and 






Table 4.1 Entry 5 
Separation Method/Eluent: 
SFC – OD-H column, 0.5% iPrOH, 2.5 mL/min, 220 nm; tR (minor): 2.000 min, tR(major): 2.533 








(rac)-2c SFC trace 
 
 




Table 4.2 Entry 11 
Separation Method/Eluent: 









 (R)-2c HPLC2 trace from the cooperative enzymatic reduction of (Z)-1c with 0.5% XenB and 1% 





Table 4.1 Entry 7 
Separation Method/Eluent: 
HPLC1 - OJ-H column, 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (major): 8.607 min, 
tR(minor): 10.121 
Enantiomeric Excess = 93% ee 
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(rac)-2d HPLC1 trace 
 
 
(R)-2d HPLC1 trace from enzymatic reduction of (E)-1d with XenB (93% ee) ( 
 
 
Table 4.2 Entry 14 
Separation Method/Eluent: 
HPLC2 - OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (major):  7.736 min, 
tR(minor): 9.231 
 







(R)-2d HPLC2 trace from the cooperative enzymatic reduction of (Z)-1d with 0.5% XenB and 1% 






HPLC2 - OJ-H (250mm), 10% iPrOH, 90% hexanes 1.0 mL/min, 220 nm; tR (minor):  6.916 min, 
tR(major): 7.450 
 
HPLC2 - OJ-H (150mm), 10% iPrOH, 90% hexanes 1.0 mL/min, 220 nm; tR (major):  4.949 min, 
tR(minor): 5.260 
 






Table 4.2 Entry 16 
(R)-2e HPLC2 trace from the cooperative enzymatic reduction of (62/38) (E/Z)-1e with 0.5% 








Table 4.2 Entry 17 
 (R)-2e HPLC2 trace from the cooperative enzymatic reduction of (62/38) (E/Z)-1e with 0.5% 






Table 4.1 Entry 9 
Separation Method/Eluent: 
HPLC1 OJ-H, 1% iPrOH, 99% hexanes 1.0 mL/min, 220 nm; tR (minor): 14.412 min, tR(major): 
16.004 min 
Enantiomeric Excess = >99% ee 
 




(R)-2e HPLC1 trace from prep-scale cooperative enzymatic reduction of 62:38 (E/Z)-1e with OPR1 and 1% 
















Table 4.2 Entry 19 
(R)-2f HPLC2 trace from the cooperative enzymatic reduction of (61/39) (E/Z)-1f with 0.5% 




Table 4.2 Entry 20 
 (R)-2f HPLC2 trace from the cooperative enzymatic reduction of (61/39) (E/Z)-1f with 0.5% 








Table 4.1 Entry 10 
Separation Method/Eluent: 
Chiral SFC - OD-H column, 2% iPrOH, 2.5 mL/min, 220 nm; tR (minor): 3.060 min, tR(major): 
4.087 
Enantiomeric Excess = 88% ee 
 




(R)-2f SFC trace from enzymatic reduction of 61:39 (E/Z)-1f with XenB (88% ee) (0.0330 g scale 









HPLC2 - OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (minor):  22.210 min, 
tR(major): 26.681 
 




Table 4.1 Entry 11 







Table 4.2 Entry 23 
(R)-2g HPLC2 trace from the cooperative enzymatic reduction of (Z)-1g with 0.5% OPR1 and 1% 
Ir-16 in the presence of blue light  (>99% ee) 
 
 
There is a shift in retention time of the major enantiomer compared to the same enantiomer on 
the HPLC trace of the racemic product. The identity of the product was confirmed by GC-MS: 
The GC trace of reaction: 
 






HPLC2 - OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (minor):  28.587 min, 
tR(major): 31.567 
 




Table 4.1 Entry 13 






Table 4.2 Entry 25 
 (R)-2h HPLC2 trace from the cooperative enzymatic reduction of (Z)-1h with 0.2% TOYE and 




Table 4.2 Entry 26 
 (R)-2h HPLC2 trace from the cooperative enzymatic reduction of (Z)-1h with 0.2% TOYE and 




There is a significant shift in retention time of the major enantiomer compared to the same 
enantiomer on the HPLC trace of the racemic product. The identity of the product was confirmed 
by GC-MS: 
 









HPLC2 - OJ-H (150mm), 5% iPrOH, 95% hexanes 0.8 mL/min, 220 nm; tR (minor):  17.493 min, 
tR(major): 18.994 
 






Table 4.2 Entry 28 
(R)-2i HPLC2 trace from the cooperative enzymatic reduction of (Z)-1i with 0.2% OYE2 and 1% 




Table 4.2 Entry 29 
 (R)-2i HPLC2 trace from the cooperative enzymatic reduction of (Z)-1i with 0.2% OYE2 and 1% 




Table 4.2 Entry 30 
 (R)-2i HPLC2 trace from the cooperative enzymatic reduction of (50/50) (E/Z)-1i with 0.2% 






Table 4.2 Entry 31 
 (R)-2i HPLC2 trace from the cooperative enzymatic reduction of (50/50) (E/Z)-1i with 0.2% 





Table 4.1 Entry 15 
Separation Method/Eluent: 
HPLC1 - OJ-H column, 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (minor):  34.510 min, 
tR(major): 38.378 
Enantiomeric Excess = 94% 
(rac)-2i HPLC1 trace 
 
 











HPLC2 - OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (minor):  25.616 min, 
tR(major): 28.421 
 




Table 4.2 Entry 33 
(R)-2j HPLC2 trace from the cooperative enzymatic reduction of (Z)-1j with 0.5% OYE2 and 5% 






Table 4.2 Entry 34 
 (R)-2j HPLC2 trace from the cooperative enzymatic reduction of (Z)-1j with 0.5% OYE2 and 5% 




Table 4.1 Entry 17 
Separation Method/Eluent: 
HPLC1 – OJ-H, 10% iPrOH, 90% hexanes 1.0 mL/min, 220 nm; tR (minor):  13.360 min, 
tR(major): 14.563 
 
(rac)-2j HPLC1 trace (OJ-H) 
 
 
(R)-2j HPLC1 (OD-H) trace from the enzymatic reduction of (E)-1j with OYE2 (76% ee) (0.0221 










HPLC2 - OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (minor):  33.103 min, 
tR(major): 35.794 
 




Table 4.1 Entry 19 






Table 4.2 Entry 36 
 (R)-2k HPLC2 trace from the cooperative enzymatic reduction of (Z)-1k with 0.2% YersER and 




Table 4.2 Entry 37 
 (R)-2k HPLC2 trace from the cooperative enzymatic reduction of (Z)-1k with 0.2% YersER and 







HPLC2 - OJ-H (250mm), 10% iPrOH, 90% hexanes 1.0 mL/min, 220 nm; tR (minor):  33.295 
min, tR(major): 39.70 
 






Table 4.2 Entry 37 
(R)-2l HPLC2 trace from the stereoconvergent enzymatic reduction of (Z)-1l with 0.2% OYE2 in 




Table 4.1 Entry 21 
Separation Method/Eluent: 
SFC - OD-H column, 10% MeOH, 2.5 mL/min, 220 nm; tR (minor): 3.342 min, tR(major): 3.933 
min 
Enantiomeric Excess = 99% 












HPLC2 - OJ-H (250mm), 10% iPrOH, 90% hexanes 1.0 mL/min, 254 nm/220 nm; tR (major):  
24.092 min, tR(minor): 42.281 
 






Table 4.1 Entry 23 




Table 4.2 Entry 41 
(R)-2m HPLC2 trace from the stereoconvergent enzymatic reduction of (Z)-1m with 0.5% OPR1 




Table 4.2 Entry 42 
 (R)-2m HPLC2 trace from the cooperative enzymatic reduction of (Z)-1m with 0.5% OPR1 and 






Table 4.2 Entry 43 
 (R)-2m HPLC2 trace from the cooperative enzymatic reduction of (Z)-1m with 0.5% OPR1 and 






HPLC2 - OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (major):  19.551 min, 
tR(minor): 20.986 
 






Table 4.1 Entry 25 




Table 4.2 Entry 45 
(S)-2n HPLC2 trace from the cooperative enzymatic reduction of (Z)-1n with 0.5% SYE1 and 5% 




Table 4.2 Entry 46 
 (S)-2n HPLC2 trace from the cooperative enzymatic reduction of (Z)-1n with 0.5% SYE1 and 1% 








HPLC2 – ID-3 (150mm), 5% iPrOH, 95% hexanes 0.8 mL/min, 220 nm; tR (major):  6.834 min, 
tR(minor): 7.324 
 




Table 4.1 Entry 27 







HPLC2 – OJ-H (250mm), 5% iPrOH, 95% hexanes 1.0 mL/min, 220 nm; tR (major):  14.896 min, 
tR(minor): 15.616 
 
(rac)-2o HPLC2 trace 
 
 
Table 4.2 Entry 48 
(R)-2o HPLC2 trace from the cooperative enzymatic reduction of (Z)-1o with 0.5% YersER and 



















Table 4.2 Entry 49 
 (R)-2o HPLC2 trace from the cooperative enzymatic reduction of (Z)-1o with 0.5% YersER and 






HPLC2 – OJ-H (250mm), 20% iPrOH, 80% hexanes 1.0 mL/min, 220 nm; tR (minor):  10.824 
min, tR(major): 13.382 
 






Table 4.1 Entry 29 




Table 4.2 Entry 52 
(S)-2p HPLC2 trace from the cooperative enzymatic reduction of (E)-1p with 0.5% OYE2 and 1% 
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CHAPTER 5. Automated Cellular Engineering of 
Saccharomyces cerevisiae Strains with High Resistance 
and Production of Lactic Acid  
5.1 Introduction 
Lactic acid (LA) has broad applications in the food, cosmetics, pharmaceutical and chemical 
industries. Recently, LA demand has grown dramatically, mainly due to its potential as a building 
block of poly-lactic acid materials.1 Poly-lactic acid is a biodegradable alternative to petroleum-
based plastics, preferably synthesized from optically pure monomers. Given this prerequisite of 
LA optical purity in PLA synthesis, microbial fermentation is the optimum choice since chemical 
synthesis generally generates racemic LA.2,3 
Mainly thanks to its high acid tolerance, Saccharomyces cerevisiae serves as a promising 
host for LA production under acidic fermentation condition. Increasing the acid tolerance of LA 
producing S. cerevisiae could reduce the usage of neutralizing reagents such as CaCO3 and 
simplify the downstream purification steps, thus reducing the cost of LA production. Coupled with 
metabolic engineering efforts, heterologous expression of stereospecific lactate dehydrogenase 
(LDH) gene in S. cerevisiae enables the production of optically pure L- or D-LA with titer as high 
as 142 g/L, albeit at an industrially non-preferred pH (pH 4.7).4 Adaptive evolution was also 
applied to create a S. cerevisiae mutant producing up to 82.6 g/L LA at a lower pH (pH 3.5).5  
Recently, we developed two advanced genome-scale engineering tools in S. cerevisiae: 
CRISPR-AID,6 and RNA interference-assisted genome evolution (RAGE)7. CRISPR-AID is a 
combinatorial metabolic engineering strategy based on an orthogonal tri-functional CRISPR 
system that combines transcriptional activation, transcriptional interference and gene deletion in 
the S. cerevisiae in a high-throughput manner. RAGE is based on RNA interference for genome-
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scale overexpression and downregulation in S. cerevisiae. Standardized genetic parts encoding 
overexpression and knockdown mutations of >90% yeast genes could be created in a single step 
from a full-length cDNA library.7 Through iterative cycles of creating a library of mutants with 
high throughput screening or selection, RAGE can continuously improve target traits by 
accumulation multiplex beneficial genetic modification in an evolving yeast genome. Particularly. 
we also developed an automated cellular engineering (ACE) platform for yeast multiplex genome 
engineering by combining RAGE and a robotic system called Illinois Biological Foundry for 
Advanced Biomanufacturing (iBioFAB).7 This platform is capable of creating and screening 
massive genomic variants in a fully automated manner and we have used it to optimize diverse 
phenotype of S. cerevisiae including cellulase expression, isobutanol production, glycerol 
utilization, and furfural tolerance.7,8 
In this study, I applied RAGE and CRISPR-AID methods to identify a few single mutants 
with improved LA resistance and production at an industrially preferred low pH (pH 3). To adapt 
the selection process into an ACE platform for high throughput screening, I developed a growth-
based LA biosensor and an automated quantification assay based on industry-standard BioProfile 
Analyzer.  Based on the single round screening, I created a few mutants with up to 3 times 
improved acid tolerance and 1.5 times LA production compared with the parent strain. The best 
candidate could produce 52 g/L LA in fed-batch fermentation at pH 3 with SC medium.    
5.2 Results and Discussion 
5.2.1. Creation of L-LA Producing Mutants with RNAi and CRISPR-AID 
Machinery 
Hahn and co-workers recently created a D-LA producing strain JHY5610 with good D-LA 
productivity of 26.8 g/L by expressing a D-lactate dehydrogenase gene while deleting alcohol 
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dehydrogenases, glycerol-3-phosphate dehydrogenase and D-lactate dehydrogenase involved in 
ethanol production (ADH1, ADH2, ADH3, ADH4 and ADH5), glycerol production (GPD1 and 
GPD2), and degradation of D-LA (DLD1) respectively (Figure 5.1). Further adaptive evolution 
and metabolic engineering led to the mutant JHY 5730 producing up to 82.6 g/L of D-LA with a 
yield of 0.83g/g glucose and a productivity of 1.5 g/(L.h) in fed-batch fermentation at pH 3.5.9 We 
obtained JHY5610 and JHY5617 from Dr. Hahn’s lab as positive controls in this study (Table 5.1). 
 
Figure 5.1. Metabolic engineering to produce lactic acid in S. cerevisiae. 
Instead of starting with the wild type CEN.PK2-1C, we first created several L -LA mutants 
by replacing ADH5 with four different L-lactate dehydrogenase genes, Lp-ldh from Lactobacillus 
plantarum, Lpm-ldh, a mutant of Lp-ldh, Lb-ldh from Lactobacillus brevis, and Ro-ldh from 
Rhizopus oryzae, while deleting ADH1, ADH4, GPD1 and GPD2, resulting mutants PK2M2, 
PK2M3, PK2M4 and PK2M5 respectively (Table 5.1). Among them, PK2M2, PK2M3 and 




Table 5.1. Summary of CEN.PK2 mutants and their genome types  
Mutants Genome type 
JHY5610 Adh 1-5∆, gpd1-2∆, dld1∆, PTDH3-Lm.ldhA-TCYC1-
kanMX 
JHY5617* Based on JHY 5610: erf2∆, SURI245S-kanMX 
PK2-M1 Adh1,4∆, gpd1-2∆ 
PK2-M2 Adh1,4,5∆, gpd1-2∆, PTEF1p-Lp.ldh-TTEF1p-kanMX 
PK2-M3 Adh1,4,5∆, gpd1-2∆, PTEF1p-Lpm.ldh-TTEF1p-kanMX 
PK2-M4 Adh1,4,5∆, gpd1-2∆, PTEF1p-LB.ldh-TTEF1p-kanMX 
PK2-M5 Adh1,4,5∆, gpd1-2∆, PTEF1p-Ro.ldh-TTEF1p-kanMX 
PK2-M6 Adh1,2,3,4∆, gpd1-2∆ 
 
The four newly created mutants (PK2M2, PK2M3, PK2M4 and PK2M5) together with 
JHY 5610 and JHY 5617 were grown in YPG medium and a small amount of cells (OD600=1) were 
serially diluted and spotted onto YPD solid medium supplemented with or without LA at different 
pH (Figure 5.3). Increasing LA concentration with pH unchanged or decreasing pH alone inhibited 
the cell growth. Further deletion of ADH2 and AHD3 may improve the LA production (Figure 5.1, 
PK2M2-M4 versus JHY5610), but it led to worse acid tolerance (Figure 5.3). PK2M3 was selected 
as a good parent strain for genome-scale engineering due to its moderate LA production and acid 
tolerance compared with JHY5610 and JHY5617. PK2M3 was largely inhibited at pH 3.0 with 2% 
LA (Figure 5.3) and failed to grow at pH lower than 3 (data were not shown). Thus, medium 
supplemented with 2.5% LA at pH 3.0 would be chosen as selection medium to identify mutants 




Figure 5.2. L-LA production in PK2M2, PK2M3, PK2M4, PK2M5 and D-LA production in 
JHY5610 and JHY5617. The mutants were grown in YPD medium with 50 g/L glucose in a 50 
mL bioreaction tube from CELLTREAT, at 30 ◦C with shaking at 250 rpm. The error bars indicate 

























































Figure 5.3. Effects of pH and LA concentration on the mutant’s growth.  
 
The RNAi machinery originated from S. castellii was reconstructed into PK2M3 using the 
same protocol as described elsewhere.10 Green fluorescent protein (GFP) was selected as the 
reporter to test the RNAi machinery. The reporter system consisted of an GFP expression cassette 
on yeast centromere plasmid (YCp) pRS414 and an anti-sense GFP cassette (GFPrc) on YCp 
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pRS416 (Figure 5.4). The RNAi machinery cassette consisting of ago1 and dcr1 genes that were 
driven by the constitutive promoters PTEF1 and PTPI1 respectively was transformed into PK2M3 
together with a delta-integration cassette. Since the location and the copy number of integrations 
will affect the performance of the RNAi machinery. 36 mutants were screened to identify the best 
candidate with the weakest GFP expression when both GFP and GFPrc were expressed (Figure 
5.5). GFP and GFPrc were removed from the selected mutant by using the 5-fluoroorotic acid (5-
FOA) and 5-fluoroanthranilic acid (5-FAA) counterselection system. The resulting strain was 
named as PK2M3-RNAi and it was used for transformation of genome-wide single gene 
overexpression and knockdown library, RAGE 2.0.10 
 
Figure 5.4. GFP reporter system: A) GFP is overexpressed by strong constitute promoter PTEF1 
and B) anti-sense GFP is overexpressed by PTEF1.  
  
 
Figure 5.5. Flowcytometry analysis of mutants: A) PK2M3-RNAi-pRS414_GFP, B) PK2M3-
RNAi-pRS414_GFP-pRS416_GFPrc. 
 
The orthogonal tri-functional CRISPR system, CRISPR-AID, was also reconstructed in 
PK2M3 based on Lian J. et. al’s work.6 CRISPR-guided deletion in the final strain PK2M3-PAID6 
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was verified by ADE2 deletion efficiency. PK2M3-PAID6 was used as the parent strain to create 
a CRISRP-AID library.  
5.2.2. Establishing Screening Methods for L-LA Overproduction 
For high-throughput screening, we proposed two automated quantification assays using BioProfile 
Analyze, including pH indicator-based quantification assay and lactate oxidase-based 
quantification assay (LOD). We also developed a cell growth-based LA biosensor and designed a 
high-throughput system combined with the biosensor technique for screening ultracellular 
metabolites.  
5.2.2.1. Bromocresol Green Assay  
The pH indicator with no side-effect on yeast growth could be used to identify the mutant with 
high LA production in a high throughput way. We firstly aimed at making the agar plate containing 
pH indicator that enabled the obvious color change around the colony producing more LA than 
others. Since our aim was “creation a yeast strain that can produce 50 g/L LA at pH 3” , we tested 
a few pH indicators working at pHs ranging from 0.2 to 5.4 (Table 5.2). However, they are either 
not stable under the light or have poor solubility in aqueous medium. More importantly, the pH 
indicators working at low pH range are not sensitive to the small changes of LA concentration. 
We then decided to develop a pH indicator assay in 96-well plates that could be analyzed 
quantitatively by the plate reader.   
Bromocresol green was chosen as the pH indicator since it has relatively linear color 
changes with decreasing PH.  A calibration curve of LA concentration versus absorbance change 
at 616 nm was built by adding 2 ul SC liquid medium with different amount of LA into 200 ul 60 
mg/L bromocresol blue solution at pH 5.5 (Figure 5.6 A). Bromocresol green assay (BG) works 
for LA ranging from 0.01 g/L to 1 g/L. LA concentration is reverse proportional to the absorbance 
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at 616 nm and a linear correlation can be established between LA concentration versus Abs 
(A616nm)
-1. 2 ul 12-hr SC fermentation broth of different mutants was evaluated using BG assay 
(Figure 5.6 B). The lighter the color or lower the absorbance value of the culture broth, the higher 
the concentration of LA. The calculated concentration is comparable with the values measured by 
HPLC. BG assay could be integrated in iBioFAB to evaluate LA concentration from fermentation 
broth of different mutants in a high-throughput manner.   








Cresol red Red pH 0.2-pH 1.8 Yellow Unstable, poor solubility,  
Thymol blue  Red pH 1.2-pH2.8 Yellow Poor solubility, unsensitive 
Methyl yellow Red pH 2.9-pH 4.0 Yellow Unsensitive  
Bromophenol blue Yellow pH 3.0-pH 4.6 Green Unsensitive, outside range 
Bromocresol green Yellow pH 3.8-pH 5.4 Blue Outside range 
 
 
Figure 5.6. Bromocresol green (BG) assay development and verification. A) calibration curve of 
LA concentration versus absorbance at A616nm, B) LA production of different mutants measured 
by BG assay and HPLC.  
 
5.2.2.2. Lactate Oxidase Assay  
The BG assay is not specific to L-LA measurements and it can also be used for D-LA screening. 
However false-positives may also occur if the mutants produce more acids other than LA resulting 
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in low fermentation pH. To overcome this shortcoming, we developed a LOD assay specific for 
L-LA measurements.  
L-LA can be oxidized by lactate oxidase (LOD) to pyruvate and H2O2. There are several 
methods available to quantitatively measure the amount of H2O2.  I selected the lactate oxidase 
from Aerococcus viridans (L9795) and the fluorometric hydrogen peroxide assay kit (MAK165-
1KT) from sigma. The LOD reaction was successfully integrated with the fluorometric hydrogen 
peroxide assay kit. The reaction protocol was established for creating the calibration curve of LA 
(uM) versus RFU (Ex/Em = 540/590 nm) (Figure 5.7A) and for measuring the fermentation sample 
(Figure 5.7B). The fermentation supernatant should be diluted 1000 times before the 
measurements since the active interval of LOD assay is 5 uM to 30 uM. Although the concentration 
measured by LOD was about 20%~50% less than the actual concentration, the relative 
concentration of different mutants was consistent with the HPLC measurements. This assay was 
done in 96-well plates and the absorbance change was detected at 590 nm using fluorescent plate 
reader. LOD assay could be used to directly measure the L-LA concentration in fermentation 
supernatant and the process could be adapted to iBioFAB easily for high-throughput screening. 






Figure 5.7. LOD assay development and verification. A) The calibration curve of L-LA (uM) 
versus the RFU (Ex/Em=540/590 nm). B) Measurements of fermentation samples by LOD assay 
and HPLC. The error bars represent the standard deviation of biologically triplicate experiments. 
 
5.2.2.3. L-Lactic Acid Biosensor  
Inspired by L-LA biosensor constructed in E. coli,11 I planned to develop a genetic sensor 
responsive to L-LA concentration in CEN.PK2.1C, so that we would be able to rapidly screen the 
high L-LA producing strain in a high throughput manner. We designed the yeast biosensor based 
on a bacterial transcription factor LIdR and its corresponding operator O1 and O2, involved in L-
LA metabolism in E. coli.12 LIdR undergoes a conformational change when it specifically binds 
to L-LA and dissociates from its operator O1 (design 1) or O2 (design 2), allowing access of the 
RNA polymerase (Figure 5.8A). LIdR was fused with a strong NLS SV40 at the C-terminus to 
enable nuclear import. The LIdR-NLS SV40 was assembled in a YCp with TEF1 promoter and 
PGK1 terminator. To provide a quantitative readout of LIdR-O behavior, a YIp harboring the GFP 
as a reporter was constructed. The O1 or O2 regulated fluorescent protein expression cassette was 
constructed by inserting O1 or O2 into an engineered promoter GPM1 in front of GFP. The GPM1 
promoter was modified with only one upstream activation sequence conserved to eliminate native 
transcriptional regulation (Figure 5.8B). The operator sequence was inserted immediately in front 




Figure 5.8. Design of L-LA sensor/regulating circuits: (A) scheme (B) sequence  
I first evaluated the GFP expression level in PK2M1-LAb1 (PK2M1_pRS405-GPM1(O1)-
GFP-PGK1t_pRS416) and PK2M1-LAb2 (PK2M1_pRS405-GPM1(O1)-GFP-PGK1t_pRS416) 
in SC-Ura liquid medium supplemented with 20 g/L glucose and different L-LA concentration or 
at different pHs. The GFP intensity increased when L-LA concentration was increased from 0% 
to 1% while decreased at 2% (Figure 5.9A). It was interesting to find that pH value alone had 
regulation effect on GFP expression. The fluorescence intensity increased when the pH decreased 
from 6.7 to 2.7. Further decrease in pH inhibited the GFP expression (Figure 5.9B). Since SC-Ura 
liquid medium with 2% L-LA is at pH 2.4, cellular stress response to low pH maybe the reason of 





Figure 5.9. A) Dynamic response of L-LA-sensing/regulating gene circuits in SC-Ura liquid 
medium supplemented with 20 g/L glucose at A) different L-LA concentrations; B) at different 
pHs. Sensor activity was measured by fluorescence intensity of 24-hr cell culture by flow 
cytometry.  
To test the regulation effect of L-LA on GFP expression alone, I measured the GFP 
intensity of PK2M1-LAb1 and PK2M1-LAb2 individually in SC-Ura liquid medium with different 
L-LA concentration at pH 5.6. The sensor activity was measured at 6hr, 12hr, 18hr, 24hr, 24hr and 
48hr respectively. The induction ratio was maximum at 24 hr after L-LA being added. The 
fluorescence intensity was proportional to the L-LA concentrations from 0.2% to 2% and there 
was no substantial background fluorescence change in PK2M1 (Figure 5.10). Native repressor of 
O1 and O2 may present and could interact with L-LA. Introducing LIdR in PK2M1-LAb1-LIdR 
(PK2M1_ pRS405-GPM1(O1)-GFP-PGK1t_pRS416-TEF1p-LIdR-PGK1t) and PK2M1-LAb2-
LIdR (PK2M1_pRS405-GPM1(O2)-GFP-PGK1t_pRS416-TEF1p-LIdR-PGK1t) improved the 
sensitivity of L-LA-sensing/regulating gene circuit to different L-LA concentrations. Higher 
induction ratio was achieved for gene circuit containing LIdR: around 4-fold in PK2M1-LAb1-
LIdR and PK2M1-LAb2-LIdR, 2-fold in PK2M1-LAb1 and PK2M1-LAb2). In both cases, O2 has 
stronger basal level expression than O1.  
I further optimized the L-LA-sensing/regulating gene circuit by adjusting the ratio of 
O1(O2)/LIdR by using a high copy number plasmid to express LIdR. I also used a codon-optimized 
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LIdR to replace the original LIdR from E. coli to theoretically achieve higher expression level. 
More LIdR in the system reduced the induction ratio of L-LA-sensing/regulating gene circuits 
within the working range (0~4% L-LA) (Figure 5.11). So, use of single copy repressor is enough 
to achieve the best regulation effect. 
 
Figure 5.10. Dose-response curves of L-LA-sensing/regulating gene circuits. Dynamic response 
of sensors designed with different operator A) LAb1 or B) LAb2 with or without LIdR being 
expressed in SC-Ura liquid medium supplemented with 20 g/L glucose and different L-LA 
concentration at pH 5.6. The average fluorescence intensity of 24-hr liquid culture was measured 
by flowcytometry.   
 
 
Figure 5.11. Dose-response curves of L-LA-sensing/regulating gene circuits designed with 
different Operator/repressor ratio. Sensor activities were compared by fluorescence intensity of 
cells cultured in SC-Ura liquid medium with 20 g/L glucose and different L-LA concentrations 
(%) at pH 5.6. LIdRcm indicates codon-optimized LIdR. LIdRcm-H indicates that LIdRcm was 
expressed on high copy number plasmid.  
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The designed L-LA-sensors could respond to different amount of extracellular L-LA. To 
use the sensor as a high throughput screening method to identify mutants with improved LA 
production. I must confirm that L-LA-sensing/regulating gene circuit can work well in the yeast 
strains producing different amount of L-LA. I built different L-LA-sensing/regulating gene circuits, 
basically LAb1-LIdR, LAb2-LIdR and LAb3-LIdR in PK2M3, PK2M4 and PK2M5 that produced 
different amount of L-LA in flask-fermentation (Figure 5.2). LAb3-LIdR is a new design which 
placed O1 behind the UAS region and O2 just before the TATA box.  A small amount of PK2M3-
sensor, PK2M4-sensor and PK2M5-sensor strains (OD600=1) were inoculated in SC-Ura liquid 
medium supplemented with 20 g/L glucose and 100 mM citrate phosphate at pH 5.6. The 
fluorescence intensity and L-LA production of 24-hr culture were analyzed by flowcytometry and 
HPLC respectively. In LAb2-LIdR design, mutants produced more L-LA have stronger 
fluorescence intensity too (Figure 5.12A, B). The mutants produced more L-LA after 24-hr 
fermentation also have higher titer at the end of 3-day fermentation (Figure 5.12 and Figure 5.2). 
Although the Lab1-LIdR sensing/regulating gene circuits worked well in Pk2M1 that does not 
produce LA, it did not show good correlation between L-LA production and fluorescent intensity 
in those strains producing LA. The L-LA sensor works well in other two common liquid mediums 
used in this study SC-Ura and YPD, and the sensor activity assay is performed after 24 hrs (Figure 




Figure 5.12. A) and B) Different L-LA sensor activity in PK2M3, PK2M4 and Pk2M5 produced 
different amount of LA after 24-hr fermentation in SC-Ura liquid medium supplemented with 20 
g/L glucose and 100 mM citrate phosphate at pH 5.6 C) and D) LAb2qc-LIdR L-LA sensor activity 
in PK2M3, PK2M4 and PK2M5 produced different amount of LA after 24-hr fermentation in SC-
Ura liquid medium supplemented with 20g/L glucose, 12-hr and 24-hr fermentation in YPD 
medium. 
 
5.2.3. Establishing Screening Methods for Low pH Tolerance  
RAGE 2.0 library and CRISPR-AID library were constructed on the plasmid pRS416 and pRS426 
respectively.6,10 SC-Ura solid/ liquid medium supplemented with 20 g/L galactose and LA at low 
pH was chosen as the selecting medium for acid tolerance screening. To identify the optimum pH 
and LA concentration for selection purpose, 1ul (OD600 = 1) PK2M3 (approximately 10
4 cells) 
were plated on SC-Ura solid medium at pH ranging from 2.6 to 5 with LA ranging from 1% to 4% 
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respectively. SC-Ura supplemented with 20 g/L glucose and 3% LA at pH 3.0 showed around 100 
small colonies after 4-day growth and it was chosen as the selection plate for screening mutants 
with improved acid tolerance.  
Based on later study, there is no absolute relationship between strong acid tolerance and 
high LA production. The tolerance screening was coupled with the production screening based on 
the bromocresol assay since it can be applied to the iBioFAB platform more easily compared with 
other screening methods. As shown in Figure 5.13, following the transformation, the yeast library 
was plated on SC-Ura solid medium supplemented with 20 g/L galactose and 3% LA at pH 3.0. 
The first appeared colonies or those sizes were bigger than the largest colonies on the control plates 
were inoculated in deep-round 96-well plates dispensed with SC-Ura liquid medium supplemented 
with 20 g/L galactose. The saturated culture was sub-cultured one time to synchronize the growth. 
The subculture was used to do growth profile evaluation in the selecting medium and fermentation 
test. For growth profile evaluation, mutants and control strain with the initial OD600 of 0.2~0.8  
were grown in SC-Ura liquid medium supplemented with 20 g/L glucose with 3% LA at pH 3. 
The OD600 was measured at 4h intervals for the first 24hs and 12h intervals for the next 2 days. 
For fermentation, mutants and control strain with the initial OD600 of 1 were started in SC-Ura 
supplemented with 50g/L glucose. The bromocresol green assay was applied on 3-day 
fermentation culture to estimate the LA production. The top candidates from both tolerance 
screening and LA production screening were chosen for further verification and analysis. The 
plasmids from those candidates were extracted, sequenced and re-transformed back into fresh-
background parent strain confirm the improvements. The improved strain can be used as new 




Figure 5.13. Schematic of library screening and verification.  
5.2.4. CADnm-RNAi RAGE 2.0 Library  
CADnm is the mutant of CEN.PK2-1C with an reconstructed functional RNAi machinery. We 
first created CADnm-RNAi-RAGE 2.0 library to demonstrate the outperformance of RAGE 2.0 
library in terms of improving the strain tolerance at low pH compared with the wild type. To ensure 
the adequate coverage, >106 independent clones were obtained for both overexpression library 
CADnm-pRS416-TEF1p-RAGE2.0-Forward and (library size: 1.1×106) and knockdown library 
CADnm-pRS416-TEF1p-RAGE2.0-Reverse (library size: 4.4×106).  We performed the 
enrichment selection of the overexpression and the knockdown libraries in SC-Ura liquid medium 
supplemented with 20 g/L glucose and 0% to 4% LA at pH 3.0. Both libraries outperformed the 





Figure 5.14. A) Comparison of RAGE 2.0 libraries with the control strain CADnm-pRS416 in 
SC-Ura liquid medium supplemented with 20 g/L glucose and 0~4% LA at pH 3. B) The growth 
profile of CADnm-pRS416 in SC-Ura liquid medium supplemented with 20 g/L glucose and 5~9% 
LA at pH 3.  
Since the control strain also reached the same OD as the library at 4% LA. I evaluated the 
growth rate of the control strain at higher LA concentration (5% to 9%) (Figure 5.14B). CADnm 
has higher LA tolerance compared with PK2M3. The growth rate and maximum OD were reduced 
while increasing the LA concentration. Libraries in SC-Ura (20 g/L glucose, 7% LA, pH 3) were 
further enriched in the same medium four to five rounds to reach 625 to 3125-fold total enrichment. 
For each round enrichment, 2% inoculum was transformed into fresh SC-Ura (20 g/L glucose, 7% 
LA, pH 3) when the OD600 exceeded 1 in a previous round. The enrichment was also performed 
on CADnm-pRS416 as a control. After enrichment, single colonies were obtained by streaking the 
library onto a SC-Ura plate containing 5% LA at pH 3. Fifty randomly picked colonies from each 
library were examined for growth in SC-Ura (20 g/L glucose, 5% LA, pH 3) (Figure 5.15). 35 
candidates with either higher final OD600 or faster exponential growth rate compared with the 
enriched control strain CADnm-pRS416 (enriched) were selected for further verification.  
Plasmid library was isolated from the positive candidates and sequenced to elucidate the target 
gene information. 21 candidates down regulated the expression of tup1, encoding a chromatin-
silencing transcriptional regulator. Interestingly, five candidates upregulated the expression of 
225 
 
tup1 too. Other up- or downregulated candidates are summarized in Table 5.3. We transformed 
those isolated plasmids into fresh background CADnm and PK2M3-RNAi strain to confirm the 
improvements on the acid tolerance. Since CADnm strain has very strong tolerance to LA, the 
mutants did not show obvious improvements of growth in acid medium (Figure 5.16A,B). 
However, the final OD600 of mutants PK2M3-RNAi-tup1 (down), tma10 (down), tup1 (up), bmh1 
(up), stf1(down) was much larger than that of the parent strain PK2M3-RNAi-pRS416 in acidic 
medium with galactose as carbon source. Although PK2M3 has glucose “toxicity” due to gene 
modification, mutants with tup1 being overexpressed, tup1 (up), or knockdown, tup1 (down), still 
overperformed the parent strain PK2M3 in terms of growth rate and final OD600 (Figure 5.16C,D).  
 
Figure 5.15. Growth profile evaluation of CADnm RAGE 2.0 libraries versus control CADnm-
pRS416 in SC-Ura liquid medium supplemented with 20 g/L glucose and 3.5% LA at pH 3, A) 










Table 5.3. Gene targets of top candidates from growth profile evaluation in selecting medium 
Gene Regulation Repeatability Comments 
tup1 Down 21/35 Chromatin-silencing transcriptional regulator 
tma10 Down 2/35 
Protein abundance increases in response to DNA 
replication stress 
stef1 Down 1/35 ATPase-binding protein 
phd1p Down 1/35 
Transcriptional activator that enhances pseudohyphal 
growth; physically interacts with the Tup1-Cyc8 
complex and recruits Tup1p to its targets 
bmh1 Up 5/35 Regulation protein 
tup1 Up 5/35 Chromatin-silencing transcriptional regulator 
 
 
Figure 5.16. Growth profile evaluation of mutants versus control strain. A) log phase growth rate 
and B) mass accumulation of CADnm-mutants and control CADnm-pRS416 in SC-Ura with 20 
g/L glucose and 3.5% LA at pH 3. C) mass accumulation of PK2M3-RNAi-mutants and control 
PK2M3-RNAi-pRS416 in SC-Ura with 20 g/L galactose and 3.5% LA at pH 3. D) mass 
accumulation of PK2M3-RNAi-mutants and control PK2M3-RNAi-pRS416 in SC-Ura with 20 
g/L glucose and 3.5% LA at pH 3. The error bars represent the standard deviation of biologically 
triplicate experiments.  
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5.2.5. PK2M3nm-RNAi RAGE 2.0 Library  
The PK2M3-RNAi-RAGE 2.0-overexpression and knockdown libraries were created by 
transforming the plasmid library pRS416-RAGE2.0-overexpression and pRS416-RAGE2.0-
knockdown into the parent strain PK2M3-RNAi. 106 colonies were obtained for each library to 
ensure adequate coverage of all genes. The libraries were screened and analyzed by the method 
discussed in Section 5.2.3. Although the library mutants did not show as strong acid tolerance as 
the wildtype CADnm-pRS416, a lot of good candidates were identified with greatly improved acid 
tolerance compared with the parent strain PK2M3-RNAi-pRS416 (Figure 5.17). BG assay also 
indicated a few candidates with improved LA production in small-scale fermentation test.  
21 candidates with either strongest acid tolerance or highest LA production were verified 
by re-transforming the corresponding plasmids into the fresh background PK2M3-RNAi. All 
selected mutants had higher final OD600 than the parent strain PK2M3-RNAi-pRS416 (Figure 
5.18). The mutants with stronger acid tolerance may not result in higher LA production (Figure 
5.19). Permanent mutants of top three candidates, FA3, RG4, and RD5, with highest LA 
production and good acid tolerance were constructed by integrating the genetic regulation part into 
the chromosome of PK2M3-RNAi using YIp pRS404. Among them, except PK2M3-RNAi-FA3 
in which an uncharacterized gene being overexpressed, both PK2M3-RNAi-RG4 and PK2M3-
RNAi-RD5 have different genes being down-regulated. They are fba1 and htb1 encoding fructose-





Figure 5.17. Growth profile of PK2M3-RNAi-RAGE 2.0 libraries versus wild type CADnm-
pRS416 and parent strain PK2M3-RNAi-pRS416 in selection medium SC-Ura supplemented with 
20 g/L glucose and 3.5% LA at pH 3. 
 
Figure 5.18. Growth profile verification of top 21 mutants from the first-round screening versus 
the parent strain PK2M3-RNAi-pRS416 in selecting medium SC-Ura supplemented with 20 g/L 
glucose and 3.5% LA at pH 3. 
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Figure 5.19. L-LA production in 2-mL falcon tube fermentation (SC-Ura supplemented with 50 
g/L glucose) measured by HPLC. The error bars represent the standard deviation of biologically 
triplicate experiments.  
Among, PK2M3-RNAi-FA3, PK2M3-RNAi-RD5 and PK2M3-RNAi-RG4, only PK2M3-RANi-
FA3 shew stronger acid tolerance compared with the parent strain (Figure 5.20 A). Compared with 
PK2M3-RNAi-pRS416-RD5 and RG4, the permanent mutants PK2M3-RNAi-RD5 and PK2M3-
RNAi-RG4 only have single copy of gene regulation module, which may result in weaker acid 
tolerance.  In the shake-flask fermentation with minimum medium SC supplemented with 50 g/L 
glucose, the glucose consumption rate of FA3 was faster than that of other three strains (Figure 
5.20 B). Three mutants had higher L-LA production rate and production than the parent strain. 
PK2M3-RNAi-FA3 produced 1.5 times more L-LA than the parent strain and had highest final 
OD600 at the end of fermentation (Figure 5.20 C&D). Thus PK2M3-RNAi-FA3 was chosen as the 










Figure 5.20. Acidic tolerance and L-LA productivity of PK2M3-RNAi-FA3, RG4, RD5 versus 
the parent strain PK2M3-RNAi-pRS416. A) growth profile evaluation in the selecting medium 
SC-Ura supplemented with 20 g/L glucose and 3.5% LA at pH 3. B) glucose consumption in flask 
fermentation with SC supplemented with 50 g/L glucose. C) L-LA production in the flask 
fermentation. D) Final OD600 in the flask fermentation. The error bars represent the standard 
deviation of biologically triplicate experiments.  
 
5.2.6. PK2M3nm-PAID6 CRISPR-AID Library  
PK2M3-PAID6-Activation, PK2M3-PAID6-Inactivaton and PK2M3-PAID6-Deletion libraries 
were created by transforming plasmid libraries pRS426-CRISPR-Activation, pRS426-CRISPR-
Inactivation and pRS426-CRISPR-Deletion into the parent strain PK2M3-PAID6. 3×106, 2×106 
and 1×106 colonies were obtained for each library respectively to ensure the adequate coverage. 
The libraries were screened and analyzed by the method discussed in section 5.2.3. Top 28 
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candidates from the first-round acid tolerance and BG assay screening were picked for further 
verification. Among them, 14 candidates were from activation library; 11 candidates were from 
inactivation library and only 3 candidates were from the deletion library. The plasmids from the 
top candidates were extracted and sequenced to elucidate the target gene. The mutants with 
overexpression of an uncharacterized gene 4833, knockdown of tef1, or spte4 are especially 
interesting since there are more than two screened mutants targeting at those genes respectively.  
28 candidates were verified by re-transforming the corresponding plasmids into the fresh 
background PK2M3-PAID6 strain. Only four mutants A-A5, I-E5, I-H7 and I-H8 had higher final 
OD600 than the parent strain PK2M3-PAID6-pRS426 (Figure 5.21). They are mutants with 4833 
being overexpressed, tef1, spt4 and som1 being down regulated respectively. Tef1 and spt4 encode 
translational elongation factor and transcriptional elongation factor respectively. SOM1 is the 
subunit of the mitochondrial inner membrane peptidase. None of them has been reported to 
improve yeast acid tolerance in the literature.   
 
Figure 5.21. Growth profile verification of top 28 mutants from the first-round screening versus 
the parent strain PK2M3-PAID6-pRS426 in selecting medium SC-Ura supplemented with 20 g/L 
glucose and 3.5% LA at pH 3.  
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To make the stable mutant, gene-targeting module including the gRNA were integrated into the 
pre-tested spots in the genomic DNA of the parent strain by using CRISPR-based gene-editing 
strategy. The insertion of extracellular DNA at those spots does not affect the strain’s overall 
phenotype. The resulted mutants PK2M3-PAID6-H7, E5 and A5 still had stronger acidic tolerance 
than the parent strain PK2M3-PAID6-pRS426 (Figure 5.22A). In the shake-flask fermentation 
with minimum medium SC supplemented with 50 g/L glucose, PK2M3-PAID6-A5 and E5 grew 
faster, consumed glucose faster and produced more LA than the other three strains. Interestingly, 
although PK2M3-PAID6-H7 had strongest acid tolerance among all mutants, it produced least LA 
within 4-day fermentation, which means stronger acid tolerance may not lead to higher LA 
production.  From the first round CRISPR-AID library screening, two mutants were identified with 
improved acid tolerance and LA production compared with the parent strain. They are PK2M3-
RNAi-A5 in which an uncharacterized gene 4388 being overexpressed, and PK2M3-RNAi-E5 in 






Figure 5.22. Acidic tolerance and L-LA production of PK2M3-PAID6-A5, E5, H7 and H8 versus 
the parent strain PK2M3-PAID6. A) growth profile evaluation in the selecting medium SC-Ura 
(3.5% LA, pH 3). B) glucose consumption in flask fermentation with SC supplemented with 50 
g/L glucose. C) L-LA production in flask fermentation. D) mass accumulation in flask 
fermentation. The error bars represent the standard deviation of biologically triplicate experiments.  
 
5.2.7. Fermentation  
We also evaluated L-LA production of PK2M3-RNAi-FA3 in fed-batch bioreaction at pH 3.0 
using a 1L bench-top bioreactor. In 500 mL fed-batch fermentation, by consuming 68 g glucose, 
up to 52 g/L of L-LA was produced with a yield of 0.77 g/g.  
5.3 Conclusion  
In this study, we constructed a LA producing mutant PK2M3 that can produce 40 g/L L-LA in 
fed-batch fermentation with YPD medium. We constructed RNAi and CRISPR-AID machinery in 
PK2M3 and using PK2M3 as the parent strain to apply genome-wide engineering to improve the 
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acid tolerance and LA overproduction. The first-round engineering resulted in one permeant 
mutant from PK2M3-RAGE 2.0 library and two mutants from PK2M3-CRISPR-AID libraries 
with up to 2.5-times acid tolerance and 1.5-times LA production compared with the parent strain. 
The best mutant PK2M3-RNAi-FA3 with an unknown gene overexpressed can produce up to 52 
g/L L-LA in fed-batch fermentation with SC medium. To adapt the selection process into ACE 
platform for high throughput screening, we also developed a growth-based LA biosensor and an 
automated quantification assay based on industry-standard BioProfile Analyzer. The best 
candidates from the first-round engineering would be used as the new parent strain for multiple 
rounds engineering.  
5.4 Future Work 
Pk2M3-RNAi-FA3 will be used to perform second or third round genome-wide engineering to 
further improve the acid tolerance and LA production. We will also develop the whole engineering 
and selection process on iBioFAB and using automotive cellular platform to realize iterative 
engineering in high throughput manner.  
LA is exported out of the cell after being synthesized. At low pH, lactic acid is present in tis 
protonated form and can therefore enter the cell by diffusion.  General bulk fermentation followed 
by Fluorescence Activated Cell Sorting (FACS) cannot be used to identify the mutants producing 
more LA than others. We are establishing a microfluidics droplet system. Droplet-based 
microfluidics system can be used to generate water in oil droplet with similar size to 
compartmentalize single cells, which enable the analysis of metabolites released from or secreted 
by the cells.13 Stephanopoulos and co-workers used microfluidic system and build-in fluorescence-
based sorting facility to successfully enriched L-lactate -producing E. coli clones 5,800X from a 
population containing one L-lactate producer per 104 D-lactate producers.14 Alper and co-workers 
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recently using double emulsion (W/O/W) to sort out riboflavin overproduced Yarrowia 
lipolytica.15 We plan to combine L-lactate biosensor with both single water in oil (W/O) droplet 
system followed by breaking the droplet for FACS and double emulsion (W/O/W) that would be 
directly applied on FACS to screen out high LA producing mutants.  
5.5 Experimental Procedures  
5.5.1. Strains and Media and Culture Conditions  
All yeast mutants used in this study are described in Table 5.4. S.cerevisiae CEN.PK2-1C strain 
(MATa ura3-52 trp1-289 leu2-3,112 his3Δ1 MAL2-8C SUC2) was used as a parental strain in this 
study. The deletion of ADH and PDC gene inhibited the mutant’s growth in glucose media. All 
mutants were cultivated in YP medium (20 g/L peptone and 10 g/L yeast extract), synthetic 
complete (SC) or synthetic drop-out medium (SC drop-out) (1.67 g/L Difco Yeast Nitrogen Base 
without amino acids, 5 g/L ammonium sulfate, 0.83 g/L synthetic complete drop out mix) 
supplemented with 20 g/L galactose.  
For rich medium fermentation, all yeast cells were cultivated in YP medium supplemented 
with 20, 50 or 100 g/L glucose. For selective medium fermentation, yeast cells were cultivated in 
synthetic complete (SC) or synthetic drop-out medium (SC drop-out) supplemented with 20, 50 or 
100 g/L glucose. Pre-cultured cells (OD600 =1) were inoculated in 5 mL of media containing 50 
g/L glucose in a 50 mL screw cap conical tube, and then cultured at 30 ◦C with shaking at 250 rpm. 
For shake flask fermentation, precultured cells (OD600 =1) were cultivated in 20 mL of media 
medium containing 50 g/L glucose in a 125 mL conical flask. 
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Acidic selecting agar plates were made of normal SC or SC-Ura plate supplemented with 3.5% 
LA at pH 3.0. Acidic selecting medium were made of normal SC or SC-Ura plate supplemented 
with 3.5% LA at pH 3.0.  
Fed-batch fermentation was performed in 500 mL SC medium containing 50 g/L glucose using a 
1L bench-top bioreactor at 30°C with agitation speed of 450 rpm and air flow rate of 1.0 vvm. The 
pH of the culture medium was maintained at 3.5 by using 4 N NaOH. Strain PK2M3-RNAi-FA3 
was pre-cultured in SC medium containing 20 g/L glucose an inoculated into the fermenter with 
initial OD600 of 10. The feeding solution (600 g/L glucose and half the vol of 2XSC) was 
intermittently added to the culture medium when the glucose concentration was lower than 5 g/L. 
Table 5.4. The strain information of this study.  
Strains Genotype and description Reference 





PK2M2 PK2M1 adh1Δ::PTEF1-Lp.ldh-TTEF1 This Study 
PK2M3 PK2M1 adh1Δ::PTEF1-Lpm.ldh-TTEF1 This Study 
PK2M4 PK2M1 adh1Δ::PTEF1-Lb.ldh-TTEF1 This Study 
PK2M5 PK2M1 adh1Δ::PTEF1-Ro.ldh-TTEF1 This Study 





CADnm CEN.PK2-1C d::TEF1p-Ago-TPI1-Dcr 7 
PK2M3-RNAi-FA3 PK2M3-RNAi pRS404-TEF1p-fa3-PGK1t This Study 
PK2M3-RNAi-RD5 PK2M3-RNAi pRS404-PGK1t-htb1-TEF1p This Study 
PK2M3-RNAi-RG4 PK2M3-RNAi pRS404-PGK1t-fba1-TEF1p This Study 
PK2M3-PAID6-A5 Pk2M3-PAID6 SAR52p-LbCpf1 scaffold-4833 gRNA-SUP4t This Study 
Table 5.4. cont. 
PK2M3-PAID6-H7 Pk2M3-PAID6 SAR52p-SpSgRNA structure-spt4 gRNA-SUP4t This Study 
PK2M3-PAID6-E5 Pk2M3-PAID6 SAR52p-SpSgRNA structure-tef1 gRNA-SUP4t This Study 
PK2M3-PAID6-H8 




CEN.PK2-1C  adh1Δ::loxP adh2Δ::loxP adh3Δ::loxP 
adh4Δ::loxP::adh5Δ::loxP gpd1Δ::loxP gpd2Δ::loxP:: 
dld1Δ::PTDH3-Lm.ldhA-TCYC1-loxP-kanMX-loxP 
9 
JHY5617* JHY 5610: erf2∆, SURI245S-kanMX 9 
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5.5.2. Plasmid Construction  
All major primer and plasmids used in this study are described in Table 5.5 and Table 5.6 
respectively. 
Table 5.5. All major primers used in this study 








TEF1t-loxP-for gatattgtcgtaacaaatactttgatcggcgctat cagctgaagcttcgtacg 
TEF1t-rev atagcgccgatcaaagta 
ADH5-TEF1p-for atgccttcgcaagtcattcctgaaaaacaaaaggctattgtcttt gcggatagcttcaaaatg 
ADH5-for atgccttcgcaagtcatt 
ADH5-rev cgataggccagctaagtg 
GFP-for tagcaatctaatctaagttttaattacaaa atgcgtaaaggagaagaa 
Construct pRS414-GFP 
GFP-rev tgatcatgaattaataaaagtgttcgcaaattatttgtatagttcatc 
GFPrc-for atctaagttttaattacaaactatttgtatagttcatc Construct pRS416-
GFPrc GFPrc-rev cgatttcaattcaattcaatatgagtaaaggagaagaa 
pRS404-
Insert_fwd  






X-3-INT-SNR52F atcaggcacgaaggcacactcgtatatgcatgttgttgaactttgaaaagataatgtatg Together with pSg335 to 
make mutant PK2M3-
PAID6-H7 X-3-INT-M13R ttccatggggtcgcaacttttcccggtgacctctacatgtaggaaacagctatgaccatg 
XI-1-INT-SNR52F gcgccggttttcattttcttccacggaataccaagcccatctttgaaaagataatgtatg Together with pSg337 to 
make mutant PK2M3-
PAID6-H8 XI-1-INT-M13R ctgtacgcagcatttagcagagatttgccaatgccaagaaaggaaacagctatgaccatg 
XII-2-INT-SNR52F tgcgtctaacgcttttgccacttggatttctattataggactttgaaaagataatgtatg Together with pSg341 to 
make mutant PK2M3-
PAID6-E5 XII-2-INT-M13R aagaaattcttcctgtgcttcatcaaaacgcgaaaattcgaggaaacagctatgaccatg 
XI-3-INT-SNR52F ccaatcaaagaagcatcggttcagatcgagcaaactgtagctttgaaaagataatgtatg Together with pSg339 to 
make mutant PK2M3-
PAID6-A5 XI-3-INT-M13R tgacatccaaactacaaaaccgagattggacatatagcacaggaaacagctatgaccatg 
LA001 gtaccgggccccccctcgagaagcttcgtcttttcttg Construct pRS405-
LAb1/LAb2 LA002 agttcttctcctttactcattattgtaatatgtgtgtttgtttg 











LIdR-cm-GA-for aatctaagttttaattacaaa atgattgttttgccaaga Construct pRS416-










Table 5.6. The major plasmids used in this study  
Plasmid Genotype Source or Reference 
pH5-Lpldh pRS425-TEF1p-Lpldh-TEF1t This study 
pH5-Lpmldh pRS425-TEF1p-Lpmldh-TEF1t This study 
pH5-Lbldh pRS425-TEF1p-Lbldh-TEF1t This study 
pH5-Roldh pRS425-TEF1p-Roldh-TEF1t This study 
pRS414-GFP pRS414-TEF1p-GFP-HX7Tt This study 




pRS404-FA3 pRS404-TEF1p-fa3-PGK1t This study 
pRS404-RD5 pRS404-PGK1t-htb1-TEF1p This study 
pRS404-RG4 pRS404-PGK1t-fba1-TEF1p This study 
pSg335 pRS426-X-3-gRNA Lian et. al. 
(unpublished) 
pSg337 pRS426-XI-1-gRNA Lian et. al. 
(unpublished) 
pSg341 pRS426-XII-2-gRNA Lian et. al. 
(unpublished) 
pSg339 pRS426-XI-3-gRNA Lian et. al. 
(unpublished) 
pRS405-LAb1 pRS405-LAb3-GFP-PGK1t This study 
pRS405-LAb2 pRS405-LAb3-GFP-PGK1t This study 
pRS405-LAb3 pRS405-LAb3-GFP-PGK1t This study 
pRS416-LIdR pRS416-TEF1p-LIdR-PGK1t This study 
pRS416-LIdRcm pRS416-TEF1p-LIdRcm-PGK1t This study 









Lian et. al. 
(unpublished) 
Table 5.6. cont.   
pRS426-CRISPR-I pRS426-SAR52p-SpSgRNA structure-
gRNA-SUP4t 




Lian et. al. 
(unpublished) 
 
5.5.3. Construction of Genetically Manipulated Strains  
PK2M1 was created by deleting adh1, adh4, gpd1 and gpd 2 in CEN.PK2-1C consecutively using 
Cre-mediated gene knockouts methods.16  PK2M2, PK2M3, PK2M4 and PK2M5 were created by 
239 
 
replacing ADH5 with Lp-ldh, Lpm-ldh, Lp-ldh and Ro-ldh respectively using Cre-mediated gene 
knock-in methods.16 
5.5.4. Analytical Methods  
To determine the concentration of acetate, ethanol, glucose and lactate, all samples collected from 
culture supernatants were centrifuged 10 minutes at 13000 rpm and the supernatant were quantified 
by high performance liquid chromatography (HPLC). HPLC analysis was performed in UltiMate 
3000 HPLC system (Thermo Fishers Scientific) equipped with a Bio-Rad Aminex HPX-87H 
column at 60 °C with 5 mM H2SO4 at a flow rate of 0.6 mL/min and refractive index (RI) as a 
detector keeping at 35 °C. Cell growth was monitored by determining optical density at 600 nm.  
5.5.5. Bromocresol Green Assay  
Lactic acid and bromocresol green were purchased from Sigma-Aldrich (St. Louis. MO). 
Bromocresol green reaction solution (BG) was prepared by dissolving 60 mg bromocresol green 
powder into 1 L distillation water. The pH of the solution was adjusted to 5.5 while the solution 
just turned into deep blue by using sodium hydroxide. All fermentation samples (around 20 g/L) 
were diluted 5 times. While doing the measurements, 200 uL BG solution was added in a Corning 
UV-Transparent Microplates with clear flat bottom (ThermoFisher Scientific, Rockford, IL). 2 uL 
diluted fermentation sample was mixed well with reaction solution and the A616 nm absorbance was 
recorded with Cary 300 UV-Vis spectrophotometer (Agilent Technologies, Santa Clara, CA) 
5.5.6. LOD Assay  
L-Lactic acid, lactate oxidase from Aerococcus viridans (L9795) and Fluorometric Hydrogen 
Peroxide Assay kit (FHP) were purchased from Sigma-Aldrich (St. Louis. MO). Lactate oxidase 
master mix (LOD-MM) was prepared by suspended LOD with assay buffer from FHP assay kit 
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resulting in 0.01 U/uL solution. FHP master mix (MM) was prepared right before the 
measurements by following the FHP assay kit protocol. All fermentation samples (around 20 g/L 
concentration) were diluted 200 times with assay buffer. While doing the measurements, 50 uL 
LOD-MM mixed with 50 uL MM and was added in a Corning 96-well, clear bottom fluorescence 
plate (ThermoFisher Scientific, Rockford, IL). 2 uL diluted fermentation sample was mixed well 
with reaction solution. The plate was incubated at room temperature for 30 minutes. The 
fluorescent signal was detected using a Tecan Infinite M1000 PRO microplate reader (Morrisville, 
NC). The excitation and emission wavelength of FHP kit were set at 540 nm and 590 nm 
respectively. All experiments were performed in triplicate.    
5.5.7. Sensor Activity Assays   
For the characterization of L-LA sensor/regulating gene circuit in S. cerevisiae CEN.PK2.1C, 
PK2M1 strain was transformed with each circuit-containing plasmid and plated on SC-His-Ura 
plates supplemented with 20 g/L glucose. Single colonies were inoculated into 2 mL SC-Ura-His 
liquid medium supplemented with 20 g/L glucose. Overnight culture was sub-cultured one time to 
synchronize the growth.  The subculture was inoculated in 2 mL of SC-Ura liquid medium 
supplemented with 20 g/L glucose and different amount of L-LA with an initial OD600 of 1.0. 
Strains were cultured at 30 °C and 250 rpm. Samples were taken at 24 hr for flow cytometry 
analysis.  
For the characterization of L-LA sensor/regulating gene circuit in L-LA producing S. 
cerevisiae. PK2M3, PK2M4 and PK2M5 was transformed with each circuit-containing plasmid 
and plated on SC-His-Ura plates supplemented with 20 g/L glucose. Single colonies were 
inoculated into 2mL SC-Ura-His liquid medium supplemented with 20 g/L glucose. Overnight 
culture was sub-cultured one time to synchronize the growth. The subculture was inoculated in 2 
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mL of SC-Ura liquid medium supplemented with 20 g/L glucose, or 100 mM citrate-phosphate 
with an initial OD600 of 1.0 or YPD liquid medium with an initial OD600 of 0.4. Strains were 
cultured at 30 °C and 250 rpm. Samples were taken at 24 hr for flow cytometry analysis.  
5.5.8. Library Construction and Screening   
In the CAD, PK2M3-RNAi or PK2M3-PAID6 strains, the standard LiAc/ssDNA/PEG protocol 
was used to transform 10 ug to 20 ug RAGE or CRISPR-AID library plasmids based on the 
transformation efficiency of about 0.5 ~ 3×105 cfu/ug. The library DNA (20 ug) was able to 
achieve a library size of more than 1×106 to ensure a nearly complete coverage of the yeast 
genome.10 Following the transformation, the RAGE library yeast cells were plated onto 150 mm 
diameter Petri-dish plates of solid SC(G)-U medium supplemented with 3.5% LA at pH 3.0. The 
CRIRSPR-AID library yeast cells were recovered in SC(G)-URA medium to saturation and plated 
onto150 mm diameter Petri-dish plates of solid SC(G)-U medium supplemented with 3.5% LA at 
pH 3.0. The number of cells were adjusted so that each plate would form about 104 on SC-URA 
plate while about 103 on an SC-URA (pH3, 3% LA) plate. The library and control plates were 
incubated at 30 °C for 3-4 days. Nighty three colonies whose sizes were bigger than the largest 
colonies on the control plates or first appeared on the selection plate were picked from the library 
plates. The growth performances of the selected colonies and the control strain were compared in 
SC(D)-Ura liquid medium with 3.5% LA at pH3. The LA production levels of the mutants and 
control were compared in SC-Ura medium supplemented with 50g/L glucose and evaluated by BG 
assay. The plasmids from the top strains whose growth behaviors or LA production were 
considerably better than the control strain were isolated and amplified by E. Coli. The plasmids 
were sequenced to identify the gene targets. The selected plasmids where then individually 
retransformed in a fresh background parent strain. Growth behaviors and LA production were 
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evaluated again to confirm the improved quality compared with the parent strain. To confirm a 
given gene-target, a designed mutant was constructed by integrating the corresponding RNAi 
cassette or CRISPR AID modular part into the chromosome of a fresh background strain. 
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